Clinical trial NCT02475733
Conditions: Complicated Intra-abdominal Infections
Sponsor: Pfizer
Start date: 2015-08-01; Completion date: 2017-06-01
Enrollment: 83 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
This study will assess the safety , efficacy and pharmacokinetics of ceftazidime avibactam and metronidazole versus meropenem in paediatric population (from 3 months to less than 18 years of age )with complicated intra-abdominal infections (cIAIs)

Detailed description:
This is a multicentre, multinational, single blind, randomised and active controlled trial of intravenous ceftazidime avibactam in combination with metronidazole versus meropenem. Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before having the option to switch to an oral therapy. The decision to switch to oral therapy is entirely at the Investigator's discretion, if the patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food.Patients will be assessed for safety and efficacy throughout the study, and blood samples will be taken for pharmacokinetic (PK) assessment. The duration of each patient's participation in the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment (defined as the time point at which first dose of study treatment is administered) at which time there will be a late follow up (LFU) assessment visit. The LFU is to be performed 20 to 35 days after the last dose of any treatment.The assessments at the test of cure (TOC) visit should be performed in person 8 to 15 days after last dose of any study drug (IV or oral). The maximum duration of IV study drug or oral switch therapy is up to Day 15.

Arms: arm 1: CAZ-AVI to be administered every 8 hours as a 2 hour infusion (CAZ-AVI dose and frequency of IV administration will depend upon body weight and renal function) followed by metronidazole (no later than 30 minutes after CAZ-AVI infusion ) to be administered every 8 hours as 20 to 30 minutes infusion arm 2: administered every 8 hours infused over 15 to 30 minutes or up to 1 hour or infusion duration as per local guidelines.
Interventions: intervention 1: Ceftazidime -avibactam intervention 2: Meropenem intervention 3: Metronidazole
Intervention descriptions: intervention 1: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment intervention 2: Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment intervention 3: Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment

Protocol documents:
Prot_000.pdf: 
.9/L"H(A"L 
.-4*.LDF KL09E:92L
Qe2ne"V`J'+n
^f)knL),n
*6Z7LIneE",Pn
[,n
')PX-$-9'T/Z!J:Z

Z

Z
ZC!+Z
Z
@4 +'@ ( ,@+.) 4@)8'5!+51@ 6 :@.,51.''@52 '@6.@;'95@
45=@ 5.'7 ' 6=@/).& +6!4@+@"=@.@5>  *@+@
; 5)@<-@ #;,@ #,@.) +5 .,@< 5@)51.+!?.(@ .)02@< 5@
32./+)@ +@ (1,@2.)@	).+64@6.@'44@5+@ =24@ .@@<$6@
.)0( 6@ ,6
	.)!,'@  +5!.+4@%%4@
<97A9=L	V`P'I&' 	
n
bD),P[;?<,ni,*,In
AE="5"L"B">%L5L)!#
B(E"L>";?"B"6DE+I"L
\f*ln-).Pn
n
n


n
n,Z4,P?!I)Wn

 \,n
n
n

+' *+($"+(+ (6(AE)H+'5$"BL*5.G "L(7LD&*AL >"H*A"L;>9E991L
%+9L
	Z

Z
3(6*AE=D(H"L
46$+9L
%+9#L&+


Z'@J': 'BZ	
	C!+Z
Z	Z
D"L 9#L3*4*AE>E+J"L
'6$"L
%
9.L3"53"7EL9L
92L!3+8+CD@E+J"L
'6$"L	+
E"L++%+
%+9#L.9/L
	 3+4,CD>D+J"L+
%

% 
%

Y+/HZ4.;-!5ZKQ%VZC?L?!?5Z+HZ '';ZHR3'!MZM?ZZA''DZC'T/'UZ!!?C$-;*ZM?Z
L<$C$Z@E?!'%SC'HZ ,'Z !5/>-!5ZHMR$WZ@C?M?!?5Z -HZAR6-!5WZ F'*/HM'C'$Z;$ZJ+'Z G'HR8MHZC!Z
&0H#7?H'$Z;%?CZ@S51H+($Z!!?C$-;*Z M?Z	
INC2';'!Z5?6Z?6/!WZ?;Z-?'M+-!HZ;$Z/;Z
Z!?:A5/;!'ZU/O,Z AC'T/5-;*Z 5UHZ;$ZC(*R5L1?=HZ
PPD
PP
D
PPD
PPD
PP
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


2(88)
PROTOCOL SYNOPSIS
A single blind, randomised, multi-centre, active controlled, trial to evaluate 
safety, tolerability, pharmacokinetics and efficacy of ceftazidime and 
avibactam when given in combination with metronidazole, compared with 
meropenem, in children from 3 months to less than 18 years of age with 
complicated intra-abdominal infections (cIAIs)
International Co-ordinating Investigator
, MD
United States
Study site(s) and number of patients planned
A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 
72 hours (3 full days, ie, 9 doses) of study treatment (ie, evaluable patients; at least 60 patients 
in the ceftazidime and avibactam [CAZ-AVI] plus metronidazole group and at least 
20 patients in the meropenem group).  
Patient recruitment will ensure that no more than 90% of evaluable patients will have 
diagnosed complicated appendicitis in all cohorts combined.  Patients will be allocated to 1 of 
4 cohorts based on age. Randomisation will be stratified as follows:

Cohort 1: At least 15:5 evaluable patients aged from 12 years to <18 years 

Cohort 2: At least 15:5 evaluable patients aged from 6 years to <12 years 

Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 years

Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 years, 
comprising Cohorts 4a and 4b as follows:

Cohort 4a: Patients aged from 1 year to <2 years

Cohort 4b: Patients aged from 3 months to <1 year
PPD
PPD
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
3(88)
Approximately 70 study centres are planned.
Study period
Phase of development
Estimated date of first patient enrolled
Q3 2015
2
Estimated date of last patient completed
Q3 2017
Study design
This study will be a single blind, randomised, multi-centre, active controlled trial.  Patients 
aged from 3 months to less than 18 years with complicated intra-abdominal infections (cIAIs) 
will be randomised to 1 of 2 treatment groups (3:1 ratio): CAZ-AVI in combination with 
metronidazole versus meropenem. Randomisation will be stratified appropriately.  Patients 
aged from 3 months to <1 year (Cohort 4b) must have been born at term (defined as 
gestational age ≥37 weeks).
Patients will receive intravenous (IV) treatment for a minimum of 72 hours (3 full days, ie, 
9 doses) before having the option to switch to an oral therapy as specified below.  The 
decision to switch to oral therapy is entirely at the Investigator’s discretion, if the patient has 
good or sufficient clinical response, and the patient is tolerating oral fluids or food.
Patients will be assessed for safety and efficacy throughout the study, and blood samples will 
be taken for pharmacokinetic (PK) assessment.  The duration of each patient’s participation in 
the study will be a minimum of 27 days to a maximum of 50 days after start of study treatment 
(defined as the time point at which first dose of study treatment is administered) at which time 
there will be a late follow-up (LFU) assessment visit.  The LFU is to be performed 20 to 
35 days after the last dose of any treatment.
Objectives
Primary (Safety) Objective:
Outcome Measure:
Evaluate the safety and tolerability of 
CAZ-AVI plus metronidazole given at the 
selected dose regimen versus meropenem in 
paediatric patients aged ≥3 months to 
<18 years with cIAI

Adverse events (AEs) and serious adverse events 
(SAEs) from the signing of the Informed 
Consent/Assent Form to the LFU visit (27 to 
50 days after start of study treatment)

Cephalosporin class effects and additional AEs 
(including, but not limited to seizures, 
Clostridium difficile-associated diarrhoea, allergic 
reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function)

Clinical: vital signs (pulse, blood pressure, 
respiratory rate, temperature), electrocardiogram 
(ECG), and physical examinations

Laboratory: complete blood count with 
differential and comprehensive metabolic panel

Creatinine clearance (CrCl) 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
4(88)
Secondary Objective:
Outcome Measure:
Evaluate the descriptive efficacy of CAZ-AVI 
plus metronidazole versus meropenem in 
paediatric patients aged ≥3 months to 
<18 years with cIAI

Clinical Outcomes at End of 72 hours’ 
Treatment, End of Intravenous Treatment 
(EOIV), End of Treatment (EOT) and Test of 
Cure (TOC)

Microbiological response at EOIV, EOT, TOC 
and LFU

Clinical relapse at LFU

Emergent infections
Evaluate the PK of CAZ-AVI in paediatric 
patients aged ≥3 months to <18 years with 
cIAI

PK data of ceftazidime and avibactam will be 
analysed separately

Plasma concentration will be listed and 
summarised by nominal sampling time window 
using appropriate descriptive statistics

PK parameters derived from population PK 
analysis and potential PK/pharmacodynamic 
(PD) relationships will be reported separately
Target patient population
Patients aged from 3 months to less than 18 years with cIAI.  
Duration of treatment
The IV study treatment is to be given for a minimum of 72 hours (3 full days, ie, 9 doses).  At 
any time after a minimum of 72 hours of IV study treatment has been received, there is an 
option to switch to an oral therapy, as specified below.  The decision to switch to oral therapy 
is entirely at the Investigator’s discretion, if the patient has good or sufficient clinical 
response, and the patient is tolerating oral fluids or food. The total period of treatment (ie, IV 
drug or oral switch therapy) is to be between 7 and 15 days.  Patients may remain on the IV 
study treatment for the full 7 to 15 days.
Investigational product, dosage and mode of administration
The study is single blind, ie, a Blinded Observer will not know the patient’s treatment 
assignment and will conduct clinical assessments (including efficacy and safety).  There is no 
use of placebo to act as a treatment blind.
Intravenous CAZ-AVI infusions will be given at doses based on the age and weight of the 
patient with adjustment according to renal function: 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
5(88)
Cohort
Age range
Body 
weight
CAZ-AVI dose
CrCl ≥50 mL/min
CAZ-AVI dose
CrCl ≥30 to <50 mL/min
CAZ-AVI must be administered as a 50 to 100 mL infusion (dependent on dose) over 2 hours 
every 8 hours (±30 minutes)
11
12 years to 
<18 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
11
12 years to 
<18 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
21
6 years to 
<12 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
21
6 years to 
<12 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
31
2 years to 
<6 years
All
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4a2
1 year to 
<2 years
All
50 mg/kg ceftazidime /12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b2
6 months to 
<1 year
All
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b2
3 months to 
<6 months
All
40 mg/kg ceftazidime/10 mg/kg avibactam
20 mg/kg ceftazidime/5 mg/kg avibactam
1
Patients considered for entry into the study will be within the normal range of body mass index (BMI) for their age, (2 to <18).  A healthy weight BMI 
for this age group falls between the 5th percentile and ≤95th percentile according to height, weight, and age.
2
BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
6(88)
The Investigator should follow the package insert for meropenem for dose modifications 
associated with renal impairment.
Patients whose CrCl drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the Case Report Form.  If possible, patients 
should still be followed for safety.  Because the CrCl determination is only an estimate of 
renal function, in instances where the CrCl is approaching thresholds that would require 
intervention such as a dose change or discontinuation of therapy (ie CrCL approaching 50 or 
30 mL/min), the Investigator should use his or her discretion in determining (ie confirming the 
value by repeat testing, if feasible) whether an immediate dose change, a short period of 
continued observation, or discontinuation of therapy is warranted. If in the opinion of the 
Investigator there is a clinically significant reduction in a patient’s estimated CrCl during the 
treatment period, then the Investigator should contact the Medical Monitor to discuss the 
above mentioned options (immediate dose change, a short period of continued observation, or 
discontinuation of therapy). Additionally, in instances of rapidly changing renal function, the 
Investigator should increase the frequency of CrCl monitoring, depending on the patient’s 
clinical status, extent of renal function change and Investigator’s clinical evaluation.
The suggested dosing regimen of metronidazole is 10 mg/kg IV over 20 to 30 minutes every 
8 hours (±30 minutes), but it can also be prescribed/adjusted by the Investigator according to 
local labels. The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ-AVI infusion.
An optional switch to oral therapy is permitted on or after Study Day 4 (ie, after 72 hours of 
IV study drug).  The decision to switch to oral therapy is entirely at the Investigator’s 
discretion, if the patient has good or sufficient clinical response, and the patient is tolerating 
oral fluids or food:

Oral amoxicillin/clavulanic acid (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or

Oral ciprofloxacin (only in countries where its use for children is permitted; according 
to local guidelines, administered at a dose and formulation per standard of care) plus 
metronidazole (administered at a dose and formulation per standard of care), or

Pathogen-based therapy (in discussion with the Medical Monitor).  The choice of oral 
antibacterial agent for pathogen-based therapy will be driven by the results of a 
susceptibility test, which will be provided to the Investigator by either the local or 
central laboratory.  Initiation of pathogen-based therapy is at the Investigator’s 
discretion.  Before administering pathogen-based therapy, the Investigator will discuss 
the results of the susceptibility test and the selected antibacterial drug (which should be 
approved for use in children) with the Medical Monitor.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
7(88)
The patient may continue on IV study drug for the entire duration of the study therapy (7 to 
15 days), at the discretion of the Investigator.  
Comparator
Meropenem 20 mg/kg every 8 hours (±1 hour) given by IV infusion over approximately 15 to 
30 minutes or up to 1 hour, or infusion duration as per local guidelines, with optional oral 
switch therapy as described above.  For patients weighing over 50 kg, the maximum dose of 
meropenem should not exceed 1 g every 8 hours.  
Statistical methods
Block randomisation using an interactive voice/web response system will be used to assign 
patients in a ratio of 3:1 to the study treatment groups of CAZ-AVI plus metronidazole or 
meropenem, respectively, in each of the cohorts for the age groups.  All study data will be 
summarised within each age cohort separately and also overall (regardless of age cohort).
Safety data
The primary objective will be to assess the safety and tolerability of CAZ-AVI plus 
metronidazole compared with comparator (meropenem).  Safety data include AEs, clinical 
laboratory parameters, vital signs, ECG parameters, and physical examinations.  For each 
safety variable, the last assessment made prior to the first dose of study drug will be defined as 
the baseline.  All safety data collected from this study will be summarised by the received 
treatment group (ie, for CAZ-AVI plus metronidazole versus meropenem irrespective of 
switching to oral therapy) for all patients who received any amount of study treatment (termed 
the ‘Safety analysis set’), and key data will also be summarised for those patients who 
received at least 72 hours of study treatment (termed the ‘Safety evaluable analysis set’) by 
received treatment group.  Descriptive statistics will be produced to summarise the safety data.  
Safety data from this study will be combined with those from another CAZ-AVI paediatric 
study for complicated urinary tract infections (D4280C00016) and will be presented in the 
same way.
The incidence of AEs and SAEs will be summarised by system organ class and preferred 
term, according to the Medical Dictionary for Regulatory Activities vocabulary, by treatment 
group.  The summaries will also be produced by relationship to study drug, and by AE 
intensity.  AEs leading to discontinuation from study treatment will also be summarised.  
Summary tables for clinical laboratory tests, vital signs, ECGs, and physical examination 
findings will be produced.
Descriptive efficacy data and patient characteristic/Baseline data
Efficacy will be assessed descriptively in the intent-to-treat (ITT) set (all randomised 
patients), the microbiological ITT (micro-ITT) set (all randomised patients who have a 
baseline pathogen known to cause cIAI), the clinically evaluable (CE) analysis set (patients 
who meet minimal disease criteria for cIAI and all evaluability criteria, including patients who 
received at least 72 hours of the intended dose and duration of IV study drug, and for whom 
sufficient information regarding the infection is available to determine the patient’s outcome), 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
8(88)
and the microbiologically evaluable (ME) analysis set (patients who meet minimal disease 
criteria for cIAI and all evaluability criteria similar to the CE analysis set, and have at least 
1 typical IAI bacterial pathogen at Baseline that is susceptible to both study agents, ie, 
CAZ-AVI and meropenem). 
Efficacy will be assessed in the ITT, micro-ITT, CE, and ME analysis sets with respect to the 
proportion of patients with clinical response outcome of cure (at the end of 72 hours’ 
treatment, EOIV, the EOT, and the TOC visit) and clinical response outcome of relapse (at the 
LFU visit).  Favourable microbiological response will be assessed in the ME and the 
micro-ITT analysis sets, and the number of patients with emergent infections (up to LFU) will 
be assessed in the ME analysis set.  Patients in the ITT, micro-ITT, CE, and ME analysis sets 
will be summarised according to the randomised treatment assignment.
Descriptive statistics (number, mean, standard deviation [SD], median, minimum, and 
maximum) will be provided for continuous variables, and counts and percentages will be 
presented for categorical variables.  All summaries will be presented by treatment group.  
Demographic data and other baseline characteristic data will also be summarised.
Pharmacokinetic data
Pharmacokinetic assessment will be conducted for the PK analysis data set.  The data set will 
consist of all patients who will receive CAZ-AVI treatment, and have at least 1 ceftazidime 
and/or avibactam plasma measurement available. 
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided.  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean ±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 to 4b will be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  The 
actual dosing and plasma sampling times will be used for the analysis.  The developed 
population PK model may be used to conduct simulations to determine probability of PK/PD 
target attainment to help to justify the CAZ-AVI dose regimens for paediatric patients with 
cIAI.  A stand-alone population PK modelling and simulation analysis plan will be prepared 
and the results will be reported in a stand-alone report outside of the clinical study report.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
9(88)
TABLE OF CONTENTS
PAGE
TITLE PAGE...........................................................................................................1
PROTOCOL SYNOPSIS.........................................................................................2
TABLE OF CONTENTS.........................................................................................9
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS..........................14
1.
INTRODUCTION .................................................................................................16
1.1
Background and rationale for conducting this study .............................................16
1.2
Rationale for study design, doses and control groups............................................17
1.3
Benefit/risk and ethical assessment........................................................................17
1.4
Study design...........................................................................................................22
2.
STUDY OBJECTIVES..........................................................................................25
2.1
Primary objective (safety)......................................................................................25
2.2
Secondary objectives .............................................................................................25
2.3
Safety objectives ....................................................................................................25
2.4
Exploratory objectives not applicable....................................................................26
3.
SUBJECT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL......................26
3.1
Inclusion criteria ....................................................................................................26
3.2
Exclusion criteria ...................................................................................................28
3.3
Subject enrolment and randomisation....................................................................30
3.4
Procedures for handling incorrectly enrolled or randomised patients ...................31
3.5
Methods for assigning treatment groups................................................................31
3.6
Methods for ensuring blinding...............................................................................31
3.7
Methods for unblinding..........................................................................................32
3.8
Restrictions ............................................................................................................32
3.9
Discontinuation of investigational product............................................................32
3.9.1
Procedures for discontinuation of a patient from investigational product.............33
3.10
Criteria for withdrawal...........................................................................................34
3.10.1
Screen failures........................................................................................................34
3.10.2
Withdrawal of the informed consent......................................................................34
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
10(88)
3.11
Discontinuation of the study ..................................................................................34
4.
STUDY PLAN AND TIMING OF PROCEDURES.............................................34
4.1
Enrolment/screening period...................................................................................39
4.2
Treatment period....................................................................................................40
4.2.1
Day 1......................................................................................................................40
4.2.2
Days 2 and 3...........................................................................................................41
4.2.3
Days 4 to ≤15.........................................................................................................41
4.2.4
End of IV treatment ...............................................................................................42
4.2.5
End of Treatment (oral switch therapy).................................................................43
4.3
Follow-up period....................................................................................................44
4.3.1
Test of Cure............................................................................................................44
4.3.2
Late Follow-up.......................................................................................................44
5.
STUDY ASSESSMENTS .....................................................................................45
5.1
Efficacy assessments..............................................................................................45
5.2
Microbiological assessments .................................................................................45
5.2.1
Intra-abdominal fluid for microbiological culture .................................................45
5.2.2
Blood samples for microbiological culture............................................................46
5.3
Safety assessments.................................................................................................46
5.3.1
Laboratory safety assessments...............................................................................46
5.3.2
Physical examination .............................................................................................48
5.3.3
Electrocardiogram..................................................................................................49
5.3.4
Vital signs ..............................................................................................................49
5.3.4.1
Pulse and blood pressure........................................................................................49
5.3.4.2
Body temperature...................................................................................................49
5.3.4.3
Respiratory rate......................................................................................................49
5.3.5
Cephalosporin class effects....................................................................................49
5.4
Other assessments ..................................................................................................49
5.5
Pharmacokinetics ...................................................................................................50
5.5.1
Collection of samples.............................................................................................50
5.5.2
Determination of drug concentration.....................................................................50
5.5.3
Storage and destruction of pharmacokinetic samples............................................50
5.6
Pharmacodynamics not applicable.........................................................................51
5.7
Pharmacogenetics not applicable...........................................................................51
5.8
Biomarker analysis not applicable.........................................................................51
5.9
Volume of blood ....................................................................................................51
6.
SAFETY REPORTING AND MEDICAL MANAGEMENT ..............................52
6.1
Definition of adverse events ..................................................................................52
6.2
Definition of serious adverse event........................................................................52
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
11(88)
6.3
Recording of adverse events ..................................................................................53
6.3.1
Time period for collection of adverse events.........................................................53
6.3.2
Follow-up of unresolved adverse events................................................................53
6.3.3
Variables ................................................................................................................53
6.3.4
Causality collection................................................................................................54
6.3.5
Adverse events based on signs and symptoms.......................................................55
6.3.6
Adverse events based on examinations and tests...................................................55
6.3.7
Actions required in cases of increases in liver chemistry values...........................55
6.3.8
Exceptions from standard adverse event collection...............................................56
6.3.8.1
Lack of Effect.........................................................................................................56
6.3.8.2
Disease progression ...............................................................................................56
6.4
Reporting of serious adverse events.......................................................................56
6.5
Overdose ................................................................................................................57
6.6
Pregnancy...............................................................................................................58
6.6.1
Maternal exposure..................................................................................................58
6.6.2
Paternal exposure...................................................................................................59
6.7
Management of investigational product-related toxicities.....................................59
6.8
Study governance and oversight ............................................................................60
6.8.1
Data and Safety Monitoring Board........................................................................60
7.
INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS ....................60
7.1
Identity of investigational product(s).....................................................................60
7.2
Dose and treatment regimens.................................................................................61
7.3
Labelling ................................................................................................................63
7.4
Storage ...................................................................................................................64
7.5
Compliance ............................................................................................................64
7.6
Accountability........................................................................................................64
7.7
Oral switch therapy................................................................................................64
7.8
Concomitant and other treatments .........................................................................65
7.8.1
Drug-drug interactions...........................................................................................71
7.8.2
Other concomitant treatment..................................................................................71
8.
STATISTICAL ANALYSES ................................................................................71
8.1
Statistical considerations........................................................................................71
8.2
Sample size estimate..............................................................................................71
8.3
Definitions of analysis sets ....................................................................................72
8.3.1
Safety analysis set..................................................................................................72
8.3.2
Safety evaluable analysis set..................................................................................72
8.3.3
Pharmacokinetic analysis set .................................................................................72
8.3.4
Efficacy analysis sets .............................................................................................72
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
12(88)
8.3.4.1
Intent-to-treat analysis set......................................................................................73
8.3.4.2
Microbiological intent-to-treat analysis set............................................................73
8.3.4.3
Clinically evaluable analysis set ............................................................................73
8.3.4.4
Microbiologically evaluable analysis set...............................................................73
8.4
Outcome measures for analyses.............................................................................74
8.4.1
Primary outcome variables.....................................................................................74
8.4.2
Secondary outcome variables.................................................................................74
8.5
Methods for statistical analyses .............................................................................74
8.5.1
Analysis of the primary variables ..........................................................................74
8.5.1.1
Adverse events.......................................................................................................75
8.5.1.2
Other safety data ....................................................................................................76
8.5.2
Analysis of the secondary variable(s)....................................................................76
8.5.2.1
Pharmacokinetic outcome variables.......................................................................76
8.5.2.2
Clinical outcome definitions..................................................................................77
8.5.2.3
Microbiological response assessments...................................................................81
8.5.2.4
Emergent infections ...............................................................................................82
9.
STUDY AND DATA MANAGEMENT...............................................................83
9.1
Training of study site personnel.............................................................................83
9.2
Monitoring of the study .........................................................................................83
9.2.1
Source data.............................................................................................................84
9.2.2
Study agreements...................................................................................................84
9.2.3
Archiving of study documents...............................................................................84
9.3
Study timetable and end of study...........................................................................84
9.4
Data management by PRA.....................................................................................84
10.
ETHICAL AND REGULATORY REQUIREMENTS.........................................85
10.1
Ethical conduct of the study...................................................................................85
10.2
Patient data protection............................................................................................85
10.3
Ethics and regulatory review..................................................................................85
10.4
Informed consent ...................................................................................................86
10.5
Changes to the protocol and Informed Consent Form...........................................87
10.6
Audits and inspections ...........................................................................................87
11.
LIST OF REFERENCES.......................................................................................88
LIST OF TABLES
Table 1 
Study plan detailing study procedures......................................................35
Table 2
Laboratory safety variables ......................................................................47
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
13(88)
Table 3
Volume of blood per patient – Cohorts 1 and 2 .......................................51
Table 4
Volume of blood per patient – Cohorts 3, 4a, and 4b...............................52
Table 5
CAZ-AVI doses by age, weight, and creatinine clearance.......................62
Table 6
Contraindications and drug-drug interactions ..........................................67
Table 7
Clinical outcome assessments at End of 72 hours....................................77
Table 8
Clinical outcome assessments at EOIV....................................................79
Table 9
Clinical outcome assessments at EOT......................................................80
Table 10
Clinical outcome assessments at TOC......................................................80
Table 11
Clinical outcome assessments at LFU......................................................81
Table 12
Per-pathogen microbiological outcome categories...................................82
Table 13
Emergent infections..................................................................................82
LIST OF FIGURES
Figure 1
Study flow chart .......................................................................................24
LIST OF APPENDICES
Appendix A
Not applicable
Appendix B
Additional Safety Information 
Appendix C
IATA 6.2 Guidance document
Appendix D
Actions required in cases of combined increase of Aminotransferase and 
Total Bilirubin – Hy’s Law
Appendix E
Tanner Staging of Development
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
14(88)
LIST OF ABBREVIATIONS AND DEFINITION OF TERMS
The following abbreviations and special terms are used in this study Clinical Study Protocol.
Abbreviation or 
special term
Explanation
AE
Adverse event
AEoSI
Adverse event of special interest
ALT
Alanine aminotransferase
AST
Aspartate aminotransferase
BAT
Best Available Therapy
BMI
Body mass index
CAZ-AVI
Ceftazidime and avibactam
CE
Clinically evaluable
cIAI
Complicated intra-abdominal infection
CrCl
Creatinine clearance
CRF
Case Report Form (electronic/paper)
CRP
C-reactive protein
CSA
Clinical Study Agreement
CSR
Clinical Study Report
CT
Computed tomography 
cUTI
Complicated urinary tract infection
DSMB
Data and Safety Monitoring Board
ECG
Electrocardiogram
EOIV
End of Intravenous Treatment
EOT
End of Treatment
ESR
Erythrocyte sedimentation rate
GCP
Good Clinical Practice
β-hCG
ß-human chorionic gonadotropin
ICF
Informed Consent Form
ICH
International Conference on Harmonisation
IEC
Independent Ethics Committee
INR
International normalised ratio
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
15(88)
Abbreviation or 
special term
Explanation
International 
Co-ordinating 
Investigator
If a study is conducted in several countries the International Co-ordinating 
Investigator is the Investigator co-ordinating the Investigators and/or 
activities internationally. 
IP
Investigational product 
IRB
Institutional Review Board
ITT
Intent-to-treat 
IV
Intravenous
IXRS
Interactive voice/web response system
KPC
Klebsiella pneumoniae carbapenemase
LFU
Late Follow-up
ME
Microbiologically evaluable
MedDRA
Medical Dictionary for Regulatory Activities
MIC
Minimum inhibitory concentration
micro-ITT
Microbiological intent-to-treat 
MRI
Magnetic resonance imaging
MRSA
Methicillin-resistant staphylococcus aureus
OAT
Organic anion transporter
PD
Pharmacodynamic
PK
Pharmacokinetic
QTcB
QT interval corrected using Bazett’s formula
QTcF
QT interval corrected using Fridericia’s formula
SAE
Serious adverse event 
SAP
Statistical Analysis Plan
SD
Standard deviation
TOC
Test of Cure
ULN
Upper limit of normal
WBC
White blood cells
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
16(88)
1.
INTRODUCTION
1.1
Background and rationale for conducting this study
Avibactam is a novel, non β-lactam, β-lactamase inhibitor.  Although avibactam itself 
possesses no intrinsic antibacterial activity, it has been shown to restore in vitro activity of 
ceftazidime against Class A, Class C and some Class D β lactamase-producing pathogens 
including those commonly associated with complicated intra-abdominal infections (cIAIs) and 
complicated urinary tract infections (cUTIs).  Avibactam, when combined with ceftazidime, 
has also been shown to be active against strains that express a combination of β-lactamase 
types, as well as strains that are concomitantly resistant to other antibacterial classes such as 
fluoroquinolones.  
Beta-lactamase inhibition by avibactam is effected through the formation of a stable covalent 
carbamoyl linkage to the enzyme complex.  It inhibited Class A and Class C β-lactamases by 
50% at lower concentrations than other currently marketed β-lactamase inhibitors such as 
clavulanic acid, tazobactam, and sulbactam.  In addition, avibactam is a potent inhibitor of 
Class C enzymes whereas clavulanic acid, tazobactam, and sulbactam lack any activity against 
this class of enzymes.  Unlike currently available β-lactamase inhibitors, avibactam does not 
induce β-lactamase production.  
Avibactam inhibited Klebsiella pneumoniae carbapenemase (KPC)-2 β-lactamase in vitro and 
restored ceftazidime susceptibility to Enterobacteriaceae-harboring KPC-2 or KPC-3 
β-lactamase (Stachyra et al 2009).  The potent in vitro activity of the ceftazidime and 
avibactam (CAZ-AVI) combination against Enterobacteriaceae-producing Class A, and 
Class C, β-lactamases has been confirmed in vivo in murine pneumonia, septicaemia, and 
pyelonephritis models.  
Currently the options for the treatment of Gram-negative infections, especially multi-drug 
resistant strains including extended-spectrum β-lactamase producers, are extremely limited.  
Until recently, there have been no new investigational compounds under early or late 
development specifically targeted to combat these organisms.  Hence, the availability and 
development of new agents to treat these infections will be a welcome addition to the existing 
treatments.  
Details of the CAZ-AVI clinical development programme to date can be found in 
Section 5.2.2 of the CAZ-AVI Investigator’s Brochure.  
The purpose of this study is to assess the safety, tolerability and descriptive efficacy of 
CAZ-AVI plus metronidazole versus meropenem in patients aged from 3 months to less than 
18 years with cIAI.  Data from this study will be compared to similar data generated in adult 
patients so as to be able to extrapolate efficacy and tolerability to children.  The dosing 
regimen(s) has been chosen based on the paediatric pharmacokinetic (PK) study and 
PK/pharmacodynamic (PD) modelling of the exposure, required for the successful treatment 
of infections used in Phase 3 adult studies.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
17(88)
1.2
Rationale for study design, doses and control groups
This study will be a single blind, randomised, multi-centre, active controlled trial. 
Single blind study observer is a well-accepted study design in a paediatric population.  
Children are a vulnerable population and need close clinical monitoring by unblinded 
observers to interject when needed whilst the Blinded Observer will assess the safety and the 
clinical cure without bias.  Given the risk to patients and severity of disease, a 
placebo-controlled trial would not be ethically appropriate.  
The study is designed to include patients <1 year of age who are born at term only (defined as 
a gestational age ≥37 weeks).  Maturation during foetal life and after birth is a process 
involving all organs and functions of the growing human.  As such, all the main steps of drug 
disposition (absorption, distribution, metabolism, catabolism, elimination/excretion) may be 
under the influence of still incomplete morphological stages.  An incompletely absorbed 
compound may be less effective whereas a poorly metabolized and/or excreted compound 
may result in an increased risk of toxicity.  Both risks will have to be evaluated.  Better 
understanding of the maturing kidney should help to anticipate possible early and late adverse 
effects of drugs in neonatal populations.  Nephrogenesis is completed by the end of 34th week 
of gestation and the kidney of a full-term neonate (ie, between 37 and 41 weeks of gestation) 
possesses a full set of nephrons and adult levels of glomerular filtration rate are reached 
between 1 and 2 years of age.  Therefore, patients <1 year of age who were born pre-term are 
excluded from this study.
This study will be conducted in hospitalised patients with cIAI requiring surgical intervention 
and treatment with intravenous (IV) antibiotics.  The CAZ-AVI doses in this trial have been 
selected to achieve similar exposures reached in the Phase 3 studies in adults (D4280C00001 
and D4280C00005), with the intention of reaching the same level of efficacy (for further 
details regarding the dose selection rationale, please refer to the CAZ-AVI Investigator’s 
Brochure).
Complicated intra-abdominal infections are typically polymicrobial, potentially involving 
anaerobes such as the Bacteroides fragilis group.  Metronidazole will be added to CAZ-AVI 
to provide coverage for anaerobic organisms.  The spectrum of activity of CAZ-AVI when 
combined with metronidazole is well suited to treatment of pathogens commonly responsible 
for cIAIs.  
Meropenem is approved and widely used for the safe treatment of cIAIs, and carbapenems are 
considered the drugs of choice for treating infections due to extended spectrum 
β-lactamase-producing Gram-negative bacilli.  The dose/regimen of meropenem to be used in 
this trial is described in Section 7.
1.3
Benefit/risk and ethical assessment
This study is the first study with therapeutic intent for CAZ-AVI in children with cIAIs; 
however, the doses of CAZ-AVI have previously shown to achieve similar exposures in adults 
and children, so efficacy of CAZ-AVI in children is likely.  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
18(88)
Cohort 4 (≥3 months to <2 years) includes very young patients (aged from 3 months to 
<6 months) who are particularly vulnerable in terms of lack of a physiological reserve and 
rapid maturation of organs.  Therefore, in order to ensure that exposure (maximum 
concentration and area under the curve) was minimised in this group, while also still assuring 
robust predictions of sufficient exposure above the PK/PD target, Cohort 4 was divided into 
2 parts for further analysis for dose selection: Cohort 4a (from 1 year to <2 years) and 
Cohort 4b (≥3 to <1 year).  This analysis indicated that a lower dose of 40 mg/kg 
ceftazidime/10 mg/kg avibactam reduces exposure in Cohort 4b, while still providing very 
high predictions of sufficient exposure above the PK/PD target (≥98% probability of target 
attainment) in patients with normal renal function and patients with mild renal impairment. 
Thus, for the purposes of dosing in this study, Cohort 4 is split into Cohort 4a, who will 
receive the same dose as Cohort 2 (50 mg/kg ceftazidime/12.5 mg/kg avibactam, every 
8 hours), and Cohort 4b, who will receive 50 mg/kg ceftazidime/12.5 mg/kg avibactam, every 
8 hours for patients from 6 months to <1 year of age, and 40 mg/kg ceftazidime/10 mg/kg 
avibactam for patients from 3 months to <6 months of age.
The doses for use in patients with renal impairment have been chosen on the basis of 
modelling and simulation to achieve similar exposures of both ceftazidime and avibactam to 
those in adults with normal or mild renal impairment and predictions of sufficient exposure 
above the PK/PD target.
Patients enrolled into this clinical study will have cIAIs that are of sufficient severity to 
require hospitalisation and treatment with IV antibiotics.  The potential benefit to patients 
participating in this study is that they will receive effective antibiotic therapy for their 
infection.  The potential benefit of this study, in general, is the identification of a novel 
antibiotic combination product that is a safe and effective treatment for cIAIs in the paediatric 
population, in the face of the changing pattern of antibiotic resistance. The safety and 
tolerability of CAZ-AVI was established in a Phase 1 study in children from 3 months to 
<18 years, during which the exposures were similar to those observed in adults.
It is possible that CAZ-AVI may not be as effective a treatment as the comparator for 
treatment of cIAIs.  Although this risk is mitigated partly by the addition of metronidazole to 
provide coverage for anaerobic infections and in that the study patients will be closely 
monitored and managed with appropriate therapies as determined by the Investigator 
providing treatment. Furthermore, drug-drug interaction studies conducted between CAZ-AVI 
and metronidazole did not demonstrate any drug interaction or adverse safety impact.
A Phase 3, randomised, multicentre, double-blind, double-dummy, parallel-group, 
comparative study to determine the efficacy, safety, and tolerability of CAZ-AVI plus 
metronidazole versus meropenem was conducted in the treatment of cIAIs in hospitalised 
adults, aged 18 to 90 years. The treatment duration was 5 to 15 days (RECLAIM study).  The 
doses administered were IV CAZ-AVI (500 mg avibactam and 2000 mg ceftazidime), 
immediately followed by 500 mg IV metronidazole, or 1000 mg IV meropenem, and 
529 patients in each treatment arm received study treatment.   Study treatments were
administered every 8 hours. CAZ-AVI was non-inferior compared with meropenem. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
19(88)
CAZ-AVI plus metronidazole was effective in treating infections due to Gram-negative 
pathogens resistant to ceftazidime with response rates similar to that seen with ceftazidime-
susceptible isolates.  The adverse events (AEs) were generally mild or moderate in severity and 
the overall frequency and pattern of AEs were comparable between the treatment groups. 
Analysis of the safety topics of interest did not reveal any new safety concerns.
Another Phase 3 study was an open-label, randomised, multicentre, study of CAZ-AVI and 
Best Available Therapy (BAT) for the treatment of infections due to ceftazidime-resistant 
Gram-negative pathogens, which was conducted in 333 adults aged 18 to 90 years diagnosed 
with cIAI or cUTI.  The dose administered was 2000 mg ceftazidime/500 mg avibactam IV
over 2 hours. Those patients diagnosed with cIAI received an additional dose of 500 mg 
metronidazole IV. Study treatments were repeated every 8 hours and the treatment duration 
was 5 to 21 days. In terms of the primary objective to estimate the per-patient clinical 
response to CAZ-AVI and BAT at the Test of Cure (TOC) visit, the estimated clinical cure 
rate at the TOC visit was 90.9% for CAZ-AVI and 91.2% for BAT. In the mMITT analysis
set, the per-patient favourable microbiological response rate for patients with cUTI at the TOC 
visit was higher in the CAZ-AVI group than in the BAT group (81.9% versus 64.2%, 
respectively). 
There were no definitive conclusions of any treatment-related trends in patients with cIAI, 
and there were no obvious safety concerns identified from the data available. In the patients 
with cUTI, the proportion who experienced an AE up to the Late Follow-up (LFU) visit was 
28.3% in the CAZ-AVI group and 35.3% in the BAT group.  For patients with cUTI and cIAI, 
the majority of AEs were mild or moderate in intensity. Up to the LFU visit, the incidence of 
serious adverse events (SAEs) was low and balanced across treatment groups (5.5% in the 
CAZ-AVI group and 6.0% in the BAT group).  All SAEs were assessed as not causally
related to the study treatment by the Investigator. The number of patients with AEs of special 
interest (AEoSI) was generally low and balanced across treatment groups, with the exception 
of diarrhoea in patients with cUTI, which was higher in the BAT group (5.9% and 2.0%, for 
BAT and CAZ-AVI, respectively).  No new safety concerns were identified from the safety
topics of interest. The frequency of potentially clinically significant changes in clinical 
laboratory tests was also low and balanced across treatment groups. There were no Hy's Law 
cases.
A Phase 2 study (NXL104/2001) examining the safety of CAZ-AVI versus imipenem 
cilastatin followed by appropriate oral therapy as a comparator was conducted in 137 patients 
aged 18 to 90 years with cUTIs.  In this study patients were randomised 1:1 and given 500 mg 
ceftazidime and 125 mg avibactam IV every 8 hours or 500 mg imipenem cilastatin IV every 
6 hours.  Approximately 35% of patients in the CAZ-AVI group and 42% of patients in the 
imipenem cilastin group experienced a local reaction at the IV infusion site.  The majority of 
the infusion site reactions were mild or moderate in intensity.  One patient in the imipenem 
cilastatin group experienced a severe local reaction (induration, swelling).  The most common 
infusion-related events across the treatment arms were erythema, pain and tenderness.  Of 
note, patients in the CAZ-AVI group received 3 infusions per day, while patients in the 
imipenem cilastatin group received 4 infusions per day.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
20(88)
In the Phase 2 study (NXL104/2002) examining CAZ-AVI plus metronidazole versus 
meropenem as a comparator in patients with cIAIs, approximately 30% of participants in both 
the CAZ-AVI and meropenem comparator treatment groups experienced at least 1 symptom 
of local intolerability, with pain, erythema, swelling and tenderness reported most frequently 
across both groups.  The majority of infusion site events were mild.  There was a somewhat 
greater percentage of patients with infusion site events of moderate/severe intensity in the 
CAZ-AVI group, who also received IV metronidazole (17/101 patients [16.8%]) versus the 
meropenem group (11/102 patients [10.8%]).  Of note, patients in the CAZ-AVI plus 
metronidazole group received an infusion of 3 different agents per dose, whilst patients in the 
meropenem group received an infusion with 1 study drug per dose.
A Phase 1, open-label, single-dose study to characterise the pharmacokinetics (PK) of
CAZ-AVI and assess its safety and tolerability following a single IV dose was conducted in 
hospitalised paediatric patients aged 3 months to <18 years, receiving systemic antibiotic 
therapy for suspected or confirmed infection. The patients in this study were stratified by age 
and patients were enrolled in each cohort as follows: Cohort 1, patients aged ≥12 to 
<18 years; Cohort 2, patients aged ≥6 to <12 years; Cohort 3, patients aged ≥2 to <6 years; 
and Cohort 4, patients aged ≥3 months to <2 years (split into 2 groups of at least 4 patients 
each, ≥3 months to <1 year and ≥1 year to <2 years).  
Patients in Cohort 1 and any patients in Cohort 2 weighing ≥40 kg received a single IV dose of 
CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) administered as a single infusion 
over a 2-hour period on Day 1.  Patients in Cohort 2 weighing <40 kg received a single IV 
dose of CAZ-AVI (50 mg/kg ceftazidime and 12.5 mg/kg avibactam) administered as a single 
infusion over a 2-hour period on Day 1.  These doses were applicable for patients with normal 
renal function and mild renal insufficiency (creatinine clearance [CrCl] >50 to ≤80 mL/min).
In Cohorts 3 and 4, patients with normal renal function or mild renal insufficiency received a 
single IV dose of CAZ-AVI (50 mg/kg ceftazidime and 12.5 mg/kg avibactam) on Day 1. 
Each patient in the study received a single IV dose of CAZ-AVI administered as a continuous 
infusion over a 2-hour period.  There were 32 patients in the safety analysis set and 32 patients 
in the PK analysis set.
Concentration versus time overlay plots suggest that the plasma ceftazidime and avibactam 
concentration profiles were similar in all 4 cohorts across sampling time points.  
Review of the haematology, coagulation, clinical chemistry, and urinalysis laboratory values 
did not reveal any unexpected findings within patients or any trends across patients; there 
were no potentially clinically significant haematology, clinical chemistry, or liver function test 
values reported.  No patients met Potential Hy’s Law criteria.  Review of vital signs values 
and physical examination findings did not identify any new safety concerns.  There were no 
clinically significant changes in electrocardiograms (ECGs) reported.  The single IV dose of 
CAZ-AVI was well tolerated, with no new safety concerns identified in hospitalised paediatric 
patients.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
21(88)
The risk considerations for this study encompass the known and potential risks for CAZ-AVI 
and its component products avibactam and ceftazidime, as well as those risks associated with 
other treatments that may be administered as described in this protocol.  Other possible 
treatments include the marketed products metronidazole and meropenem.  As the risks for 
these marketed products are widely available in their respective prescribing information, these 
risks will not be discussed within this section.
The risks for CAZ-AVI have not been fully elucidated; however it is assumed that known or 
potential risks for CAZ-AVI should include those identified in the clinical studies with 
CAZ-AVI, avibactam alone, and also for ceftazidime alone.  Additional risk information for 
avibactam and CAZ-AVI is located in the CAZ-AVI Investigator’s Brochure.
The full risk profile for ceftazidime is described in the prescribing information for the product 
(refer to local ceftazidime product labelling).  Important risks as laid out in the warnings and 
precautions in product labelling for ceftazidime include:

Hypersensitivity reactions.  Though patients with hypersensitivity and serious allergic 
reactions to cephalosporins, carbapenem or other β-lactam antibiotics are excluded 
from the trial, first-time episodes of such reactions could occur.

Antibiotic-associated diarrhoea, Clostridium difficile diarrhoea, colitis, and 
pseudomembranous colitis

Bacterial overgrowth with non-susceptible organisms

Distal necrosis as a result of inadvertent intra-arterial administration of ceftazidime

Elevated levels of ceftazidime used in patients with renal impairment have been 
associated with neurological sequelae such as tremors, myoclonus, seizures, 
encephalopathy, and coma
Potential risks for CAZ-AVI include the occurrence of events seen with ceftazidime alone, but
that go beyond the frequency and/or severity of those seen with ceftazidime.  Local 
intolerance has been seen in the preclinical studies, and has been monitored in the clinical 
programme.  In the Phase 1 studies, erythema and haematoma at the administration site were 
reported.  
In regard to hypersensitivity reactions, there was 1 report in the CAZ-AVI clinical trials, 
where the clinical Investigator considered the events of skin rash and elevated liver function 
tests to be a possible hypersensitivity reaction because of the temporal relationship of the 
events to drug administration.  In the CAZ-AVI development programme, rashes have been 
reported.  Elevations of liver enzymes, independent of skin rashes or other potential signs of 
hypersensitivity, have also been reported.  
In summary, the known and potential risks of receiving the developmental antibiotic 
combination CAZ-AVI are expected to be similar to those seen with ceftazidime and 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
22(88)
cephalosporins in general.  Thus far, no unique risks have been identified for the avibactam 
component or the combination of CAZ-AVI.  The risks of the marketed antibiotics are 
considered acceptable.  Whilst it is anticipated that CAZ-AVI will have similar efficacy for 
the treatment of cIAIs, it is possible that efficacy will not be demonstrated.  For each patient in 
the trial, appropriate treatment of the cIAI is thus determined by the clinical Investigator based 
on the clinical response of the patient.
1.4
Study design 
This study will be a single blind, randomised, multi-centre, active controlled trial.  Patients 
aged from 3 months to less than 18 years with cIAIs will be randomised to 1 of 2 treatment 
groups (3:1 ratio): CAZ-AVI in combination with metronidazole versus meropenem.  Patients 
aged from 3 months to <1 year (Cohort 4b) must have been born at term (defined as 
gestational age ≥37 weeks).
A sufficient number of patients are to be randomised 3:1 for 80 patients to complete at least 
72 hours (3 full days, ie, 9 doses) of study treatment (ie, evaluable patients; at least 60 patients 
in the CAZ-AVI group and at least 20 patients in the meropenem group).
Patients will be allocated to 1 of 4 cohorts based on age.  Randomisation will be stratified as 
follows: 

Cohort 1: At least 15:5 evaluable patients aged from 12 years to <18 years

Cohort 2: At least 15:5 evaluable patients aged from 6 years to <12 years

Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 years

Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 years, 
comprising Cohorts 4a and 4b as follows:

Cohort 4a: Patients aged from 1 year to <2 years

Cohort 4b: Patients aged from 3 months to <1 year
Intravenous CAZ-AVI infusions will be given at doses based on age and weight with 
adjustment according to renal function as detailed in Table 5.
Patients whose CrCL drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the Case Report Form (CRF).  If possible, 
patients should still be followed for safety (see Section 3.9.1).  Because the CrCl 
determination is only an estimate of renal function, in instances where the CrCl is approaching 
thresholds that would require intervention such as a dose change or discontinuation of therapy 
(ie CrCL approaching 50 or 30 mL/min), the Investigator should use his or her discretion in 
determining (ie confirming the value by repeat testing, if feasible) whether an immediate dose 
change, a short period of continued observation, or discontinuation of therapy is warranted. If 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
23(88)
in the opinion of the Investigator there is a clinically significant reduction in a patient’s 
estimated CrCl during the treatment period, then the Investigator should contact the Medical 
Monitor to discuss the above mentioned options (immediate dose change, a short period of 
continued observation, or discontinuation of therapy). Additionally, in instances of rapidly 
changing renal function, the Investigator should increase the frequency of CrCl monitoring, 
depending on the patient’s clinical status, extent of renal function change and Investigator’s 
clinical evaluation.
The suggested dosing regimen of metronidazole is 10 mg/kg IV over 20 to 30 minutes every 
8 hours (±30 minutes), but it can also be prescribed/adjusted by the Investigator according to 
local labels.  The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ-AVI infusion. The dose/regimen of meropenem will be 20 mg/kg 
every 8 hours (±1 hour) infused over approximately 15 to 30 minutes or up to 1 hour (or 
infusion duration as per local guidelines).  For patients weighing over 50 kg, the maximum 
dose of meropenem should not exceed 1 g every 8 hours.  
Patients will receive IV treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before 
having the option to switch to an oral therapy, as specified in Section 7.7 below.  The decision 
to switch to oral therapy is entirely at the Investigator’s discretion, if the patient has good or 
sufficient clinical response, and the patient is tolerating oral fluids or food.  The total period of 
treatment (ie, IV drug and oral switch treatment) is to be between 7 and 15 days.  Patients may 
remain on the IV study treatment for the full 7 to 15 days.
Patients will be assessed for safety and efficacy throughout the study, and blood samples will 
be taken for PK assessment.  The duration of each patient’s participation in the study will be a 
minimum of 27 days to a maximum of 50 days after start of study treatment at which time 
there will be a LFU assessment visit.  The LFU is to be performed 20 to 35 days after the last 
dose of any treatment.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
24(88)
Figure 1
Study flow chart






Patients with cIAI
Randomisation 
(3:1) to CAZ-AVI 
plus metronidazole 
or meropenem* 
treatment
CAZ-AVI 
infused over 
2 hours, then 
metronidazole*
infused over 20 
to 30 minutes
Meropenem* 
20 mg/kg 
infused over 
approx. 15 to 
30 minutes or up 
to 1 hour**
End of IV 
drug or oral 
switch 
therapy
visit***
Test of Cure
visit
8 to 15 days 
after last 
dose of 
study drug 
(IV or oral)
Last Follow-up 
visit
27 to 50 days 
after start of 
study treatment
Screening
Treatment
Follow Up
*Optional switch to oral therapy permitted on or after Study Day 4 (ie, after 72 hours [3 full days, ie, 9 doses] of IV study drug.  Assessment should be 
performed no later than 8 hours after the 72-hour time point.  The decision to switch to oral therapy is entirely at the Investigator’s discretion, if the 
patient has good or sufficient clinical response, and the patient is tolerating oral fluids or food:
- Oral amoxicillin/clavulanic acid (only in countries where its use for children is permitted; according to local guidelines, administered at a dose and 
formulation per standard of care), or
- Oral ciprofloxacin (only in countries where its use for children is permitted; according to local guidelines, administered at a dose and formulation per 
standard of care) plus metronidazole (administered at a dose and formulation per standard of care), or
- Pathogen-based therapy (in discussion with the Medical Monitor), see Section 7.7.
The patient may continue on IV study drug for the entire duration of the study therapy (7 to 15 days), at the discretion of the Investigator.
** Or infusion duration as per local guidelines.  For patients weighing over 50 kg, the maximum dose of meropenem should not exceed 1 g every 
8 hours.  
*** Visit performed within 24 hours of completion of last infusion or within 48 hours after the last dose of oral switch therapy.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
25(88)
2.
STUDY OBJECTIVES
2.1
Primary objective (safety)
Primary Objective:
Outcome Measure:
Evaluate the safety and tolerability of 
CAZ-AVI plus metronidazole given at the 
selected dose regimen versus meropenem in 
paediatric patients aged ≥3 months to 
<18 years with cIAI

AEs and SAEs from the signing of the Informed 
Consent Form (ICF)/Assent Form to the LFU 
visit (27 to 50 days after start of study treatment)

Cephalosporin class effects and additional AEs 
(including, but not limited to seizures, 
C. difficile-associated diarrhoea, allergic 
reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function)

Clinical: vital signs (pulse, blood pressure, 
respiratory rate, temperature), ECG, and physical 
examinations

Laboratory: complete blood count with 
differential and comprehensive metabolic panel

CrCl 
2.2
Secondary objectives
Secondary Objective:
Outcome Measure:
Evaluate the descriptive efficacy of CAZ-AVI 
plus metronidazole versus meropenem in 
paediatric patients aged ≥3 months to 
<18 years with cIAI

Clinical outcomes at End of 72 hours’ Treatment, 
End of Intravenous Treatment (EOIV), End of 
Treatment (EOT), and TOC

Microbiological response at EOIV, EOT, TOC 
and LFU

Clinical relapse at LFU

Emergent infections
Evaluate the PK of CAZ-AVI in paediatric 
patients aged ≥3 months to <18 years with 
cIAI

PK data of ceftazidime and avibactam will be 
analysed separately

Plasma concentration will be listed and 
summarised by nominal sampling time window 
using appropriate descriptive statistics

PK parameters derived from population PK 
analysis and potential PK/PD relationships will 
be reported separately
2.3
Safety objectives 
Safety is the primary objective.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
26(88)
2.4
Exploratory objectives not applicable
3.
SUBJECT SELECTION, ENROLMENT, RANDOMISATION, 
RESTRICTIONS, DISCONTINUATION AND WITHDRAWAL 
Each patient should meet all of the inclusion criteria and none of the exclusion criteria for this 
study.  Under no circumstances can there be exceptions to this rule.
3.1
Inclusion criteria
For inclusion in the study patients should fulfil the following criteria:
1.
Must be ≥3 calendar months to <18 years of age.  Patients aged ≥3 calendar months 
to <1 year must have been born at term (defined as gestational age ≥37 weeks).
2.
Written informed consent from parent(s) or other legally acceptable 
representative(s), and informed assent from patient (if age appropriate according to 
local regulations)
3.
If female and has reached menarche, or has reached Tanner stage 3 development 
(even if not having reached menarche) (refer to Appendix E for further details on 
Tanner staging), the patient is authorised to participate in this clinical study if the 
following criteria are met:
At screening:
(i)
(a) Patient reports sexual abstinence for the prior 3 months or reports use of at least 
1 of the acceptable methods of contraception, including an intrauterine device (with 
copper banded coil), levonorgestrel intrauterine system (eg, Mirena®), or regular 
medroxyprogesterone injections (Depo-Provera®); or (b) Patient agrees to initiate 
sexual abstinence from the time of screening until 7 days after end of treatment with 
study drug; and
(ii)
Patient is advised to avoid conception from the time of screening until 7 days after 
receipt of study drug and agrees not to attempt pregnancy from the time of 
screening until 7 days after end of treatment with study drug; and
(iii)
Patient is provided guidelines regarding continuation of abstinence, initiation of 
abstinence, or about allowed contraception; and
(iv)
Patient has a negative serum β-human chorionic gonadotropin (β-hCG) test just 
prior to study entry.  Since serum tests may miss an early pregnancy, relevant 
menstrual history and sexual history, including methods of contraception, should be 
considered.  Note: if the result of the serum β-hCG test cannot be obtained prior to 
dosing of investigational product, a patient may be enrolled on the basis of a 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
27(88)
negative urine pregnancy test, though a serum β-hCG test result must still be 
obtained.
Note 1: Hormonal contraceptives delivered orally, as patches, or via vaginal devices should 
not be used as a method of birth control because the effect of CAZ-AVI on the efficacy of these 
types of contraceptives has not yet been established.  
Note 2: Barrier methods (such as male condom) can be used as a means of preventing 
sexually transmitted disease but are not acceptable as a means of contraception for this 
clinical trial.  
4.
Must, based on the judgment of the Investigator, require hospitalisation initially and 
antibacterial therapy for 7 to 15 days in addition to surgical intervention for the 
treatment of the current cIAI
5.
Require surgical intervention (eg, laparotomy, laparoscopic surgery or percutaneous 
drainage) to manage the cIAI 
6.
Must have clinical evidence of cIAI as follows:
(i)
Pre-operative enrolment inclusion:
(a) Requires surgical intervention that is expected to be completed within 24 hours 
of enrolment

Laparotomy, laparoscopy, or percutaneous drainage 
(b) Evidence of a systemic inflammatory response (at least 1):

Fever (defined as oral temperature >38.5°C, or equivalent to method used) or 
hypothermia (with a core body or rectal temperature <35°C, or equivalent to 
method used)

Elevated white blood cells (WBC) (>15000 cells/mm3)

C-reactive protein (CRP) levels (>10 mg/L)
(c) Physical Findings consistent with intra-abdominal infection, such as:

Abdominal pain and/or tenderness

Localised or diffuse abdominal wall rigidity

Abdominal mass
(d) Intention to send specimens from the surgical intervention for culture
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
28(88)
(e) (Optional) Supportive radiologic findings of intra-abdominal infection, such as 
perforated intraperitoneal abscess detected on: 

Computed tomography (CT) scan or

Magnetic resonance imaging (MRI) or

Ultrasound
(ii)
Intra-operative/postoperative enrolment inclusion (in cases of postoperative 
enrolment, must be within 24 hours after the time of incision):
Visual confirmation of intra-abdominal infection associated with peritonitis at 
laparotomy, laparoscopy or percutaneous drainage (to be confirmed pending 
feasibility); must have 1 of these diagnoses:
(a) Appendiceal perforation or peri-appendiceal abscess
(b) Cholecystitis with gangrenous rupture or perforation or progression of the 
infection beyond the gallbladder wall
(c) Acute gastric or duodenal perforations, only if operated on >24 hours after 
singular perforation occurs
(d) Traumatic perforation of the intestines, only if operated on >12 hours after 
perforation occurs
(e) Secondary peritonitis (but not spontaneous bacterial peritonitis associated with 
cirrhosis and chronic ascites)
3.2
Exclusion criteria
Patients should not enter the study if any of the following exclusion criteria are fulfilled:
1.
Involvement in the planning and/or conduct of the study (applies to both 
AstraZeneca staff and/or staff at the study site)
2.
Previous enrolment or randomisation in the present study
3.
Participation in another clinical study with an investigational product (IP) during 
the last 30 days before the first dose of IV study drug or have previously 
participated in the current study or in another study of CAZ-AVI (in which an 
active agent was received) 
4.
History of hypersensitivity reactions to carbapenems, cephalosporins, penicillin, 
other β-lactam antibiotics, metronidazole, or to nitroimidazole derivatives
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
29(88)
5.
Concurrent infection, that may interfere with the evaluation of response to the study 
antibiotics at the time of randomisation
6.
Patient needs effective concomitant systemic antibacterials (oral, IV, or 
intramuscular) in addition to those designated in the 2 study groups (CAZ-AVI plus 
metronidazole group or meropenem group) (see Section 7.8)
7.
Receipt of non-study systemic antibacterial drug therapy for cIAI, for a continuous 
duration of more than 24 hours during the 72 hours preceding the first dose of IV 
drug, except in proven resistant organisms and/or worsening of the clinical 
condition.  More than 2 consecutive doses are not permitted if the individual doses 
are expected to give >12 hours’ cover (ie, giving a total cover of >24 hours.) For 
patients enrolled after a surgical procedure, only 1 dose of non-study antibiotics is 
permitted postoperatively. 
8.
Patient is considered unlikely to survive the 6 to 8 week study period
9.
Patient is unlikely to respond to 7 to 15 days of treatment with antibiotics
10.
Patient is receiving haemodialysis or peritoneal dialysis
11.
Diagnosis of abdominal wall abscess confined to musculature of the abdominal wall 
or ischaemic bowel disease without perforation, traumatic bowel perforation 
requiring surgery within 12 hours of perforation, or perforation of gastroduodenal 
ulcers requiring surgery within 24 hours of perforation (these are considered 
situations of peritoneal soiling before the infection has become established)
12.
Simple (uncomplicated), non-perforated appendicitis or gangrenous appendicitis 
without rupture into the peritoneal cavity identified during a surgical procedure OR 
presence of primary peritonitis (ie, spontaneous bacterial peritonitis) or peritonitis 
associated with cirrhosis or chronic ascites
13.
At the time of randomisation, patient is known to have a cIAI caused by pathogens 
resistant to the study antimicrobials planned to be used in the study
14.
Presence of any of the following clinically significant laboratory abnormalities: 
(a)
Haematocrit <25% or haemoglobin <8 g/dL (<80g/L, <4.9 mmol/L) 
(b)
Serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3×the 
age-specific upper limit of normal (ULN), or total bilirubin >2×ULN (except 
known Gilbert’s disease)  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
30(88)
For a) and b): unless if these values are acute and directly related to the infectious process 
being treated.  
15.
Creatinine clearance <30 mL/min/1.73 m2 calculated using the child’s measured 
height (length) and serum creatinine within the updated “bedside” Schwartz formula 
(Schwartz et al 2009): 
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
16.
History of seizures, excluding well-documented febrile seizure of childhood
17.
Any situation or condition that would make the patient, in the opinion of the 
Investigator, unsuitable for the study (eg, would place a patient at risk or 
compromise the quality of the data) or may interfere with optimal participation in 
the study
18.
If female, currently pregnant or breast feeding
See Section 3.4 for procedures for withdrawal of incorrectly enrolled patients.
3.3
Subject enrolment and randomisation
Investigator(s) should keep a record, the patient screening log, of patients who entered 
pre-study screening.  Patients will be enrolled if they meet all the inclusion criteria, including 
informed consent and assent in writing from parent(s) or other legally-acceptable 
representative(s)/patient as applicable, and none of the exclusion criteria.  The Blinded 
Observer may perform screening and enrolment; however, the Investigator must perform 
randomisation. 
The Blinded Observer/Investigator will:
1.
Obtain signed informed consent from the parent or guardian/legally acceptable 
representative(s) of the potential patient and informed assent from the potential 
patient (if age appropriate according to local regulations) before any study specific 
procedures are performed
2.
Assign potential patient a unique enrolment number, beginning with ‘E#’
3.
Determine patient eligibility (see Sections 3.1 and 3.2)
4.
Investigator only: Assign eligible patient unique randomisation code (via an 
interactive voice/web response system [IXRS] not available for access by the 
Blinded Observer)
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
31(88)
Randomisation codes will be assigned strictly sequentially as patients become eligible for 
randomisation.
3.4
Procedures for handling incorrectly enrolled or randomised 
patients
Patients who fail to meet the eligibility criteria should not, under any circumstances, be 
enrolled or receive study medication.  There can be no exceptions to this rule.  Patients who 
are enrolled, but subsequently found not to meet all the eligibility criteria, must not be 
randomised or initiated on treatment, and must be withdrawn from the study.
Where a patient does not meet all the eligibility criteria but is randomised in error, or 
incorrectly started on treatment, the Investigator should inform the Medical Monitor
immediately, and a discussion should occur between the Medical Monitor and the Investigator 
regarding whether to continue or discontinue the patient from treatment.  The Medical 
Monitor must ensure all decisions are appropriately documented.
3.5
Methods for assigning treatment groups
Block randomisation using an IXRS will be used to assign patients in a ratio of 3:1 to the 
study treatment groups of CAZ-AVI plus metronidazole or meropenem, respectively, in each 
of the cohorts for the age groups (see Section 8.2 for a description of the sample size).
A representative of AstraZeneca, under the supervision of AstraZeneca statistical personnel, 
will perform this randomisation.  
3.6
Methods for ensuring blinding
This study will be observer-blinded.  Each investigational site will be required to have a 
site-specific Blinding Plan that describes site-specific precautions being taken to ensure that 
the study is observer-blinded, taking into account the specific patient care procedures, 
equipment, and information accessibility at that site.
At each investigational site, at least 1 blinded Investigator (referred to as “Blinded Observer”
hereafter) will not know the patient’s treatment assignment and will conduct clinical 
assessments related to safety and efficacy.  The Blinded Observer may perform screening and 
enrolment activities but will not be responsible for randomising patients (the Blinded 
Observer will not have access to the IXRS).  The Blinded Observer will not ask other 
members of the study team, the patient, or the patient’s parent(s)/legally acceptable 
representative(s) which study treatment is being given, and will avoid all attempts to uncover 
treatment assignment.  The Blinded Observer should arrange to see the patient during times 
when study drug is NOT being administered, and not when assessments are being performed 
that could possibly unblind the Blinded Observer, in order to maintain the blind.  If possible, 
the same Blinded Observer should complete all clinical assessments for a patient. The 
Blinded Observer should perform all causality assessments for all AEs and SAEs. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
32(88)
At each investigational site, an unblinded Investigator (referred to as “Investigator” hereafter), 
Pharmacist or designee, study centre personnel, patient, and parent(s)/legally acceptable 
representative(s) may be aware of which IV study drug therapy is being administered and 
shall be instructed not to reveal to the Blinded Observer which drug the patient is receiving. 
Refer to Section 3.7 if the Blinded Observer learns of the treatment assignment. 
3.7
Methods for unblinding 
Individual treatment codes, indicating the treatment randomisation for each randomised 
patient, will be available to the Investigator(s) or pharmacists from the IXRS.  Routines for 
this will be described in the IXRS user manual that will be provided to each centre.
This study has an observer-blinded design.  During the study, the Blinded Observer(s) will not 
make any effort to determine which IV study drug is being administered.  The details of 
blinding will be described in the Blinding Plan.
Only in the case of an emergency, when knowledge of the study drug is essential for the 
immediate clinical management or welfare of a specific patient and the Investigator or 
designee is not available to provide or cannot provide appropriate medical care to the patient, 
may the Blinded Observer be unblinded to the patient’s treatment assignment.
Before any unblinding of the Blinded Observer, it is strongly advised to discuss options with 
the Medical Monitor or appropriate study personnel.  As soon as possible, and without 
revealing the patient’s study treatment assignment (unless important to the safety of patients 
remaining in the study), the Blinded Observer or designee must notify PRA if the observer 
blind is broken for any reason and the Blinded Observer was unable to contact PRA before 
unblinding.  PRA will inform AstraZeneca of the incident.
3.8
Restrictions
Hormonal contraceptives which are potentially subject to drug-to-drug interaction, such as 
pills, patches, and intravaginal devices, are not acceptable methods of birth control during this 
study based on potential for antibiotics to alter gut flora, hormone absorption, and hormone 
effectiveness.  If an adolescent female study participant was previously using hormonal 
contraceptives such as pills, patches, and intravaginal devices, she should follow her health 
care provider’s specific recommendations for effective use of these methods after completing 
IV study therapy.  Such recommendations may address the need for a second method of 
contraception until the hormonal method becomes fully effective.
3.9
Discontinuation of investigational product
Patients may be discontinued from IP in the following situations:

Patient or patient’s parent(s)/legally acceptable representative(s) decision.  The patient 
or the patient’s parent(s) or other legally acceptable representative(s) is at any time 
free to decide to discontinue treatment, without prejudice to further treatment

AE (eg, risk to patients, as judged by the Investigator)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
33(88)

Positive pregnancy test at any time during the study treatment period

In the absence of any alternative explanation for an increase in the following 
abnormalities, individual patients should be withdrawn if the following hepatic/liver 
criteria are met:

ALT or AST >8×ULN

ALT or AST ≥3×ULN and either total bilirubin ≥2×ULN or evidence of 
coagulopathy.  Evidence of coagulopathy should be discussed with the PRA 
physician where possible

ALT or AST ≥3×ULN and with appearance of symptoms suggestive of new or 
progressive liver disease.  Symptoms suggestive of new or progressive liver 
disease should be discussed with the PRA physician where possible

Significant reduction in CrCl measurements as judged by the Investigator

CrCl value <30 mL/min

Severe non-compliance with study protocol, as judged by the Investigator

In the opinion of the Investigator, it is not in the best interest of the patient to continue 
study therapy and/or lack of efficacy
3.9.1
Procedures for discontinuation of a patient from investigational product 
At any time, patients or the patient’s parent(s) or other legally acceptable representative(s) are 
free to decide to discontinue the child’s use of IP or withdraw from the study (ie, IP and 
assessments – see Section 3.10), without prejudice to further treatment.  A patient or the 
patient’s parent(s) or other legally acceptable representative(s) who decides to discontinue IP 
will always be asked about the reason(s) and the presence of any AEs.  If possible, they will 
be seen and assessed by an Investigator(s).  
Adverse events and SAEs will be followed up (See Section 6).  For patients who discontinue 
IP early, their follow-up assessments should be collected (see Section 6.3.2 for follow-up of 
unresolved AEs).  Liver CRF modules should be completed for patients discontinued after 
meeting hepatic/liver criteria.  The patient should be scheduled for the EOIV visit within 
24 hours after IV study therapy discontinuation, ideally before starting any new antibiotic 
treatment.
If a patient is withdrawn from study, see Section 3.10.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
34(88)
3.10
Criteria for withdrawal 
3.10.1
Screen failures 
Screen failures are patients who have provided informed consent/assent and subsequently who 
do not fulfil the eligibility criteria for the study, and therefore must not be randomised.  These 
patients should have the reason for study withdrawal recorded as ‘Failed Eligibility Criteria’ 
(ie, patient does not meet the required inclusion/exclusion criteria).  This reason for study 
withdrawal is only valid for screen failures (not randomised patients).
3.10.2
Withdrawal of the informed consent
Patients or the patient’s parent(s) or other legally acceptable representative(s) are free to 
withdraw the child from the study at any time (IP and assessments), without prejudice to 
further treatment.
A patient or the patient’s parent(s) or other legally acceptable representative(s) who withdraws 
consent will always be asked about the reason(s) and the presence of any AEs.  The 
Investigator will follow up AEs outside of the clinical study. 
If a patient withdraws from participation in the study, then his/her enrolment/randomisation 
code cannot be reused. 
3.11
Discontinuation of the study
The study may be stopped if, in the judgment of AstraZeneca, trial patients are placed at 
undue risk because of clinically significant findings that:

Meet individual stopping criteria or are otherwise considered significant 

Are assessed as causally related to study drug 

Are not considered to be consistent with continuation of the study
Regardless of the reason for termination, all data available for the patients at the time of 
discontinuation of follow-up must be recorded in the CRF.  All reasons for discontinuation of 
treatment must be documented.
In terminating the study, the Sponsor will ensure that adequate consideration is given to the 
protection of the patients’ interests.
4.
STUDY PLAN AND TIMING OF PROCEDURES 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
35(88)
Table 1
Study plan detailing study procedures
Assessment or Procedure
Baseline1
Treatment
Follow-up
Day 12
Days
2 and 3
Days
4 to ≤153
EOIV4
EOT5
(Oral 
only)
TOC6
LFU7
ICF (and Assent Form, if applicable)8
X
Verify inclusion/exclusion criteria
X
Clinical
Medical and surgical history
X
Complete physical examination9
X
X After 72 hours’ 
treatment only
X
X
X
X10
Prior and concomitant medications 
(including lactating mother)11
X
X
X
X
X
X
X
X
Vital signs12
X
X
X
X
X
X
X
X10
ECG13
X
X
X
Record adjunctive therapeutic 
procedures (if performed)
X
X
X
X
X
X
X
Record radiological examinations14
X
Clinical outcome
X15 After 72 hours’ 
treatment only
X15
X15
X15
X16
AEs and SAEs17
X
X
X
X
X
X
X
X
Laboratory
Complete blood count with 
differential, chemistry panel, CrCl 
calculation, ESR, and optional CRP 18
X
If clinically 
indicated
X19
X20
If 
clinically 
indicated
X21
If 
clinically 
indicated
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
36(88)
Assessment or Procedure
Baseline1
Treatment
Follow-up
Day 12
Days
2 and 3
Days
4 to ≤153
EOIV4
EOT5
(Oral 
only)
TOC6
LFU7
Urine or serum pregnancy test22
X
X
Urine sample routine analysis23
X
If clinically indicated
Micro
Intra-abdominal fluid sample24
X
If clinically indicated
Blood sample for culture25
Blood cultures should be performed as clinically indicated.
PK
Blood for PK analyses26
X
Randomisation27
X
Study drug administration
X
X
X
X
Oral switch therapy administration 
(optional at Investigator’s discretion)
X
ESR=erythrocyte sedimentation rate
1.
Perform baseline assessments within 24 hours before first dose of IV study drug.
2.
Day 1 is the first day of IV study drug administration; subsequent study days are consecutive days.  Perform Day 1 assessments after administration of at 
least 1 dose of IV study drug.
3.
On Days 4 to ≤15, study drug administration applies to all patients and daily assessments are to be performed only for patients on IV study drug.
4.
Perform EOIV assessments in person by the Blinded Observer within 24 hours after completion of the last infusion of study drug or at time of premature 
discontinuation of study drug or early withdrawal from study (if on IV study drug).  Conduct the EOIV assessments in place of the regular study visit (eg, 
Days 4 to ≤15) assessments that would have been performed the day of that visit.  A patient may be eligible to switch to oral therapy on or after Day 4 
(Section 7.2); EOIV assessments must occur before starting oral switch therapy.
5.
Perform EOT assessments in person within 48 hours after the last dose of oral switch therapy or at time of premature discontinuation of study drug or 
early withdrawal from study (if on oral switch therapy). 
6.
Perform TOC assessments in person 8 to 15 days after last dose of any study drug (IV or oral).
7.
Perform LFU assessments 20 to 35 days after last dose of any study drug (IV or oral).  Conduct LFU via telephone for any patient who has not 
experienced clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop AEs or SAEs since TOC. If symptoms of relapse or new AEs 
or SAEs are noted, or at the discretion of the Blinded Observer or Investigator, the patient should be immediately scheduled for an in-person visit.
8.
Obtain informed consent from parent(s) (or other legally acceptable representative[s]) in writing and informed assent from patient (if age appropriate 
according to local requirements) before initiating any study assessments or procedures.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
37(88)
9.
Height measured at Baseline only.  Weight measured at Baseline only, but should be measured at subsequent time points if clinically indicated and 
feasible.  Physical examination to be performed after completion of 72 hours’ treatment (either Day 3 or Day 4, depending on timing of treatment 
administration).  Assessment should be performed no later than 8 hours after the 72-hour time point. 
10. Not applicable if visit conducted by telephone.
11. For patients who are breast fed, all medications taken by the lactating mother in the previous 2 weeks prior to the first dose of study therapy until LFU 
will also be recorded.
12. Temperature, respiratory rate, pulse and blood pressure, by the appropriate method for the patient’s age.  To be performed before ECG on days when both 
assessments are indicated. 
13. Baseline ECG to be performed prior to obtaining blood samples for laboratory testing.  Day 1 ECG to be performed within 30 minutes following the end 
of the first study treatment infusion.  Electrocardiograms will be taken after the patient has been resting in a recumbent position for at least 10 minutes.
14. Radiological examinations are not required for the study, but the results should be recorded if done as part of the diagnosis.  Radiological examinations 
include WBC scans, plain abdominal radiographs, CT scans, ultrasound and/or MRI scans with or without contrast.
15. Blinded Observer: Assess clinical outcome per protocol, assessment after 72 hours of treatment. Assessment should be performed no later than 8 hours 
after the 72-hour time point (no assessment required on Day 2).
16. Blinded Observer: Assess patients for clinical relapse per protocol.  Emergent infections will be assessed up to LFU.
17. Investigator or Blinded Observer: Collect and report AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days after 
any dose of study drug (IV or oral) (or LFU, whichever is later); site staff are to follow unresolved AEs and SAEs at LFU until resolution or stabilisation.  
The causality assessment should be done by the Blinded Observer (not the Investigator) for all AEs and SAEs.
18. Laboratory tests indicated at Baseline do not need to be repeated if they were performed within 24 hours of the Baseline visit, unless clinically indicated.  
Perform local safety laboratory tests at additional time points as clinically indicated.  Erythrocyte sedimentation rate to be performed if clinically 
indicated or if required per standard of care.  C-reactive protein is an optional test and may be included if part of standard of care. C-reactive protein and 
CrCl calculation may be repeated at additional time points if clinically indicated.  Additionally, in instances of rapidly changing renal function, the 
Investigator should increase the frequency of CrCl monitoring, depending on the patient’s clinical status, extent of renal function change and the 
Investigator’s clinical evaluation. Direct Coombs test at Baseline and TOC only.  Test results of any samples taken as standard of care should be recorded 
in the CRF. 
19. Conduct on Day 7 if patient is still on IV study drug at that time.
20. If EOIV occurs within 48 hours after these assessments are performed on Study Day 7, do not repeat these assessments.
21. Perform at TOC only if patient had an abnormal (high/low flag) result on or after EOIV.
22. Perform test if patient is a female who has reached menarche or has reached Tanner stage 3 development (even if not having reached menarche).  If a 
pregnancy test is positive post baseline, follow reporting requirements in Section 6.6.  Note: if the result of the serum β-hCG test cannot be obtained prior 
to dosing of investigational product, a patient may be enrolled on the basis of a negative urine pregnancy test, though a serum β-hCG test result must still 
be obtained.  At TOC, a serum pregnancy test is required.  
23. At Baseline, before any antibiotics are administered. Subsequent additional time points if clinically indicated.
24. At Baseline, make every attempt to obtain intra-abdominal fluid sample preferably before any antibiotics administered. Subsequent time points if 
clinically indicated.
25. If clinically indicated and not already collected per standard of care.  
26. Blood samples for PK (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3, 4a, and 4b) will be collected from patients 
randomised to CAZ-AVI plus metronidazole treatment on Day 3 following a dose administration that is convenient for the plasma sample collections at 
the following time points: anytime within 15 minutes prior to or after stopping CAZ-AVI infusion, anytime between 30 minutes and 90 minutes after 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
38(88)
stopping CAZ-AVI infusion, and anytime between 300 minutes (5 hours) and 360 minutes (6 hours) after stopping CAZ-AVI infusion.  Every attempt 
should be made to obtain at least 1 sample from each of the 3 time windows for each patient.  Blood samples should be taken in a manner such that the 
Blinded Observer remains blinded.
27. Verify that the patient meets all study inclusion and no exclusion criteria before randomisation.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
39(88)
4.1
Enrolment/screening period
Procedures will be performed according to the Study Plan (Table 1).  Details of study 
assessments are provided in Section 5.
At screening, consenting/assenting patients will be assessed to ensure that they meet eligibility 
criteria.  Patients who do not meet these criteria must not be enrolled in the study.  Baseline 
assessments must be performed within 24 hours of administration of the first dose of IV study 
drug.  The following assessments will be performed at Baseline: 

Provision of informed consent/assent and verification of inclusion and exclusion 
criteria.  Informed consent should be obtained from the parent(s) (or other legally 
acceptable representative[s]) in writing and informed assent from the patient (if age 
appropriate according to local requirements) before initiating any study assessments or 
procedures.

Medical and surgical history

Complete physical examination, including height and weight

Prior and concomitant medication recording, including medications taken by the 
mother if the infant is breast feeding.  Prior medications include all prescription and
over-the-counter medications being taken by the patient (and lactating mother, if 
patient is breast fed) for the 2 weeks prior to study entry.

Vital signs (temperature, respiratory rate, pulse and blood pressure, by the appropriate 
method for the patient’s age).  To be performed before the ECG.

ECG (to be performed prior to obtaining blood samples for laboratory testing)

Record radiologic examinations

AEs and SAEs to be collected from the time of provision of informed consent/assent

Complete blood count with differential, Direct Coombs test, chemistry panel, ESR (if 
clinically indicated or if required per standard of care), CrCl calculation, and optional 
CRP.  Note: Laboratory tests indicated at Baseline do not need to be repeated if they 
were performed within 24 hours of the Baseline visit, unless clinically indicated.  
C-reactive protein is an optional test and may be included if part of standard of care.  
C-reactive protein and CrCl calculation may be repeated at additional time points if 
clinically indicated. Additionally, in instances of rapidly changing renal function, the 
Investigator should increase the frequency of CrCl monitoring, depending on the 
patient’s clinical status, extent of renal function change and the Investigator’s clinical 
evaluation.  Test results of any samples taken as standard of care should be recorded in 
the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
40(88)

Urine or serum pregnancy test applicable only to female patients who have reached 
menarche or have reached Tanner stage 3 development (even if not having reached 
menarche).  If a pregnancy test is positive post-baseline, follow reporting requirements 
in Section 6.6.  Note: if the result of the serum β-hCG test cannot be obtained prior to 
dosing of IP, a patient may be enrolled on the basis of a negative urine pregnancy test, 
though a serum β-hCG test result must still be obtained.

Urine sample for routine analysis 

Intra-abdominal fluid sample collection (preferably before administration of any 
antibiotics)

Blood sample for culture (if clinically indicated and not already collected per standard 
of care)

Randomisation via IXRS only after verification of all inclusion and exclusion criteria
4.2
Treatment period
The procedures for this period are listed in the Study Plan (Table 1).  Details of study 
assessments are provided in Section 5.
4.2.1
Day 1
Day 1 is the first day of IV study drug administration; subsequent study days are consecutive 
days.  Day 1 assessments should be performed after administration of at least 1 dose of IV 
study drug.  The following will be performed: 

IV study drug administration: CAZ-AVI plus metronidazole or meropenem; see 
Section 7.2 for dosing and treatment regimens

Recording of concomitant medications, including mother if patient is breast fed

Vital signs (to be performed before the ECG)

ECG within 30 minutes following the end of the first study treatment infusion

Recording of any adjunctive therapeutic procedures performed

If clinically indicated: CrCl calculation, urine sample for routine analysis, 
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional), weight (if feasible). Additionally, in instances of rapidly changing renal 
function, the Investigator should increase the frequency of CrCl monitoring, depending 
on the patient’s clinical status, extent of renal function change and the Investigator’s 
clinical evaluation.  Test results of any samples taken as standard of care should be 
recorded in the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
41(88)

Recording of any AEs/SAEs
4.2.2
Days 2 and 3
The following will be performed: 

IV study drug administration

Complete physical examination after completion of 72 hours’ treatment only.  This 
assessment may be performed on Day 4, depending on the timing of treatment 
administration.  Assessment should be performed no later than 8 hours after the 
72-hour time point.

Recording of concomitant medications, including mother if patient is breast fed

Vital signs 

Recording of any adjunctive therapeutic procedures performed

Assessment of clinical outcome after 72 hours’ treatment. Assessment should be 
performed no later than 8 hours after the 72-hour time point (assessment is not 
required on Day 2).  See Section 8.5.2.2 for definitions of clinical outcomes.

Recording of any AEs/SAEs

If clinically indicated: CrCl calculation, urine sample for routine analysis,
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional), weight (if feasible). Additionally, in instances of rapidly changing renal 
function, the Investigator should increase the frequency of CrCl monitoring, depending 
on the patient’s clinical status, extent of renal function change and the Investigator’s 
clinical evaluation.  Test results of any samples taken as standard of care should be 
recorded in the CRF.

Blood sampling for PK analysis from patients randomised to CAZ-AVI plus 
metronidazole treatment on Day 3 only.  To be performed following a dose 
administration that is convenient for the plasma sample collections at the following 
time points: anytime within 15 minutes prior to or after stopping CAZ-AVI infusion, 
anytime between 30 minutes and 90 minutes after stopping CAZ-AVI infusion, and 
anytime between 300 minutes (5 hours) and 360 minutes (6 hours) after stopping 
CAZ-AVI infusion.  Every attempt should be made to obtain at least 1 sample from 
each of the 3 time windows for each patient.
4.2.3
Days 4 to ≤15
On Days 4 to ≤15, study drug administration applies to all patients and daily assessments are 
to be performed only for patients on IV study drug.  Patients will receive IV treatment for a 
minimum of 72 hours (3 full days, ie, 9 doses) before having the option to switch to an oral 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
42(88)
therapy as specified in Section 7.7 below.  The decision to switch to oral therapy is entirely at 
the Investigator’s discretion, if the patient has good or sufficient clinical response, and the 
patient is tolerating oral fluids or food.  Patients can continue to take IV CAZ-AVI up to 
Day 15.  The following will be performed: 

IV study drug or oral switch therapy administration

Complete physical examination after completion of 72 hours’ treatment only.  This 
assessment may be performed on Day 3, depending on the timing of treatment 
administration.  Assessment should be performed no later than 8 hours after the 
72-hour time point.

Recording of concomitant medications, including mother if patient is breast fed

Vital signs 

Recording of any adjunctive therapeutic procedures performed

Recording of any AEs/SAEs

Complete blood count with differential, chemistry panel, and CrCl calculation to be 
conducted on Day 7 if the patient is still receiving IV study drug at that time  

If clinically indicated: urine sample for routine analysis, intra-abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional), weight (if feasible). 
Additionally, in instances of rapidly changing renal function, the Investigator should 
increase the frequency of CrCl monitoring, depending on the patient’s clinical status, 
extent of renal function change and the Investigator’s clinical evaluation.  Test results 
of any samples taken as standard of care should be recorded in the CRF.
4.2.4
End of IV treatment
EOIV assessments should be performed in person by the Blinded Observer within 24 hours 
after completion of the last infusion of study drug or at the time of premature discontinuation 
of study drug or early withdrawal from study (if on IV study drug).  The EOIV assessments 
should be conducted in place of the regular study visit (eg, Days 4 to ≤15) assessments that 
would have been performed the day of that visit.  A patient may be eligible to switch to oral 
therapy on or after Day 4 (Section 7); EOIV assessments must occur before starting oral 
switch therapy.  The following will be performed: 

Complete physical examination

Recording of concomitant medications, including mother if patient is breast fed

Vital signs

Recording of any adjunctive therapeutic procedures performed
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
43(88)

If clinically indicated: urine sample for routine analysis, intra-abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional), weight (if feasible). 
Additionally, in instances of rapidly changing renal function, the Investigator should 
increase the frequency of CrCl monitoring, depending on the patient’s clinical status, 
extent of renal function change and the Investigator’s clinical evaluation.  Test results 
of any samples taken as standard of care should be recorded in the CRF.

Assessment of clinical outcome

Recording of any AEs/SAEs

Complete blood count with differential, chemistry panel, and CrCl calculation. If 
EOIV occurs within 48 hours after these assessments are performed on Study Day 7, 
these assessments should not be repeated.  

Oral switch therapy administration
4.2.5
End of Treatment (oral switch therapy)
The assessments at EOT should be performed in person within 48 hours after the last dose of 
oral switch therapy or at the time of premature discontinuation of oral switch therapy or early 
withdrawal from study (if on oral switch therapy).  If a patient does not switch to oral therapy, 
the EOIV assessments should be conducted instead of the EOT assessments.  For patients 
receiving oral switch therapy only, the following will be performed: 

Complete physical examination

Recording of concomitant medications, including mother if patient is breast fed

Vital signs

Recording of any adjunctive therapeutic procedures performed

If clinically indicated: CrCl calculation, urine sample for routine analysis, 
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional), weight (if feasible). Additionally, in instances of rapidly changing renal 
function, the Investigator should increase the frequency of CrCl monitoring, depending 
on the patient’s clinical status, extent of renal function change and the Investigator’s 
clinical evaluation.  Test results of any samples taken as standard of care should be 
recorded in the CRF.

Assessment of clinical outcome

Recording of any AEs/SAEs
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
44(88)
4.3
Follow-up period
The procedures for this period are listed in the Study Plan (Table 1).  Details of study 
assessments are provided in Section 5.
4.3.1
Test of Cure
The assessments at the TOC visit should be performed in person 8 to 15 days after last dose of 
any study drug (IV or oral).  The following will be performed:

Complete physical examination

Recording of concomitant medications, including mother if patient is breast fed

Vital signs

ECG (to be performed after the vital signs)

Recording of any adjunctive therapeutic procedures performed

If clinically indicated: urine sample for routine analysis, intra-abdominal fluid sample 
for culture, blood sample for culture, ESR, CRP (optional), weight (if feasible). 
Additionally, in instances of rapidly changing renal function, the Investigator should 
increase the frequency of CrCl monitoring, depending on the patient’s clinical status, 
extent of renal function change and the Investigator’s clinical evaluation.  Test results 
of any samples taken as standard of care should be recorded in the CRF.

Assessment of clinical outcome

Recording of any AEs/SAEs

Complete blood count with differential, chemistry panel, and CrCl calculation to be 
performed only if the patient had an abnormal (high or low) result at or after EOIV.  

Direct Coombs test

Serum pregnancy test
4.3.2
Late Follow-up
Assessments at LFU should be performed 20 to 35 days after last dose of any study drug (IV 
or oral).  The LFU visit may be conducted via telephone for any patient who has not 
experienced clinical relapse, did not have ongoing AEs or SAEs at TOC, or did not develop 
AEs or SAEs since TOC.  If symptoms of relapse or new AEs or SAEs are noted, or at the 
discretion of the Blinded Observer or Investigator, the patient should be immediately 
scheduled for an in-person visit.  The following will be assessed at LFU: 

Complete physical examination (not applicable if visit conducted by telephone)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
45(88)

Recording of concomitant medications, including mother if patient is breast fed

Vital signs (not applicable if visit conducted by telephone)

Recording of any adjunctive therapeutic procedures performed

If clinically indicated: CrCl calculation, urine sample for routine analysis, 
intra-abdominal fluid sample for culture, blood sample for culture, ESR, CRP 
(optional), weight (if feasible). Additionally, in instances of rapidly changing renal 
function, the Investigator should increase the frequency of CrCl monitoring, depending 
on the patient’s clinical status, extent of renal function change and the Investigator’s 
clinical evaluation.  Test results of any samples taken as standard of care should be 
recorded in the CRF.

Assessment of clinical relapse

Recording of any AEs/SAEs
5.
STUDY ASSESSMENTS
5.1
Efficacy assessments 
Clinical outcome, relapse, and emergent infections will be assessed by the Blinded Observer 
at the time points specified in Table 1.  The Blinded Observer will assess clinical outcome, 
(including at LFU, assessment of patients for clinical relapse) and collection and reporting of 
AEs and SAEs from signing of the ICF (and Assent Form if applicable) until at least 30 days 
after any dose of study drug (IV or oral) or LFU. 
5.2
Microbiological assessments
Culture and organism identification should be performed at the local or regional laboratory, as 
applicable.  Susceptibility testing should be done at the local or regional laboratory to support 
patient care.  All isolates should be sent to the central laboratory for organism identification 
and susceptibility testing.
Refer to the study-specific clinical and microbiology laboratory manual for specific 
procedures pertaining to the collection, processing, storage, and shipment of intra-abdominal 
fluid and blood culture samples or isolates.
5.2.1
Intra-abdominal fluid for microbiological culture
Intra-abdominal fluid samples (such as tissue or aspirate suitable for isolation of both aerobic 
and anaerobic bacteria) should be obtained for culture at Baseline (preferably before any 
antibiotics are administered) for all patients and at any time until LFU, if clinically indicated 
and performed as part of the patient’s regular medical care.  Baseline intra-abdominal fluid 
samples for culture must be obtained from the site of abdominal infection during surgical 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
46(88)
intervention.  Intra-abdominal fluid samples should be collected only when collection of a 
sample is medically feasible.  If a sample is collected, isolation of bacteria and susceptibility 
testing on identified bacteria should be done by the local or regional laboratory per the 
laboratory’s standard processes. In cases where the number of potential pathogens seen in the 
initial culture is numerous, the local or regional laboratory should follow standard processes in 
identifying pathogens causing the intra-abdominal infection. All pathogens prepared and 
evaluated should be sent to the central laboratory for reconfirmation.  
5.2.2
Blood samples for microbiological culture
If clinically indicated, blood samples (1 mL) may be obtained for culture at Baseline 
(preferably before any antibiotics are administered) and at any time until LFU.  
This protocol complies with European Union’s recommendations for blood loss associated 
with paediatric research (European Commission 2008) and the World Health Organisation 
guidelines “Blood Sample Volumes in Child Health Research: Review of Safe Limits” 
(Howie 2011).  To minimise risk from blood loss associated with this study, standard of care 
laboratory results will be used whenever possible.  In addition, paediatric blood collection 
tubes will be used and capillary methods of blood draw will be implemented whenever 
feasible.  PK samples will be collected from patients unless deemed unsafe due to the risk 
from additional blood loss (per the Investigator’s judgment).
5.3
Safety assessments
5.3.1
Laboratory safety assessments
Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis 
will be taken at the times indicated in Table 1.
The following laboratory variables will be measured:
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
47(88)
Table 2
Laboratory safety variables
Comprehensive Metabolic 
Panel 
Haematology
Urinalysis
Magnesium
Haematocrita
Urinalysis (routine and 
microscopy) will be performed 
according to the study centre’s 
standard procedures
Bicarbonate
Haemoglobin
Sodium
Erythrocyte count
Potassium
Mean cell volume
Phosphorus
Leukocyte count (WBC)
Chloride
Neutrophils
Calcium
Lymphocytes
Alkaline phosphatase
Monocytes
Gamma glutamyltransferase
Eosinophils
ALT
Basophils
AST
Platelets
Creatine kinase
Immunohaematology
Lactate dehydrogenase
Coombs test (direct)
Total bilirubin
Pregnancy testing
Indirect bilirubin
Serum β-hCG (females only)
Glucose, non-fasting
Inflammation index
Creatinine
CRP (optional)
Blood urea nitrogen
Erythrocyte sedimentation rateb
Note: any other laboratory parameter that is deemed to be important as per local practices can be assessed if 
considered necessary, but will not be part of the required laboratory parameters as per protocol.  
Assessment of any additional laboratory parameters should not impact the blood volume to be drawn. 
a
If a patient’s haemoglobin or haematocrit decreases significantly (in the Investigator’s judgment) after 
administration of the CAZ-AVI infusion, a workup for haemolytic anaemia should be performed per 
standard of care. 
b
To be collected if clinically indicated or if required per standard of care.
Additional safety samples may be collected if clinically indicated at the discretion of the 
Investigator.  The date, time of collection and results (values, units and reference ranges) will 
be recorded on the appropriate CRF.
The clinical chemistry, haematology and urinalysis will be performed at a local laboratory at 
or near to the Investigator site.  Sample tubes and sample sizes may vary depending on 
laboratory method used and routine practice at the site.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
48(88)
The Direct Coombs test is required at Baseline and TOC only. 
The Investigator should make an assessment of the available results with regard to clinically 
relevant abnormalities.  The laboratory results should be signed and dated and retained at 
centre as source data for laboratory variables.  For information on how AEs based on 
laboratory tests should be recorded and reported, see Section 6.3.
NB. If a patient shows an AST or ALT ≥3×ULN or total bilirubin ≥2×ULN please refer to 
Appendix D for further instructions.
Creatinine clearance will be measured at Baseline and at each time that serum creatinine is 
being assessed as part of the clinical chemistry panel using the child’s measured height 
(length) and serum creatinine within the updated “bedside” Schwartz formula (Schwartz et al 
2009). It is recommended that serum creatinine, and therefore CrCl obtained using the 
Schwartz bedside formula, are assessed at additional time points if the Investigator deems that 
the test is required for the safety of the patient, based on previous results and the patient’s 
clinical condition, and if the additional test(s) does not exceed the maximum volume of blood 
allowed per protocol.  The Investigator should also consider the balance of the risk and benefit 
of taking additional samples when making the decision.  If a biochemistry panel is requested 
and serum creatinine can be added and evaluated without increasing the volume of blood 
allowed per protocol, the site should record the result in the CRF.  Note: measurement of 
height is not required at each point that CrCl is estimated: 
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
If there is a significant reduction (according to the Investigator) in a patient’s estimated CrCl 
during the treatment period, the Investigator should contact the Medical Monitor for 
discussion.
5.3.2
Physical examination 
A complete physical examination will be performed and will include an assessment of the 
following: general appearance, skin, head and neck  (including ears, eyes, nose and throat), 
lymph nodes, thyroid, respiratory, cardiovascular, abdomen, musculoskeletal (including spine 
and extremities) and neurological systems. Height and weight will be measured at Baseline 
only.  Weight may be measured at subsequent time points if clinically indicated and feasible.  
Body mass index (BMI) (kg/m2) will be calculated as the ratio of weight in kg/(height in 
cm/100)2.  BMI will only be calculated at Baseline (Day -1/Day 1).  BMI will not be 
calculated for children <2 years of age (Cohorts 4a and 4b) as BMI is not considered a 
screening tool for healthy weight in children <2 years of age.  Tanner staging of development 
(refer to Appendix E for further details on Tanner staging) will be assessed at Baseline only 
(Day -1/Day 1) for females who have not reached menarche but may reasonably have the 
potential to become pregnant.  
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
49(88)
5.3.3
Electrocardiogram
A single 12-lead (or as appropriate per Investigator decision) ECG recording will be 
performed at the times indicated in Table 1.  At Baseline, the ECG will be performed prior to 
obtaining blood samples for laboratory testing.  The Day 1 ECG will be performed within 
30 minutes following the end of the first study treatment infusion.  Electrocardiograms will be 
taken after the patient has been resting in a recumbent position for at least 10 minutes.  The 
results for the ECG will be paper reports provided locally for safety review by the 
Investigator.  
Each ECG will be interpreted as appropriate for the patient’s age.
5.3.4
Vital signs
Vital signs will be measured as required as well as at the time intervals indicated in Table 1
before the ECG on the days when both assessments are indicated.  On days when more than 
1 vital signs assessment is performed, the first set of vital sign measurements for the day and 
the highest temperature of the day should be recorded in the CRF.
5.3.4.1
Pulse and blood pressure
Supine blood pressure and pulse rate will be measured.  The patients will be required to rest in 
the supine position for at least 10 minutes prior to heart rate and blood pressure 
measurements.  For timings of vital signs assessments refer to Table 1.
5.3.4.2
Body temperature
Body temperature will be measured in degrees Celsius using an automated thermometer at the 
times indicated in Table 1 and the actual time of body temperature collection will be recorded.  
For each individual patient, the method of temperature measurement (oral, rectal, temporal, 
axillary, or tympanic, as appropriate) ideally should be consistent for the duration of the study.  
5.3.4.3
Respiratory rate
Respiratory rate will be measured in breaths per minute at the times indicated in Table 1.
5.3.5
Cephalosporin class effects
In addition to AE and SAE monitoring as described in Section 6, cephalosporin class effects 
and additional AEs will also be closely monitored (including, but not limited to seizures, 
C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic anaemia 
and changes in renal function).
5.4
Other assessments 
Medical and surgical history and prior and concomitant medications will be recorded at 
Baseline and, if applicable, during the study according to Table 1.  See Section 7.8 for further 
details on concomitant medications.  Serum β-hCG pregnancy tests will be performed at 
Baseline and TOC in female patients who have reached menarche or have reached Tanner 
stage 3 development.  If the result of the serum β-hCG test cannot be obtained prior to dosing 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
50(88)
of investigational product, a urine pregnancy test may be done at Baseline though a serum 
β-hCG test result must still be obtained.
If performed, adjunctive therapeutic procedures will be recorded throughout the treatment 
period until TOC. 
Radiological examinations are not required for the study, but the results should be recorded if 
done as part of the diagnosis.  Radiological examinations include WBC scans, plain 
abdominal radiographs, CT scans, ultrasound and/or MRI scans with or without contrast.  
5.5
Pharmacokinetics
5.5.1
Collection of samples
Blood samples (1 mL per sample for Cohorts 1 and 2, and 0.5 mL per sample for Cohorts 3, 
4a, and 4b) for determination of ceftazidime and avibactam in plasma will be taken at the 
times presented in Table 1 in a manner such that the Blinded Observer remains blinded (ie, the 
Investigator should collect the samples).  The date and time of sample collection will be 
recorded, as well as the date and time of the dose of IV study therapy immediately preceding 
the sample collection.
Samples will be collected, labelled, stored and shipped as detailed in the Laboratory Manual. 
5.5.2
Determination of drug concentration
Samples for determination of ceftazidime and avibactam concentration in plasma will be 
analysed by Covance on behalf of AstraZeneca, using an appropriate bioanalytical method.  
Full details of the analytical method used will be described in a separate bioanalytical report.
5.5.3
Storage and destruction of pharmacokinetic samples
Pharmacokinetic samples will be disposed of after the Bioanalytical Report finalisation 
or 6 months after issuance of the draft Bioanalytical Report (whichever is earlier), unless 
requested for future analyses. 
Pharmacokinetic samples may be disposed of or destroyed or anonymised by pooling. 
Additional analyses may be conducted on the anonymised, pooled PK samples to further 
evaluate and validate the analytical method. Any results from such analyses may be reported 
separately from the Clinical Study Report (CSR).
Incurred sample reproducibility analysis, if any, will be performed alongside the bioanalysis 
of the test samples.  The results from the evaluation will not be reported in the CSR but 
separately in a Bioanalytical Report.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
51(88)
5.6
Pharmacodynamics not applicable
5.7
Pharmacogenetics not applicable
5.8
Biomarker analysis not applicable
5.9
Volume of blood
The minimum total volume of blood that will be drawn from each patient in the study is 
displayed in Table 3 for Cohorts 1 and 2, Table 4 for Cohorts 3, 4a, and 4b.  Assessments that 
are to be performed if clinically indicated and are not mandated by the protocol are not 
included in the tables below.  The combined volume of all blood samples taken from a subject 
by the end of the study for investigational laboratory tests (ie, complete blood count with 
differential, chemistry panel, Direct Coombs test, pregnancy testing, and PK analyses) is to be 
no more than 2.4 cc/kg. Any deviation from this should be clinically justified.
Table 3
Volume of blood per patient – Cohorts 1 and 2
Blood 
Volume 
(mL)
Day
Baseline
Day 3
EOIV
TOC
Totals 
(minimum 
blood 
volume)
Chemistry
2
2
2
6
Haematology
0.75
0.75
0.75
2.25
Direct
Coombs
1.5
1.5
3
Serum 
pregnancy
2
2
4
PK
3
3
Totals
6.25
3
2.75
6.25
18.25
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
52(88)
Table 4
Volume of blood per patient – Cohorts 3, 4a, and 4b
Blood 
Volume 
(mL)
Day
Baseline
Day 3
EOIV
TOC
Totals 
(minimum 
blood 
volume)
Chemistry
2
2
2
6
Haematology
0.75
0.75
0.75
2.25
Direct
Coombs
1.5
1.5
3
Serum 
pregnancy
0
PK
1.5
1.5
Totals
4.25
1.5
2.75
4.25
12.75
6.
SAFETY REPORTING AND MEDICAL MANAGEMENT
The Principal Investigator is responsible for ensuring that all staff involved in the study are 
familiar with the content of this section.
6.1
Definition of adverse events
An AE is the development of an undesirable medical condition or the deterioration of a 
pre-existing medical condition following or during exposure to a pharmaceutical product, 
whether or not considered causally related to the product.  An undesirable medical condition 
can be symptoms (eg, nausea, chest pain), signs (eg, tachycardia, enlarged liver) or the 
abnormal results of an investigation (eg, laboratory findings, ECG).  In clinical studies, an AE 
can include an undesirable medical condition occurring at any time, including run-in or 
washout periods, even if no study treatment has been administered.
The term AE is used to include both serious and non-serious AEs.
6.2
Definition of serious adverse event
An SAE is an AE occurring during any study phase (ie, run-in, treatment, washout, 
follow-up), that fulfils 1 or more of the following criteria:

Results in death

Is immediately life-threatening

Requires in-patient hospitalisation or prolongation of existing hospitalisation 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
53(88)

Results in persistent or significant disability/incapacity or substantial disruption of the 
ability to conduct normal life functions

Is a congenital abnormality or birth defect

Is an important medical event that may jeopardise the patient or may require medical 
intervention to prevent one of the outcomes listed above
For further guidance on the definition of a SAE, see Appendix B.
6.3
Recording of adverse events
6.3.1
Time period for collection of adverse events
Non-serious AEs and SAEs will be collected for each patient from the time of signature of 
informed consent/assent until the LFU visit (27 to 50 days after start of study treatment).
6.3.2
Follow-up of unresolved adverse events
Any AEs that are unresolved at the patient’s last visit in the study are followed up 
by the study staff for as long as medically indicated.  AstraZeneca and its 
representatives retain the right to request additional information for any patient
with ongoing AE(s)/SAE(s) at the end of the study, if judged necessary.
6.3.3
Variables 
The following variables will be collected for each AE:

AE (verbatim)

Date and time when the AE started and stopped

Maximum intensity

Whether the AE is serious or not

Blinded Observer causality rating against the IV study therapy (yes or no) and against 
metronidazole (yes or no)

Action taken with regard to IV study therapy

Outcome of AE
In addition, the following variables will be collected for SAEs:

Onset Date (date AE met criteria for serious AE)

Detection date (date Investigator became aware of serious AE)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
54(88)

AE is serious due to:
(a)
Death, if fatal outcome, the following will be collected:

Date of death

Autopsy performed

Primary/secondary cause of death
(b)
Life threatening
(c)
Inpatient hospitalisation or prolongation of existing hospitalisation (note: patients 
will be hospitalised at study entry.  The initial hospitalisation that made the patient 
eligible for the study will not be considered an SAE but if the hospitalisation is 
prolonged due to an AE, the hospitalisation becomes an SAE)

Date of hospitalisation

Date of discharge
(d)
Congenital abnormality or birth defect
(e)
Important medical event
(f)
Suspected transmission via a medicinal product of an infectious agent

Blinded Observer causality assessment in relation to study procedures (yes/no)

Blinded Observer causality assessment in relation to other medication (yes/no)

Description of AE
It is important to distinguish between serious and severe AEs.  Severity is a measure of
intensity whereas seriousness is defined by the criteria above.  An AE of severe intensity need 
not necessarily be considered serious.  For example, nausea that persists for several hours may 
be considered severe nausea, but not a SAE.  On the other hand, a stroke that results in only a 
limited degree of disability may be considered a mild stroke but would be a SAE.  The 
Blinded Observer should provide an assessment of the severity of each AE/SAE.
6.3.4
Causality collection
The Blinded Observer will assess causal relationship between IP and each AE, and answer 
‘yes’ or ‘no’ to the question ‘Do you consider that there is a reasonable possibility that the 
event may have been caused by the investigational product?’
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
55(88)
For SAEs, the Blinded Observer will also assess causal relationship for other medication and 
study procedures and additional study drug.  Note that for SAEs that could be associated with 
any study procedure the causal relationship is implied as ‘yes’.
A guide to the interpretation of the causality question is found in Appendix B.
6.3.5
Adverse events based on signs and symptoms
All AEs spontaneously reported by the patient or care provider or reported in response to the 
open question from the study personnel: ‘Have you/the child had any health problems since
the previous visit/you were last asked?’, or revealed by observation will be collected and 
recorded in the CRF.  When collecting AEs, the recording of diagnoses is preferred (when 
possible) to recording a list of signs and symptoms.  However, if a diagnosis is known and 
there are other signs or symptoms that are not generally part of the diagnosis, the diagnosis 
and each sign or symptom will be recorded separately.
6.3.6
Adverse events based on examinations and tests
The results from protocol-mandated laboratory tests and vital sign measurements will be 
summarised in the CSR.  Deterioration as compared to Day 1 (Baseline) in protocol-mandated 
laboratory values, vital signs, ECGs, and other safety assessments should therefore only be 
reported as AEs if they fulfil any of the SAE criteria or are the reason for discontinuation of 
treatment with the IV study therapy.
If deterioration in a laboratory value or vital sign is associated with clinical signs and 
symptoms, the sign or symptom will be reported as an AE and the associated laboratory result 
or vital sign will be considered as additional information.  Wherever possible, the reporting 
Investigator uses the clinical, rather than the laboratory term (eg, anaemia versus low 
haemoglobin value).  In the absence of clinical signs or symptoms, clinically relevant 
deteriorations in non-mandated parameters should be reported as AE(s).
Deterioration of a laboratory value, which is unequivocally due to disease progression, should 
not be reported as an AE or SAE (see Section 6.3.8.2).
Any new or aggravated clinically relevant abnormal medical finding at a physical examination 
as compared with the screening assessment will be reported as an AE.
6.3.7
Actions required in cases of increases in liver chemistry values
The Investigator is responsible for, without delay, determining whether the patient meets 
potential Hy’s law criteria; AST or ALT ≥3×ULN and total bilirubin ≥2×ULN irrespective of 
the value of the patient’s alkaline phosphatase, at any point during the study following the 
start of study medication.
A Hy’s Law case is defined as study patient with an increase in serum AST or ALT ≥3×ULN 
together with total bilirubin ≥2×ULN, where no other reason can be found to explain the 
combination of increases, eg, elevated serum ALP indicating cholestasis, viral hepatitis, or 
another drug.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
56(88)
For potential Hy’s Law and Hy’s Law the elevation in transaminases must precede or be 
coincident with (ie, on the same day) the elevation in total bilirubin, but there is no specified 
timeframe within which the elevations in transaminases and total bilirubin must occur.  
Details regarding the actions required in the cases of increases in ALT, AST, and total 
bilirubin can be found in Appendix D.
If a patient reaches an ALT or AST=5×ULN, the patient may continue with the IP as planned 
unless discontinuation criteria as described in Section 3.10 are met.  The patient should be 
seen within 48 hours to instigate enhanced follow-up and monitoring.  Enhanced follow-up 
should include collection of clinical and historical information to determine the cause of ALT 
and/or AST elevations.  Additional testing for liver laboratory test results must be done every 
48 hours until the peak value has been reached as documented by a decline in the values
and/or until the patient is feeling better.  The frequency of retesting can decrease to once per 
week or less if abnormalities stabilise or study drug has been discontinued and the patient is 
asymptomatic.  The patient should be followed until resolution (including laboratory testing).
6.3.8
Exceptions from standard adverse event collection
6.3.8.1
Lack of Effect
Where there is deterioration in the condition for which the IV study therapy is being used, 
there may be uncertainty as to whether this is lack of efficacy, disease progression, and 
whether it constitutes an AE.  In such cases, unless the AstraZeneca or reporting physician 
considers that the IV study therapy contributed to the deterioration or local regulations state 
the contrary, the deterioration should be considered to be lack of efficacy and not an AE.
Insufficient therapeutic effect will be captured as an efficacy outcome.  Instances of, or 
discontinuation due to insufficient therapeutic effect (ie, lack of efficacy) should not be 
collected as AEs.  A clinical failure should not be recorded as an AE.
6.3.8.2
Disease progression
Disease progression can be considered as a worsening of a patient’s condition attributable to 
the disease for which CAZ-AVI is being studied.  It may be an increase in the severity of the 
disease under study and/or increases in the symptoms of the disease.  Expected progression of 
the disease under study and/or expected progression of signs and symptoms of the disease 
under study, unless more severe in intensity or more frequent than expected for the patient’s 
condition, should not be reported as an AE.  Any event or extended hospitalisation that is 
unequivocally due to disease progression must not be reported as an SAE unless it is believed 
that IV study therapy actively contributed to the progression of the disease (ie, not by way of 
insufficient therapeutic effect).  Events that are unequivocally due to disease progression 
should not be reported as an AE during the study.
6.4
Reporting of serious adverse events
All SAEs have to be reported, whether or not considered causally related to the IP, or to the 
study procedure(s). All SAEs will be recorded in the CRF.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
57(88)
If any SAE occurs in the course of the study, then Investigators will enter SAE information 
into the Electronic Data Capture system within 1 day ie, immediately but no later than 
24 hours of when he or she becomes aware of it.
The designated PRA representative, on behalf of AstraZeneca, works with the Investigator to 
ensure that all the necessary information is provided to the PRA Drug Safety Department.  
PRA Drug Safety will forward all SAE information to the AstraZeneca Patient Safety data 
entry site within 1 calendar day of initial receipt for fatal and life threatening events (if 
received for instance during a weekend or a public holiday, the information is forwarded as 
early as possible on the first business day following the weekend or holiday) and within 
3 calendar days of initial receipt for all other SAEs.
For fatal or life-threatening AEs where important or relevant information is missing, active 
follow-up is undertaken immediately.  Investigators or other site personnel inform PRA 
representatives of any follow-up information on a previously reported SAE within 1 calendar 
day ie, immediately but no later than 24 hours of when he or she becomes aware of it.
Once the Investigators or other site personnel indicate an AE is serious in the PRA Datalabs 
system, an automated email alert is sent to the PRA Drug Safety Department.  Tata 
Consultancy Services will be responsible for processing all SAEs onto the AstraZeneca 
Patient Safety Database, and the information will be passed on to AstraZeneca.  
If the PRA Datalabs system is not available, then the Investigator or other study site personnel 
reports the SAE to the PRA Drug Safety Department by telephone, fax, or email.
PRA contact information for SAE reporting: 
FAX: +44 1792 525 720
E-mail: MHGsafety@prahs.com
Telephone: +49 621 8782 154
PRA, on behalf of AstraZeneca, is responsible for reporting certain SAEs as expedited safety 
reports to applicable regulatory authorities, Ethics Committees, and participating 
Investigators, in accordance with International Conference on Harmonisation (ICH) 
Guidelines and/or local regulatory requirements.  PRA may be required to report certain SAEs 
to regulatory authorities within 7 calendar days of being notified about the event; therefore, it 
is important that Investigators submit additional information requested by AstraZeneca or 
PRA as soon as it becomes available.
The reference document for definition of expectedness/listedness is the Investigator’s 
Brochure for the AstraZeneca drug CAZ-AVI and the EU Summary of Product Characteristics 
for the active comparator product (including any AstraZeneca comparator). 
6.5
Overdose
Overdose is defined as a dose administered to a patient in excess of that specified in this 
protocol. Overdose does not automatically make an AE serious but if the consequences of the 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
58(88)
overdose are serious for example death or hospitalisation, the event is serious and should be 
reported as such.
Recording an overdose will be done according to the following:

An overdose with associated AEs is recorded as the AE diagnosis/symptoms on the 
relevant AE modules in the CRF and on the Overdose CRF module.

An overdose without associated symptoms is only reported on the Overdose CRF 
module.

If an overdose on an AstraZeneca IV study therapy occurs in the course of the study, 
then Investigators or other study centre personnel will inform appropriate AstraZeneca 
representatives within 1 day, ie, immediately but no later than the end of the next 
business day from when he or she becomes aware of it.

The designated AstraZeneca representative works with the Investigator to ensure that 
all relevant information is provided to the AstraZeneca patient safety data entry site.

For overdoses associated with an SAE, standard reporting time lines apply, see 
Section 6.4. For other overdoses, reporting should be done within 30 days.
6.6
Pregnancy
All pregnancies and outcomes of pregnancy should be reported to the PRA Drug Safety 
Department.
6.6.1
Maternal exposure
If a patient becomes pregnant during the course of the study, IP should be discontinued 
immediately.
Pregnancy itself is not regarded as an AE unless there is a suspicion that the IP under study 
may have interfered with the effectiveness of a contraceptive medication.  Congenital 
abnormalities/birth defects and spontaneous miscarriages should be reported and handled as 
SAEs.  Elective abortions without complications should not be handled as AEs.  The outcome 
of all pregnancies (spontaneous miscarriage, elective termination, ectopic pregnancy, normal 
birth or congenital abnormality) should be followed up and documented even if the patient 
was discontinued from the study.
If any pregnancy occurs in the course of the study, then the Investigator or other site personnel 
informs the PRA Drug Safety Department immediately but no later than 24 hours of when 
he or she becomes aware of it.
PRA works with the Investigator to ensure that all relevant information is provided to the PRA 
Drug Safety Department within 1 or 3 calendar days for SAEs (see Section 6.4) and within 
30 days for all other pregnancies.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
59(88)
The same timelines apply when outcome information is available.
All outcomes of pregnancy should be reported to the PRA Drug Safety Department.  Any 
patient who becomes pregnant during the course of the study will be followed so that 
pregnancy outcome can be determined and reported to AstraZeneca and the regulatory 
authorities.
A pregnancy report form (electronic copy of the PREGREP form) will be used to report the 
pregnancy to the PRA Drug Safety Department.  The outcome of the pregnancy will be 
reported on the pregnancy report form (paper copy of the PREGOUT form) and provided by 
site staff to the PRA Drug Safety Department, but the outcome of the pregnancy will not be 
documented in the clinical database.
6.6.2
Paternal exposure 
There is no restriction on fathering children or donating sperm during the study.  Pregnancy of 
the patient’s partner is not considered to be an AE.  However, the outcome of all pregnancies 
(spontaneous miscarriage, elective termination, ectopic pregnancy, normal birth, or congenital 
abnormality) should if possible be followed up and documented.  The outcome of any 
conception occurring from the date of the first IP administration until 7 days after the last IP 
administration should be followed up and documented.
6.7
Management of investigational product-related toxicities 
Clostridium difficile-associated diarrhoea has been reported with ceftazidime as with nearly all 
antibacterial agents, and may range in severity from mild diarrhoea to fatal colitis.  This is as a 
result of alteration of the normal flora of the colon by ceftazidime leading to overgrowth of 
C. difficile. If C. difficile-associated diarrhoea is suspected or confirmed, ongoing antibiotic 
use not directed against C. difficile may need to be discontinued.  Appropriate fluid and 
electrolyte management, protein supplementation, antibiotic treatment of C. difficile, and 
surgical evaluation should be instituted as clinically indicated.
Ceftazidime overdosage has occurred in patients with renal failure.  Reactions have included 
tremors, myoclonus, seizures, encephalopathy, and coma.  Patients who receive an acute 
overdosage should be carefully observed and given supportive treatment.  In the presence of 
renal insufficiency, haemodialysis or peritoneal dialysis may aid in the removal of ceftazidime 
from the body.  Continued dosage should be determined by degree of renal impairment, 
severity of infection, and susceptibility of the causative organisms. 
Cephalosporins may be associated with a fall in prothrombin activity.  Those at risk include 
patients with renal and hepatic impairment, or poor nutritional state, as well as patients 
receiving a protracted course of antimicrobial therapy.  Prothrombin time should be monitored 
in patients at risk and exogenous vitamin K administered as indicated.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
60(88)
6.8
Study governance and oversight
The safety of all AstraZeneca clinical studies is closely monitored on an on-going basis by 
AstraZeneca representatives in consultation with Patient Safety.  Issues identified will be 
addressed; for instance this could involve amendments to the study protocol and letters to 
Investigators.
6.8.1
Data and Safety Monitoring Board
As this study is descriptive in nature, no interim or final inferential analyses will be performed 
for either efficacy or safety.  A Data and Safety Monitoring Board (DSMB) is deemed 
necessary since the trial has a long period of enrolment, is multi-centre and multi-national, and 
represents one of the first safety and efficacy trials of CAZ-AVI in children.  
The DSMB is charged with reviewing and evaluating the study safety (AEs, SAEs, and 
potentially clinically significant laboratory results) at periodic intervals.  The DSMB members 
will be familiarised with AEs and SAEs likely to occur in this patient population, based on 
experience in adults and adolescents, as well as with this class of drugs (cephalosporins).  The 
DSMB will conduct pre-planned and possibly ad hoc reviews of accumulating data.
Based on the findings of these reviews, the DSMB may make recommendations to 
AstraZeneca regarding the study, including, but not limited to: continue the study without 
modification, modify the protocol or informed consent/assent document(s), or temporarily 
stop enrolment in all or some of the study centres.  AstraZeneca will be responsible for 
discussing and, if considered appropriate, implementing the DSMB recommendations.  
Further details can be found in the DSMB charter. 
7.
INVESTIGATIONAL PRODUCT AND OTHER TREATMENTS
7.1
Identity of investigational product(s)
Investigational product
Dosage form and strength
CAZ-AVI
Ceftazidime avibactam powder for concentrate for solution for 
infusion 2000 mg/500 mg
Meropenem
Meropenem powder for solution for infusion 1000 mg
CAZ-AVI and meropenem will be supplied centrally by AstraZeneca.  Kits containing the 
labelled vials will be provided to the study centre as an open label supply for reconstitution 
and dilution in accordance with the handling instructions.
Commercially available IV metronidazole for infusion will be provided centrally by 
AstraZeneca.
For metronidazole, consult the product package insert, label, and local dosing guidelines for 
further information regarding dosage, administration, storage, maximum doses, 
contraindications, warnings, precautions, and AEs reported.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
61(88)
7.2
Dose and treatment regimens
The study is single blind, ie, a Blinded Observer will not know the patient’s treatment 
assignment and will conduct clinical assessments (including efficacy and safety).  There is no 
use of placebo to act as a treatment blind.
The doses of CAZ-AVI are based on age and weight with adjustment according to renal 
function as detailed in Table 5.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
62(88)
Table 5
CAZ-AVI doses by age, weight, and creatinine clearance
Cohort
Age range
Body 
weight
CAZ-AVI dose
CrCl ≥50 mL/min
CAZ-AVI dose
CrCl ≥30 to <50 mL/min
CAZ-AVI must be administered as a 50 to 100 mL infusion (dependent on dose) over 
2 hours every 8 hours (±30 minutes)
11
12 years to 
<18 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
11
12 years to 
<18 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
21
6 years to 
<12 years
≥40 kg
2000 mg ceftazidime/500 mg avibactam
1000 mg ceftazidime/250 mg avibactam
21
6 years to 
<12 years
<40 kg
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
31
2 years to 
<6 years
All
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4a2
1 year to <2 years
All
50 mg/kg ceftazidime /12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b2
6 months to 
<1 year
All
50 mg/kg ceftazidime/12.5 mg/kg avibactam
25 mg/kg ceftazidime/6.25 mg/kg avibactam
4b2
3 months to 
<6 months
All
40 mg/kg ceftazidime/10 mg/kg avibactam
20 mg/kg ceftazidime/5 mg/kg avibactam
1
Patients considered for entry into the study will be within the normal range of BMI for their age, (2 to <18).  A healthy weight BMI for this age group 
falls between the 5th percentile and ≤95th percentile according to height, weight, and age.
2
BMI will not be calculated for children <2 years of age as BMI is not considered a screening tool for healthy weight in children under 2 years of age.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
63(88)
Full details of infusion preparation are given in the Pharmacy Manual.
Patients whose CrCl changes during treatment should receive the appropriate dose reduction 
or increase according to Table 5.
The Investigator should follow the package insert for meropenem for dose modifications 
associated with renal impairment.
Patients whose CrCL drops below 30 mL/min should be withdrawn from study therapy.  
Patients withdrawing from study therapy can be administered alternative therapies at the 
Investigator’s choice, which should be recorded in the CRF.  If possible, patients should still 
be followed for safety (see Section 3.9.1).  Because the CrCl determination is only an estimate 
of renal function, in instances where the CrCl is approaching thresholds that would require 
intervention such as a dose change or discontinuation of therapy (ie CrCL approaching 50 or 
30 mL/min), the Investigator should use his or her discretion in determining (ie confirming the 
value by repeat testing, if feasible) whether an immediate dose change, a short period of 
continued observation, or discontinuation of therapy is warranted. If in the opinion of the 
Investigator there is a clinically significant reduction in a patient’s estimated CrCl during the 
treatment period, then the Investigator should contact the Medical Monitor to discuss the 
above mentioned options (immediate dose change, a short period of continued observation, or 
discontinuation of therapy). Additionally, in instances of rapidly changing renal function, the 
Investigator should increase the frequency of CrCl monitoring, depending on the patient’s 
clinical status, extent of renal function change and Investigator’s clinical evaluation.
The suggested dosing regimen of metronidazole is 10 mg/kg IV over 20 to 30 minutes every 
8 hours (±30 minutes), but it can also be prescribed/adjusted by the Investigator according to 
local labels. The metronidazole infusion will be started no later than 30 minutes after 
completion of the CAZ-AVI infusion.  
The dose/regimen of meropenem will be 20 mg/kg every 8 hours (±1 hour) infused over 
approximately 15 to 30 minutes or up to 1 hour (or infusion duration as per local guidelines).  
For patients weighing over 50 kg, the maximum dose of meropenem should not exceed 1 g 
every 8 hours.  The time interval between the beginning of reconstitution and the end of the 
infusion should not exceed 1 hour due to the stability of meropenem when reconstituted with 
sodium chloride. 
7.3
Labelling
Labels will be prepared in accordance with Good Manufacturing Practice and local regulatory 
guidelines.  Label text will be translated into the local language.
Personnel at the study centre will prepare and label the individual IV infusions as assigned by 
the IXRS, and according to the handling instructions.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
64(88)
7.4
Storage
All study drugs should be kept in a secure place under appropriate storage conditions.  The 
storage conditions will be stated on the study drug labelling and in the handling instructions.
7.5
Compliance
The site will monitor patient compliance, which will be documented in the patient’s source 
documents, and relevant data will be reported in the CRF.  To ensure that the patient is 
compliant with administration of study drug, oral switch therapy, and study procedures, the 
date and dose of the medication should be recorded in the appropriate sections of the CRF.  
7.6
Accountability
The study drug provided for this study will be used only as directed in the study protocol.
The study personnel will account for all study drugs dispensed to and returned from the 
patient.
Study site personnel, if applicable, or the PRA monitor will account for all study drugs 
received at the site, unused study drugs and for appropriate destruction.  Certificates of 
delivery, destruction, and return should be signed.  For general drug destruction (eg, left over 
drug at site), accepted practices for destruction within specific sites, countries, or regions 
should be used, through PRA’s standard operating procedures (SOPs).  Therefore, where at all 
possible the IP should be destroyed locally at site and a third party supplier for return and 
destruction should only be used where specific country regulations or local procedures state 
this is not possible. Documentation should be provided by PRA or AstraZeneca’s Research 
and Development Procurement Manager identifying that this is the case. For IP associated 
with a recall, AstraZeneca will determine what is to be destroyed, but PRA will manage the 
execution of destruction using standards acceptable to AstraZeneca or its representative.
7.7
Oral switch therapy
The choice of oral switch therapy, among the options listed below, should be in line with the 
approved and marketed drugs in the respective country, and should observe the local specific 
regulations and local therapeutic guidelines (if existent), regarding posology.  The decision to 
switch to oral therapy is entirely at the Investigator’s discretion, if the patient has good or 
sufficient clinical response, and the patient is tolerating oral fluids or food.
For the optional oral switch therapy, the following should be given: 

Oral amoxicillin/clavulanic acid (only in countries where its use for children is 
permitted; according to local guidelines, administered at a dose and formulation per 
standard of care), or

Oral ciprofloxacin (only in countries where its use for children is permitted; according 
to local guidelines, administered at a dose and formulation per standard of care) plus 
metronidazole (administered at a dose and formulation per standard of care), or
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
65(88)

Pathogen-based therapy (in discussion with the Medical Monitor).  The choice of oral 
antibacterial agent for pathogen-based therapy will be driven by the results of a 
susceptibility test, which will be provided to the Investigator by either the local or 
central laboratory.  Initiation of pathogen-based therapy is at the Investigator’s 
discretion.  Before administering pathogen-based therapy, the Investigator will discuss 
the results of the susceptibility test and the selected antibacterial drug (which should be 
approved for use in children) with the Medical Monitor. 
The optional oral switch therapies will be sourced locally by the study centres or sourced as 
agreed between the study centres and PRA.
Consult the Summary of Product Characteristics or product package insert, label, and local 
dosing guidelines for further information regarding dosage, administration, storage, maximum 
doses, contraindications, warnings, precautions, and AEs reported.
7.8
Concomitant and other treatments 
All prescription and over-the-counter medications being taken by the patient for the 2 weeks 
prior to study entry (considered prior treatment) and from randomisation through the LFU 
visit (considered concomitant treatment) must be documented on the appropriate pages of the 
CRF.  Systemic antibiotics should be documented for the entire duration of the study (from 
2 weeks prior to study entry through the LFU visit).  For patients who are being breast fed, all 
medications taken by the lactating mother in the previous 2 weeks before the first dose of 
study therapy until LFU will also be recorded.
If Enterococcus species or methicillin-resistant staphylococcus aureus (MRSA) is one of the 
pathogens suspected or isolated and, in the opinion of the Investigator, specific therapy is 
indicated, then open-label vancomycin, linezolid, or daptomycin may be added to either of the 
study regimens according to the usual practice of the Investigator.  If vancomycin, linezolid, 
or daptomycin are started empirically to cover MRSA or Enterococcus species, and if final 
culture results did not isolate MRSA or Enterococcus species, then the Investigator should 
discontinue the additional Gram-positive coverage that was empirically added.
The use of other systemic antimicrobials not specified by this protocol is not permitted during 
the study.  Antibiotic peritoneal lavage and peritoneal lavage with saline or other 
non-antibacterial containing solution are allowed.  Topical antibacterial and antifungals are 
permitted except that they may not be applied to the surgical site.  
Other medication, which is considered necessary for the patient’s safety and well-being, may 
be given at the discretion of the Investigator and recorded in the appropriate sections of the 
CRF.  If analgesic medications are needed for pain, the use of analgesic medication without 
antipyretic properties is preferred.  Should a patient require immunosuppressive agents or 
chemotherapy after being randomised to IV study therapy, the Investigator should contact the 
PRA Medical Monitor (as an AstraZeneca delegate) before initiating therapy.  Continued 
patient study participation will be determined based upon assessment of the safety risk to the 
patient if he or she were to continue in the study.  Patients who have completed IV study 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
66(88)
therapy and are in the follow-up (FU) period should remain in the study as they are not 
actively on IV study therapy but being followed for outcomes.
Simultaneous administration of meropenem and/or metronidazole with warfarin may augment 
its anticoagulant effects.  There have been many reports of increases in the anticoagulant 
effects of orally administered anticoagulant agents, including warfarin, in patients who are 
concomitantly receiving antibacterial agents.  The risk may vary with the underlying infection, 
age, and general status of the patient so that the contribution of the antibiotic to the increase in 
international normalised ratio (INR) is difficult to assess.  In addition to the standard study 
safety laboratory assessments, frequent monitoring of the INR should be performed during 
and shortly after co-administration of study therapy with an oral anticoagulant agent, as per 
local practice.  
In vitro, avibactam is a substrate of organic anion transporter (OAT) 1 and OAT3, which 
might contribute to the active uptake from the blood compartment and, thereby its 
excretion. Probenecid (a potent OAT inhibitor) inhibits this uptake by 55% to 70% in vitro 
and, therefore, has the potential to alter the elimination of avibactam when co-dosed.  Since a 
clinical interaction study of avibactam and probenecid has not been conducted, co-dosing of 
avibactam with probenecid is not recommended.  Probenecid interferes with the active tubular 
secretion of meropenem, resulting in increased plasma concentrations of meropenem.  
Therefore, co-administration of probenecid with meropenem is not recommended.  There is 
significant drug-drug interaction between meropenem and valproic acid or sodium valproate; 
therefore co-administration of meropenem and valproic acid or sodium valproate should be 
avoided.
A number of unfavourable reactions with other drugs are known for ceftazidime.  
Contraindications and known drug interactions for ceftazidime are summarised in Table 6.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
67(88)
Table 6
Contraindications and drug-drug interactions
Ceftazidime
Concurrent administration with chloramphenicol should be avoided.  Chloramphenicol has been shown to be 
antagonistic to β-lactam antibiotics, including ceftazidime.
Concurrent administration with aminoglycoside antibiotics or potent diuretics such as furosemide may result in 
nephrotoxicity.  Because of potential nephrotoxicity and ototoxicity of aminoglycosidic antibiotics, renal function 
should be carefully monitored, especially if higher dosages of aminoglycosides are to be administered or if therapy is 
prolonged.
Concurrent administration with combined oral oestrogen/progesterone contraceptives may result in lower oestrogen 
reabsorption and reduced efficacy of these contraceptives secondary to the effects of ceftazidime on gut flora.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
68(88)
Ciprofloxacin
Administration in pregnant or lactating women is contraindicated.
Concurrent administration with tizanidine is contraindicated.
Concurrent administration with methotrexate is not recommended; methotrexate may inhibit renal tubular transport 
of ciprofloxacin, potentially leading to increased plasma levels of methotrexate and increased risk of methotrexate-
associated toxic reactions.
Concurrent administration with theophylline decreases theophylline clearance, resulting in elevated serum 
theophylline levels and increased risk of a patient developing central nervous system or other adverse reactions.
Concurrent administration with caffeine or pentoxifylline (oxpentifylline) may raise serum concentrations of these 
xanthine derivatives.
Concurrent administration with antacids containing magnesium hydroxide or aluminium hydroxide may reduce the 
bioavailability of ciprofloxacin by as much as 90%.
Concurrent administration with probenecid interferes with renal secretion of ciprofloxacin and increases 
ciprofloxacin serum concentrations.
Concurrent administration with phenytoin may result in increased or reduced serum levels of phenytoin; monitoring 
of drug levels is recommended.
Concurrent administration with warfarin may augment its anticoagulant effects. The risk may vary with the 
underlying infection, age, and general status of the patient so that the contribution of a fluoroquinolone to an 
increased INR is difficult to assess.  It is recommended that INR be monitored frequently during and shortly after 
co-administration of ciprofloxacin with an oral anticoagulant agent.
Concurrent administration with ropinirole increases the maximum plasma concentration of ropinirole by as much as 
60%.  Monitoring of ropinirole-related side effects and dose adjustment as appropriate is recommended during and 
shortly after co-administration with ciprofloxacin.
Concurrent administration with clozapine increases serum concentrations of clozapine and N-desmethylclozapine, a 
metabolite, by as much as 29% and 31%, respectively.  Clinical surveillance and appropriate adjustment of clozapine 
dosage during and shortly after co-administration with ciprofloxacin are recommended.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
69(88)
Amoxicillin-
clavulanic acid
Concurrent administration with probenecid decreases the renal tubular secretion of amoxicillin but does not delay 
renal excretion of clavulanic acid.  Concurrent use with amoxicillin-clavulanic acid may result in increased and 
prolonged blood concentrations of amoxicillin.  Co-administration of probenecid is not recommended.
Concurrent administration of amoxicillin with oral anticoagulants may result in abnormal prolongation of 
prothrombin time (increased INR).  Appropriate monitoring should be undertaken when anticoagulants are 
prescribed concurrently with amoxicillin-clavulanic acid.  Adjustments in the dose of oral anticoagulants may be 
necessary to maintain the desired level of anticoagulation.
Concurrent administration of allopurinol and amoxicillin increases the incidence of rashes in patients receiving both 
drugs as compared to patients receiving amoxicillin alone.
Concurrent administration of oral contraceptives and amoxicillin-clavulanic acid may affect intestinal flora, leading 
to lower estrogen reabsorption and reduced efficacy of combined oral estrogen/progesterone contraceptives.
High urine concentrations of amoxicillin may result in false-positive reactions when testing for the presence of 
glucose in urine using Clinitest®, Benedict's solution, or Fehling's solution.  Since this effect may also occur with 
amoxicillin-clavulanic acid, it is recommended that glucose tests based on enzymatic glucose oxidase reactions be 
used.
Following administration of amoxicillin to pregnant women, a transient decrease in plasma concentration of total 
conjugated estriol, estriol-glucuronide, conjugated estrone, and estradiol has been noted.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
70(88)
Meropenem
No specific medicinal product interaction studies other than probenecid have been conducted.
Probenecid competes with meropenem for active tubular secretion and thus inhibits the renal excretion of 
meropenem with the effect of increasing the elimination half-life and plasma concentration of meropenem.  Caution 
is required if probenecid is co-administered with meropenem.
The potential effect of meropenem on the protein binding of other medicinal products or metabolism has not been 
studied.  However, the protein binding is so low that no interactions with other compounds would be expected on the 
basis of this mechanism.
Decreases in blood levels of valproic acid have been reported when it is co-administered with carbapenem agents 
resulting in a 60 to 100 % decrease in valproic acid levels in about 2 days. Due to the rapid onset and the extent of 
the decrease, co-administration of valproic acid/sodium valproate/valpromide with carbapenem agents is not 
considered to be manageable and therefore should be avoided.
Oral anticoagulants
Simultaneous administration of antibiotics with warfarin may augment its anticoagulant effects. There have been 
many reports of increases in the anticoagulant effects of orally administered anticoagulant agents, including warfarin 
in patients who are concomitantly receiving antibacterial agents. The risk may vary with the underlying infection, 
age and general status of the patient so that the contribution of the antibiotic to the increase in INR is difficult to 
assess. It is recommended that the INR should be monitored frequently during and shortly after co-administration of 
antibiotics with an oral anticoagulant agent.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
71(88)
7.8.1
Drug-drug interactions
Drug-antibiotic interactions occur with many medications commonly prescribed in children, 
particularly those drugs with a narrow therapeutic index.  Therefore, extra caution is advised 
in the event that concomitant medications need to be changed or added for children.
7.8.2
Other concomitant treatment
Other medication other than that described above, which is considered necessary for the 
patient’s safety and well-being, may be given at the discretion of the Investigator and recorded 
in the appropriate sections of the CRF.
8.
STATISTICAL ANALYSES
8.1
Statistical considerations
All personnel involved with the analysis of the study will remain blinded until database-lock.  
Analyses will be performed by AstraZeneca or its representatives.  
A comprehensive Statistical Analysis Plan (SAP) will be prepared prior to the randomisation 
of the first patient to the study.  Any subsequent amendments to the SAP will be documented, 
with final amendments completed prior to unblinding of the data for the analysis.
8.2
Sample size estimate
Patients will continue to be recruited into this study until 80 patients complete at least 
72 hours (3 full days, ie, 9 doses) of study treatment (deemed to be evaluable patients).  
Patients will be randomised 3:1 to the CAZ-AVI plus metronidazole or meropenem study 
treatment groups.  At least 60 and 20 evaluable patients, respectively, are required in the 
CAZ-AVI plus metronidazole and meropenem groups.
The proposed sample size is based on the probability of observing a ‘rare’ safety event.  
Safety data from this study and from Study D4280C00016 for cUTI will be combined for 
analysis.  As a total of at least 120 patients will be treated with CAZ-AVI in both studies 
combined, when assuming an underlying incidence rate of 3% for a specific ‘rare’ event, this 
will ensure that the probability of observing such an event in at least 1 patient treated with 
CAZ-AVI exceeds 95%.
Patients will be allocated to 1 of 4 cohorts based on age. Randomisation will be stratified as 
follows:

Cohort 1: At least 15:5 evaluable patients aged from 12 years to <18 years

Cohort 2: At least 15:5 evaluable patients aged from 6 years to <12 years

Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 years
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
72(88)

Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 years,
comprising Cohorts 4a and 4b as follows:

Cohort 4a: Patients aged from 1 year to <2 years

Cohort 4b: Patients aged from 3 months to <1 year
Considering patients over all cohorts combined, the maximum number of evaluable patients 
allowed to have been recruited having been diagnosed with complicated appendicitis is 90%.
8.3
Definitions of analysis sets
The analysis of data will be based on different analysis sets according to the purpose of 
analysis, ie, for safety and efficacy.  The decision regarding validity of data for each of the 
analysis sets will be based on a blinded review of data, which will occur prior to declaring 
database lock.
8.3.1
Safety analysis set
The Safety analysis set will include all randomised patients who received any amount of IV 
study therapy (ie, CAZ-AVI plus metronidazole or meropenem).  For the Safety analysis set, 
patients will be included in all outputs according to the study treatment they actually received.
8.3.2
Safety evaluable analysis set
The safety evaluable analysis set will be a subset of the patients in the Safety analysis set that 
received at least 9 doses of study treatment.  Each subject’s dosing profile will be reviewed by 
the evaluability review committee to confirm whether the scheduling and number of doses 
received is acceptable for inclusion in the safety evaluable analysis set.
8.3.3
Pharmacokinetic analysis set
The PK analysis set will be a subset of the patients in the Safety analysis set who have at least 
1 ceftazidime and/or avibactam plasma measurement available.
8.3.4
Efficacy analysis sets
The efficacy analysis of data in this study will be based on 4 analysis sets of patients (intent-
to-treat [ITT], microbiological ITT [micro-ITT], clinically evaluable [CE]. and 
microbiologically evaluable [ME] analysis sets) as defined in Sections 8.3.4.1 to 8.3.4.4.  
Each of these analysis sets will be defined separately for each of the visits at which efficacy is 
assessed.
Patients who receive both study therapies will be excluded from the CE and ME analysis sets.  
Patients in the ITT, micro-ITT, CE, and ME analysis sets will be summarised according to the 
randomised treatment assignment.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
73(88)
8.3.4.1
Intent-to-treat analysis set 
The ITT analysis set will include all patients who have been assigned a randomised treatment.
8.3.4.2
Microbiological intent-to-treat analysis set
The micro-ITT analysis set will include all randomised patients who have a baseline pathogen 
known to cause cIAI.
8.3.4.3
Clinically evaluable analysis set
The CE analysis set is defined separately at the end of 72 hours of study treatment, and at each 
of the EOIV, EOT, TOC and LFU visits.  The CE analysis set is a subset of all patients 
randomised and will include all randomised patients who receive any amount of IV study drug 
and have a confirmed diagnosis of cIAI; patients must also meet the following specific 
conditions:

Have received at least 48 hours of IV study drug in order to be considered an evaluable 
clinical failure, unless deemed a clinical failure based on a treatment-limiting AE

Have received at least 72 hours of IV study drug in order to be considered an evaluable 
clinical cure

Have been evaluated at the End of 72 hours and at the  specific visits of EOIV, EOT, 
and TOC with a clinical response of cure or failure (or have been assessed as a clinical 
failure before the planned assessment visit), or for LFU, have been evaluated with a 
clinical response of sustained cure or relapse

Had no important protocol deviations that would affect assessment of efficacy
8.3.4.4
Microbiologically evaluable analysis set
The ME analysis set is defined separately at the end of 72 hours of study treatment, and at 
each of the EOIV, EOT, TOC, and LFU visits.  It includes all patients meeting the following 
criteria:

Are a subset of all randomised patients who have received any amount of IV study 
drug and have a confirmed diagnosis of cIAI

Have received at least 48 hours of IV study drug in order to be considered an evaluable 
clinical failure, unless deemed a clinical failure based on a treatment-limiting AE

Have received at least 72 hours of IV study drug in order to be considered an evaluable 
clinical cure

At the specific visit had a microbiological response which was not indeterminate (note; 
presumed eradication or presumed persistence is acceptable)

Had no important protocol deviations that would affect assessment of efficacy
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
74(88)

Have at least 1 typical IAI bacterial pathogen which has been isolated from an 
adequate microbiological specimen at Baseline that is susceptible to both study agents 
(CAZ-AVI and meropenem)
8.4
Outcome measures for analyses
8.4.1
Primary outcome variables
The primary outcome variables are for safety and tolerability as assessed by:

AEs and SAEs

Cephalosporin class effects and additional AEs

Vital signs (pulse, blood pressure, respiratory rate, temperature)

Physical examination

Laboratory parameters

ECG

CrCl 
8.4.2
Secondary outcome variables

Plasma concentrations of CAZ and AVI will be listed and summarised by nominal 
sampling time window using appropriate descriptive statistics

Clinical response at End of 72 hours’ treatment, EOIV, EOT, and TOC

Microbiological response at EOIV, EOT, TOC, and LFU

Clinical relapse at LFU

Emergent infections
8.5
Methods for statistical analyses
8.5.1
Analysis of the primary variables
The primary variables are for safety and tolerability.  No inferential statistical tests will be 
performed for any safety variables.  All data will be presented by treatment group and by 
cohort (and also by summed cohorts).  Descriptive statistics (number, mean, standard 
deviation [SD], median, minimum, and maximum) will be provided for continuous variables, 
and counts and percentages will be presented for categorical variables.  Demographic data,
other baseline characteristic data, and concomitant medications will also be summarised.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
75(88)
Safety assessments will be based on AE reports and the results of vital sign measurements, 
physical examinations, ECGs and clinical laboratory tests.  For each safety variable, the last 
assessment made prior to the first dose of study drug will be defined as the baseline.  All 
safety data collected from this study up to the LFU visit will be presented within the Safety 
analysis set (as defined in Section 8.3.1) by the received study treatment group (ie, for 
CAZ-AVI plus metronidazole or meropenem), irrespective of whether the patient switched to 
oral therapy.  Key safety data reported up to the LFU visit will also be summarised for the 
Safety evaluable analysis set (ie, those who received at least 72 hours of study treatment as 
defined in Section 8.3.2) by received treatment group.
Safety data from this study and from Study D4280C00016 for cUTI will be combined for 
analysis.  This analysis of combined safety data will be reported separately of the data from 
this study, and will include the summaries of top-line data using the same formats as presented 
for this study.
8.5.1.1
Adverse events
The incidence of AEs will be tabulated and reviewed for potential significance and clinical 
importance.  AEs occurring before the start of study treatment will be reported separately from 
all other AEs.  AEs occurring from the start of the first infusion of IV study therapy will be 
summarised by preferred term and system organ class using the latest version of Medical 
Dictionary for Regulatory Activities (MedDRA) vocabulary.
All recorded AEs will be listed and tabulated by system organ class, preferred term and for 
each cohort.  
Summaries and listings of AEs leading to death, SAEs and AEs leading to discontinuation of 
study treatment will also be presented.  Summaries will also be presented by relationship to IV 
study therapy and by AE intensity.
The number of patients reporting AEs among the following topic groups of AEoSI, for which 
prior review has identified groupings of specific AE preferred terms from the MedDRA 
vocabulary, will also be tabulated by cohort:

Liver disorder

Diarrhoea

Hypersensitivity/anaphylaxis

Haematological disorder

Renal disorder
The number of patients with at least 1 AE within each AEoSI topic group will be presented by 
study treatment group, together with a further presentation of the AE incidence rates for each 
PT within each AEoSI topic group.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
76(88)
8.5.1.2
Other safety data
Summaries and listings of data for vital signs, clinical laboratory and urinalysis laboratory 
tests, ECGs and physical examination findings will be presented.  Appropriate data will be 
summarised for the observed value at each scheduled assessment and for the corresponding 
change from Baseline.  
For clinical laboratory tests, listings of patient data will also flag up any abnormal or 
out-of-range values.  Potentially clinically significant changes in the laboratory test 
parameters will also be identified, listed, and summarised at scheduled visits.  This summary 
will present data for patients meeting the criteria at any time during the study up to the EOT 
visit, and separately at any time up to the LFU visit.  Clinical laboratory data will be reported 
in Système International units.
The following number of patients meeting the following criteria at any time during the study 
up to the LFU visit will be assessed: (maximum ALT ≥3×ULN or maximum AST ≥3×ULN) 
and (maximum total bilirubin ≥2×ULN).  The AST, ALT, total bilirubin elevations can occur 
at any time in the specific review period and do not need to occur simultaneously.
For ECG variables, the QT correction factor will be based on both the Bazett and Fridericia 
formulae (QTcB and QTcF).  Categorical summaries of absolute QT, QTcB and QTcF values 
(≥450 ms, ≥480 ms, ≥500 ms) and change from Day 1 (Baseline) values in QT, QTcB and 
QTcF values (≥30 ms, ≥60 ms), and additionally the number and percentage of patients who 
have a post-baseline value of ≥500 ms with a change from Day 1 of ≥60 ms will be presented 
by treatment, visit and cohort.  The number of patients meeting these criteria at any time after 
the start of study treatment until the LFU visit will also be summarised by treatment and 
cohort.
The number and percentage of patients with CrCl in the following ranges: <30 mL/min, 30 to 
50 mL/min, >50 mL/min will be tabulated at each of the TOC and LFU visits for each 
treatment group.
8.5.2
Analysis of the secondary variable(s)
No inferential statistical tests will be performed for any secondary variables.
8.5.2.1
Pharmacokinetic outcome variables
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided.  For Cohorts 1 to 4b, the plasma concentration will be 
summarised by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean ±SD], and coefficient of variation).
In addition, the avibactam and ceftazidime concentration, paediatric patient demographics, 
and disease status data from Cohorts 1 to 4b will be combined with the data from appropriate 
previous clinical studies in paediatric patients and/or adults for a population PK analysis.  The 
actual dosing and plasma sampling times will be used for the analysis.  The developed 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
77(88)
population PK model may be used to conduct simulations to determine probability of PK/PD 
target attainment to help to justify the CAZ-AVI dose regimens for paediatric patients with 
cIAI.  A stand-alone population PK modelling and simulation analysis plan will be prepared 
and the results will be reported in a stand-alone report outside of the CSR.
Avibactam and ceftazidime PK parameters derived from population PK analysis and potential 
PK/PD relationships will be reported separately.
8.5.2.2
Clinical outcome definitions
Clinical response outcomes will be summarised by visit, treatment, and cohort in each of the 
CE and ME analysis sets at End of 72 hours’ treatment, EOIV, EOT, TOC, and LFU, as well 
as the ITT and micro-ITT analysis sets.  A clinical failure occurring at the EOIV timepoint or 
later will always be carried forward to any subsequent assessment time.  The Blinded 
Observer will make the assessment of clinical outcome.
For each baseline pathogen identified with sufficient frequency, the number and percentage of 
patients in each treatment group and cohort classified as having a favourable clinical outcome 
for the particular pathogen will also be summarised.
Clinical Outcome at End of 72 hours 
The clinical outcome categories at the End of 72 hours are defined in Table 7.  Favourable 
clinical outcomes are clinical improvement and clinical cure.
Table 7
Clinical outcome assessments at End of 72 hours
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement
Patients who are improving but not enough to switch to oral therapy and are still 
on IV study drug at End of 72 hours and meet the following criterion:
-
Absence of new signs and symptoms, and improvement in at least 
1 symptom or sign (ie, fever, pain, tenderness, elevated WBCs, 
elevated CRP) from Baseline, and with no worsening of any symptom 
or sign
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
78(88)
Table 7
Clinical outcome assessments at End of 72 hours
Outcome
Definition
Clinical Failure
Patients who meet any of the following criteria:
-
Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or worsening in 
signs and symptoms of cIAI that requires alternative non-study 
antimicrobial therapy
-
Discontinuation of study drug due to an AE and requirement for 
alternative non-study antimicrobial therapy for cIAI
-
Death in which cIAI is contributory
-
Postsurgical wound infections defined as an open wound with signs of 
local infection such as purulent exudates, erythema, or warmth that 
requires additional antibiotics and/or nonroutine wound care
-
Patients who are improving but not enough to switch to oral therapy 
and are still on IV study drug at End of 72 hours and who fail to meet 
the following criterion:
Absence of new signs and symptoms, and improvement in at least 
1 symptom or sign (ie, fever, pain, tenderness, elevated WBCs, 
elevated CRP) from Baseline, and with no worsening of any symptom 
or sign
Indeterminate
Study data are not available for evaluation of efficacy for any reason, including:
-
Death in which cIAI is clearly non-contributory
-
Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
Within each analysis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the analysis set)
Clinical Outcome at EOIV
The clinical outcome categories at EOIV are defined in Table 8.  Favourable clinical outcomes 
are clinical improvement and clinical cure.  A clinical failure at EOIV will be carried forward 
to the EOT and TOC visits.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
79(88)
Table 8
Clinical outcome assessments at EOIV
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Improvement
Patients who switch to oral therapy and meet all of the following criteria at 
EOIV:
-
Afebrile (temperature ≤38.0°C) for at least 24 hours
-
Absence of new and improvement in at least 1 symptom or sign (ie, 
fever, pain, tenderness, elevated WBCs, elevated CRP) from Baseline 
and worsening of none.
Clinical Failurea
Patients who meet any of the following criteria:
-
Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or worsening in 
signs and symptoms of cIAI that requires alternative non-study 
antimicrobial therapy
-
Discontinuation of study drug due to an AE and requirement for 
alternative non-study antimicrobial therapy for cIAI
-
Death in which cIAI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, including:
-
Death in which cIAI is clearly non-contributory
-
Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
a A clinical failure at EOIV will be carried forward to EOT and TOC.
Within each analysis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the analysis set)
Clinical Outcome at EOT
The clinical outcome categories at EOT are defined in Table 9.  A favourable clinical outcome 
is clinical cure.  A clinical failure at EOT will be carried forward to the TOC visit.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
80(88)
Table 9
Clinical outcome assessments at EOT
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Failurea
Patients who meet any of the following criteria:
-
Discontinuation of study drug due to insufficient therapeutic effect, 
including persistence, incomplete clinical resolution, or worsening in 
signs and symptoms of cIAI that requires alternative non-study 
antimicrobial therapy
-
Discontinuation of study drug due to an AE and requirement for 
alternative non-study antimicrobial therapy for cIAI
-
Death in which cIAI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, including:
-
Death in which cIAI is clearly non-contributory
-
Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
a A clinical failure at EOT will be carried forward to TOC.
Within each analysis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure 
(Number of patients in the analysis set)
Clinical Outcome at TOC
The clinical outcome categories at TOC are defined in Table 10.  A favourable clinical 
outcome is clinical cure.  Clinical response by pathogen at TOC will also be determined for 
each pathogen isolated at Baseline.
Table 10
Clinical outcome assessments at TOC
Outcome
Definition
Clinical Cure
Resolution of all acute signs and symptoms of cIAI or improvement to such an 
extent that no further antimicrobial therapy is required
Clinical Failure
Patients who meet either of the following criteria:
-
Incomplete resolution or worsening of cIAI signs or symptoms or 
development of new signs or symptoms requiring alternative 
non-study antimicrobial therapy
-
Death in which cIAI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, including:
-
Death in which cIAI is clearly non-contributory
-
Extenuating circumstances precluding classification as a cure or failure 
(eg, patient lost to follow-up)
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
81(88)
Within each analysis set, the proportion of patients with a favourable outcome is defined using 
the following formula: 
Number of patients with clinical cure 
(Number of patients in the analysis set)
Clinical Outcome at LFU
Each patient who was considered clinically cured at TOC will be reassessed at LFU by the 
Blinded Observer for evidence of clinical relapse of cIAI symptoms.  The clinical outcome 
categories at LFU are defined in Table 11.  A favourable clinical outcome at LFU is sustained 
clinical cure.
Table 11
Clinical outcome assessments at LFU
Outcome
Definition
Sustained Clinical Cure
Continued favourable response, defined as resolution of all acute signs and 
symptoms of cIAI and no further antimicrobial therapy is required
Clinical Relapse
Patients who meet either of the following criteria:
-
Reappearance or worsening of signs and symptoms of cIAI that 
requires further antimicrobial therapy and/or surgery
-
Death after TOC in which cIAI is contributory
Indeterminate
Study data are not available for evaluation of efficacy for any reason, including:
-
Death in which cIAI is clearly non-contributory
-
Extenuating circumstances precluding classification as sustained 
clinical cure or clinical relapse (eg, patient lost to follow-up)
Note: Clinical outcome at LFU will only be assessed in patients who were considered clinically cured at TOC.
The proportion of patients with clinical relapse at the LFU visit will be summarised by 
treatment and cohort in both the CE and ME analysis sets.
Within each analysis set, the proportion of patients with a clinical relapse is defined using the 
following formula: 
Number of patients with clinical relapse
(Number of patients in the analysis set)
8.5.2.3
Microbiological response assessments
The proportion of patients with a favourable per-patient microbiological response (ie, 
eradication or presumed eradication) will be summarised by treatment and cohort in the 
micro-ITT and ME analysis sets at the EOIV, EOT, TOC and LFU visits.
The per-pathogen microbiological outcome categories are defined in Table 12.  Favourable 
microbiological outcomes are eradication or presumed eradication.  Baseline pathogens will 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
82(88)
be determined based on central laboratory data (see Section 5.2.1 for details on culture and 
organism identification).  Rules for determination of pathogens will be described in the SAP.  
In order for a patient to have a favourable microbiological response, the outcome for each 
baseline pathogen must be favourable (eradicated or presumed eradicated).  If the outcome for 
any pathogen is unfavourable (persistence or presumed persistence), the patient will be 
considered to have an unfavourable microbiological response.
Table 12
Per-pathogen microbiological outcome categories
Outcome
Definition
Eradication
Source specimen demonstrates absence of the original baseline pathogen
Presumed eradication
Source specimen not available to culture, and the patient assessed as a clinical 
cure or sustained clinical cure or (for EOIV only) clinical improvement
Persistence
Source specimen demonstrates continued presence of the original baseline 
pathogen
Persistence with increasing 
MICa
Source specimen demonstrates continued presence of the original baseline 
pathogen with a minimum inhibitory concentration (MIC) value ≥4-fold larger 
than that observed for the baseline pathogen
Presumed persistence
Source specimen was not available to culture and the patient was assessed as a 
clinical failure or clinical relapse
Indeterminate
Source specimen was not available to culture and the patient’s clinical outcome 
was assessed as indeterminate
a Persistence with increasing MIC is a subset of the Persistence outcome.
For patients who have a microbiological outcome of persistence or presumed persistence at 
the EOIV timepoint or later, this outcome will be carried forward to subsequent visits.
8.5.2.4
Emergent infections
Pathogens first appearing after Baseline (“emergent infections”) until the LFU in patients with 
a baseline pathogen are categorised in Table 13 and these will be summarised separately by 
treatment and cohort.
Table 13
Emergent infections
Infection category
Definition
Superinfection
Isolation of a new pathogen or pathogens (other than the original 
baseline pathogen[s]) from intra-abdominal cultures which is 
accompanied by signs and symptoms of infection requiring alternative 
antimicrobial therapy during the period up to and including EOT.
New infection
Isolation of a new pathogen or pathogens (other than the original 
baseline pathogen[s]) from intra-abdominal cultures which is 
accompanied by signs and symptoms of infection requiring alternative 
antimicrobial therapy in the time period after EOT.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
83(88)
The proportion of patients with an emergent infection (and by infection category) will be 
summarised by treatment and cohort in both the CE and ME analysis sets.
9.
STUDY AND DATA MANAGEMENT 
9.1
Training of study site personnel
Before the first patient is entered into the study, a PRA representative will review and discuss 
the requirements of the Clinical Study Protocol and related documents with the investigational 
staff and also train them in any study specific procedures and the PRA Datalabs data capture 
system.
The Principal Investigator will ensure that appropriate training relevant to the study is given to 
all of these staff, and that any new information relevant to the performance of this study is 
forwarded to the staff involved.
The Principal Investigator will maintain a record of all individuals involved in the study 
(medical, nursing and other staff).
9.2
Monitoring of the study
During the study, an AstraZeneca representative will have regular contacts with the study site, 
including visits to:

Provide information and support to the Investigator(s)

Confirm that facilities remain acceptable

Confirm that the investigational team is adhering to the protocol, that data are being 
accurately and timely recorded in the CRFs, that biological samples are handled in 
accordance with the Laboratory Manual and that study drug accountability checks are 
being performed

Perform source data verification (a comparison of the data in the CRFs with the 
patient’s medical records at the hospital or practice, and other records relevant to the 
study) including verification of informed consent/assent of participating patients.  This 
will require direct access to all original records for each patient (eg, clinic charts)

Ensure withdrawal of informed consent/assent to the use of the patient’s biological 
samples is reported and biological samples are identified and disposed of/destroyed 
accordingly, and the action is documented, and reported to the patient.
The AstraZeneca representative will be available between visits if the Investigator(s) or other 
staff at the centre needs information and advice about the study conduct.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
84(88)
9.2.1
Source data
Refer to the Clinical Study Agreement (CSA) for location of source data.
9.2.2
Study agreements
The Principal Investigator at each/the centre should comply with all the terms, conditions, and 
obligations of the CSA, or equivalent, for this study.  In the event of any inconsistency 
between this Clinical Study Protocol and the CSA, the terms of Clinical Study Protocol shall 
prevail with respect to the conduct of the study and the treatment of patients and in all other 
respects, not relating to study conduct or treatment of patients, the terms of the CSA shall 
prevail.
Agreements between AstraZeneca or AstraZeneca’s representatives, and the Principal 
Investigator should be in place before any study-related procedures can take place, or patients 
are enrolled.
9.2.3
Archiving of study documents
The Investigator follows the principles outlined in the CSA.
9.3
Study timetable and end of study
The end of the study is defined as ‘the last visit of the last patient undergoing the study’.
The study is expected to start in Q3 2015 and to end by Q3 2017.
The study may be terminated at individual centres if the study procedures are not being 
performed according to Good Clinical Practice (GCP), or if recruitment is slow.  AstraZeneca 
may also terminate the entire study prematurely if concerns for safety arise within this study 
or in any other study with CAZ-AVI.
9.4
Data management by PRA
The PRA Datalabs system will be used for data collection and query handling.  The 
Investigator will ensure that data are recorded on the CRFs as specified in the study protocol 
and in accordance with the instructions provided.
The Investigator ensures the accuracy, completeness, and timeliness of the data recorded and 
the provision of answers to data queries according to the CSA.  The Investigator will sign the 
completed CRFs.  A copy of the completed CRFs will be archived at the study site.
Data management will be performed by PRA, according to the Clinical Informatics Plan.  
Adverse events and medical/surgical history will be classified according to the terminology of 
the latest version of the MedDRA.  Medications will be classified according to the 
AstraZeneca Drug Dictionary.  All coding will be performed by the PRA coding group.  Data 
queries will be raised for inconsistent, impossible or missing data.  All entries to the study 
database will be available in an audit trail.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
85(88)
The data will be validated as defined in the Clinical Informatics Plan and Edit Specifications 
Document.  Quality control procedures will be applied to each stage of data handling to ensure 
that all data are reliable and have been processed correctly.  The Clinical Informatics Plan will 
also clarify the roles and responsibilities of the various functions and personnel involved in 
the data management process.
When all data have been coded, validated, signed and locked, clean file will be declared.  Any 
treatment revealing data may thereafter be added and the final database will be locked.
Serious Adverse Event Reconciliation
Serious adverse event reconciliation reports are produced and reconciled with the patient 
safety database and/or the investigational site.  SAE reconciliation between safety data and 
clinical data will be performed by PRA.  The frequency depends on the expected volume of 
SAE reports and will be defined in the AE/SAE Reconciliation Plan.
Management of external data
The data collected through third party sources will be obtained and reconciled against study 
data.
10.
ETHICAL AND REGULATORY REQUIREMENTS
10.1
Ethical conduct of the study
The study will be performed in accordance with ethical principles that have their origin in the 
Declaration of Helsinki and are consistent with ICH/GCP, applicable regulatory requirements 
and the AstraZeneca policy on Bioethics and Human Biological Samples.
10.2
Patient data protection
The ICF/Assent Form will incorporate (or, in some cases, be accompanied by a separate 
document incorporating) wording that complies with relevant data protection and privacy 
legislation.
10.3
Ethics and regulatory review
An Independent Ethics Committee (IEC)/Institutional Review Board (IRB) should approve 
the final study protocol, including the final version of the ICF, Assent Form, and any other 
written information and/or materials to be provided to the patients.  The Investigator will 
ensure the distribution of these documents to the applicable IEC/IRB, and to the study site 
staff.
The opinion of the IEC/IRB should be given in writing.  The Investigator should submit the 
written approval to PRA before enrolment of any patient into the study. 
The IEC/IRB should approve all advertising used to recruit patients for the study.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
86(88)
PRA should approve any modifications to the ICF and Assent Form that are needed to meet 
local requirements.
If required by local regulations, the protocol should be re-approved by the IEC/IRB annually.
Before enrolment of any patient into the study, the final study protocol, including the final 
version of the ICF, and Assent Form, is approved by the national regulatory authority or a 
notification to the national regulatory authority is done, according to local regulations.
PRA will handle the distribution of any of these documents to the national regulatory 
authorities.
PRA will provide Regulatory Authorities, IECs/IRBs and Principal Investigators with safety 
updates/reports according to local requirements.
Each Principal Investigator is responsible for providing the IEC/IRB with reports of any 
serious and unexpected adverse drug reactions from any other study conducted with the IP.  
PRA will provide this information to the Principal Investigator so that he/she can meet these 
reporting requirements.
10.4
Informed consent
The Principal Investigator(s) at each centre will:

Ensure each patient's parent(s) or other legally acceptable representative(s) and patient 
when applicable (if age appropriate according to local regulations) is given full and 
adequate oral and written information about the nature, purpose, possible risk and 
benefit of the study

Ensure each patient's parent(s) or other legally acceptable representative(s) and patient 
when applicable (if age appropriate according to local regulations) is notified that they 
are free to discontinue from the study at any time

Ensure that each patient's parent(s) or other legally acceptable representative(s) and 
patient when applicable (if age appropriate according to local regulations) is given the 
opportunity to ask questions and allowed time to consider the information provided

Ensure each patient’s parent(s) or other legally acceptable representative(s) provides 
signed and dated informed consent and patient (if age appropriate according to local 
regulations) provides signed and dated assent before conducting any procedure 
specifically for the study

Ensure the original, signed ICF(s) and Assent Form (if age appropriate according to 
local regulations) is/are stored in the Investigator’s Study File
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
87(88)

Ensure a copy of the signed ICF(s) and Assent Form (if age appropriate according to 
local regulations) is/are given to the patient’s parent(s) or other legally acceptable 
representative(s)

Ensure that any incentives for patients who participate in the study as well as any 
provisions for patients harmed as a consequence of study participation are described in 
the ICF(s) and Assent Form (if age appropriate according to local regulations) that is 
approved by an IEC/IRB
10.5
Changes to the protocol and Informed Consent Form
Study procedures will not be changed without the mutual agreement of the International 
co-ordinating Investigator and AstraZeneca.
If there are any substantial changes to the study protocol, then these changes will be 
documented in a study protocol amendment and where required in a new version of the study 
protocol (Revised Clinical Study Protocol).
The amendment is to be approved by the relevant IEC/IRB and if applicable, also the national 
regulatory authority approval, before implementation.  Local requirements are to be followed 
for revised protocols.
AstraZeneca will distribute any subsequent amendments and new versions of the protocol to 
each Principal Investigator(s). For distribution to IEC/IRB see Section 10.3.
If a protocol amendment requires a change to a centre’s ICF and/or Assent Form, AstraZeneca 
and the centre’s IEC/IRB are to approve the revised ICF and/or Assent Form (if applicable) 
before the revised form(s) is/are used. 
If local regulations require, any administrative change will be communicated to or approved 
by each IEC/IRB.
10.6
Audits and inspections
Authorised representatives of AstraZeneca, a regulatory authority, or an IEC may perform 
audits or inspections at the centre, including source data verification.  The purpose of an audit 
or inspection is to systematically and independently examine all study-related activities and 
documents, to determine whether these activities were conducted, and data were recorded, 
analysed, and accurately reported according to the protocol, GCP, guidelines of the ICH, and 
any applicable regulatory requirements.  The Investigator will contact AstraZeneca 
immediately if contacted by a regulatory agency about an inspection at the centre.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Global Revised Clinical Study Protocol
Drug Substance Ceftazidime-avibactam  
Study Code D4280C00015
Edition Number 2
Date 07 March 2017
88(88)
11.
LIST OF REFERENCES
European Commission 2008
European Commission.  Ethical considerations for clinical trials on medicinal products 
conducted with the paediatric population: Recommendations of the ad hoc group for the 
development of implementing guidelines for Directive 2001/20/EC relating to good clinical 
practice in the conduct of clinical trials on medicinal products for human use.  2008.  
Available from: http://ec.europa.eu/health/files/eudralex/vol-10/ethical_considerations_en.pdf.
Howie 2011
Howie SR.  Blood sample volumes in child health research: review of safe limits.  Bull World 
Health Organ 2011;89:46-53.
Schwartz et al 2009
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al.  New equations 
to estimate GFR in children with CKD.  J Am Soc Nephrol 2009 Mar;20(3):629-37.
Stachyra et al 2009
Stachyra T, Levasseur P, Péchereau MC, Girard AM, Claudon M, Miossec C, et al.  In vitro 
activity of the β-lactamase inhibitor NXL104 against KPC-2 carbapenemase and 
Enterobacteriaceae expressing KPC carbapenemases.  J Antimicrob Chemother 
2009;64(2):326-9.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix B
Drug Substance
Ceftazidime-avibactam
Study Code
D4280C00015
Edition Number
1
Date
20 January 2015
Appendix B
Additional Safety Information
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix B
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(3)
FURTHER GUIDANCE ON THE DEFINITION OF A SERIOUS 
ADVERSE EVENT (SAE)
Life threatening
‘Life-threatening’ means that the subject was at immediate risk of death from the AE as it 
occurred or it is suspected that use or continued use of the product would result in the 
subject’s death.  ‘Life-threatening’ does not mean that had an AE occurred in a more severe 
form it might have caused death (eg, hepatitis that resolved without hepatic failure).
Hospitalisation
Outpatient treatment in an emergency room is not in itself a serious AE, although the reasons 
for it may be (eg, bronchospasm, laryngeal oedema).  Hospital admissions and/or surgical 
operations planned before or during a study are not considered AEs if the illness or disease 
existed before the subject was enrolled in the study, provided that it did not deteriorate in an 
unexpected way during the study.
Important medical event or medical intervention
Medical and scientific judgement should be exercised in deciding whether a case is serious in 
situations where important medical events may not be immediately life threatening or result in 
death, hospitalisation, disability or incapacity but may jeopardize the subject or may require 
medical intervention to prevent one or more outcomes listed in the definition of serious.  
These should usually be considered as serious.
Simply stopping the suspect drug does not mean that it is an important medical event; medical 
judgement must be used.
Examples of such events are:

Angioedema not severe enough to require intubation but requiring iv hydrocortisone 
treatment

Hepatotoxicity caused by paracetamol (acetaminophen) overdose requiring 
treatment with N-acetylcysteine

Intensive treatment in an emergency room or at home for allergic bronchospasm

Blood dyscrasias (eg, neutropenia or anaemia requiring blood transfusion, etc) or 
convulsions that do not result in hospitalisation

Development of drug dependency or drug abuse.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix B
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(3)
A GUIDE TO INTERPRETING THE CAUSALITY QUESTION
The following factors should be considered when deciding if there is a “reasonable 
possibility” that an AE may have been caused by the drug.

Time Course.  Exposure to suspect drug.  Has the subject actually received the 
suspect drug?  Did the AE occur in a reasonable temporal relationship to the 
administration of the suspect drug?

Consistency with known drug profile.  Was the AE consistent with the previous 
knowledge of the suspect drug (pharmacology and toxicology) or drugs of the same 
pharmacological class? OR could the AE be anticipated from its pharmacological 
properties?

Dechallenge experience.  Did the AE resolve or improve on stopping or reducing 
the dose of the suspect drug?

No alternative cause.  The AE cannot be reasonably explained by another aetiology 
such as the underlying disease, other drugs, other host or environmental factors.

Rechallenge experience.  Did the AE reoccur if the suspected drug was reintroduced 
after having been stopped? AstraZeneca would not normally recommend or support 
a rechallenge.

Laboratory tests.  A specific laboratory investigation (if performed) has confirmed 
the relationship?
A “reasonable possibility” could be considered to exist for an AE where one or more of these 
factors exist.
In contrast, there would not be a “reasonable possibility” of causality if none of the above 
criteria apply or where there is evidence of exposure and a reasonable time course but any 
dechallenge (if performed) is negative or ambiguous or there is another more likely cause of 
the AE.
In difficult cases, other factors could be considered such as:

Is this a recognised feature of overdose of the drug?

Is there a known mechanism?
Ambiguous cases should be considered as being a “reasonable possibility” of a causal 
relationship unless further evidence becomes available to refute this.  Causal relationship in 
cases where the disease under study has deteriorated due to lack of effect should be classified 
as no reasonable possibility.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix C
Drug Substance
Ceftazidime-avibactam
Study Code
D4280C00015
Edition Number
1
Date
20 January 2015
Appendix C
International Airline Transportation Association (IATA) 6.2 Guidance 
Document
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix C
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(3)
LABELLING AND SHIPMENT OF BIOHAZARD SAMPLES
International Airline Transportation Association (IATA) classifies biohazardous agents into 
3 categories (http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substance
s.htm). For transport purposes the classification of infectious substances according to risk 
groups was removed from the Dangerous Goods Regulations (DGR) in the 46th edition 
(2005).  Infectious substances are now classified either as Category A, Category B or Exempt.  
There is no direct relationship between Risk Groups and categories A and B.
Category A Infectious Substances are infectious substances in a form that, when exposure to 
it occurs, is capable of causing permanent disability, life-threatening or fatal disease in 
otherwise healthy humans or animals.  Category A pathogens are eg, Ebola, Lassa fever virus:

are to be packed and shipped in accordance with IATA Instruction 602.
Category B Infectious Substances are infectious Substances that do not meet the criteria for 
inclusion in Category A.  Category B pathogens are eg, Hepatitis A, B, C, D, and E viruses, 
Human immunodeficiency virus (HIV) types 1 and 2.  They are assigned the following UN 
number and proper shipping name:

UN 3373 – Biological Substance, Category B

are to be packed in accordance with UN3373 and IATA 650
Exempt - all other materials with minimal risk of containing pathogens

Clinical trial samples will fall into Category B or exempt under IATA regulations

Clinical trial samples will routinely be packed and transported at ambient 
temperature in IATA 650 compliant packaging 
(http://www.iata.org/whatwedo/cargo/dangerous_goods/infectious_substances.
htm)

Biological samples transported in dry ice require additional dangerous goods 
specification for the dry-ice content

IATA compliant courier and packaging materials should be used for packing and 
transportation and packing should be done by an IATA certified person, as 
applicable
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix C
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(3)

Samples routinely transported by road or rail are subject to local regulations which 
require that they are also packed and transported in a safe and appropriate way to 
contain any risk of infection or contamination by using approved couriers and 
packaging/containment materials at all times.  The IATA 650 biological sample 
containment standards are encouraged wherever possible when road or rail transport 
is used.
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance
Ceftazidime-avibactam
Study Code
D4280C00015
Edition Number
1
Date
20 January 2015
Appendix D
Actions Required in Cases of Combined Increase of Aminotransferase and 
Total Bilirubin - Hy’s Law
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(6)
TABLE OF CONTENTS
PAGE
TABLE OF CONTENTS.........................................................................................2
1.
INTRODUCTION ...................................................................................................3
2.
DEFINITIONS.........................................................................................................3
3.
IDENTIFICATION OF POTENTIAL HY’S LAW CASES...................................3
4.
FOLLOW-UP ..........................................................................................................4
4.1
Potential Hy’s Law Criteria not met ........................................................................4
4.2
Potential Hy’s Law Criteria met ..............................................................................4
5.
REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW CASES...............5
6.
REFERENCES ........................................................................................................6
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(6)
1.
INTRODUCTION
During the course of the study the Investigator will remain vigilant for increases in liver
biochemistry.  The investigator is responsible for determining whether a patient meets 
potential Hy’s Law (PHL) criteria at any point during the study.
The Investigator participates, together with AstraZeneca clinical project representatives, in 
review and assessment of cases meeting PHL criteria to agree whether Hy’s Law (HL) criteria 
are met.  HL criteria are met if there is no alternative explanation for the elevations in liver 
biochemistry other than Drug Induced Liver Injury (DILI) caused by the Investigational 
Medicinal Product (IMP). 
The Investigator is responsible for recording data pertaining to PHL/HL cases and for 
reporting Adverse Events (AE) and Serious Adverse Events (SAE) according to the outcome 
of the review and assessment in line with standard safety reporting processes.
2.
DEFINITIONS
Potential Hy’s Law (PHL)
Aspartate Aminotransferase (AST) or Alanine Aminotransferase (ALT) ≥ 3x Upper Limit of 
Normal (ULN) and Total Bilirubin (TBL) ≥ 2xULN irrespective of an increase in Alkaline 
Phosphatase (ALP), at any point during the study following the start of study medication.  The 
elevations do not have to occur at the same time or within a specified time frame.
Hy’s Law (HL)
AST or ALT ≥ 3x ULN and TBL ≥ 2xULN, where no other reason, other than the IMP, can 
be found to explain the combination of increases, eg, elevated ALP indicating cholestasis, 
viral hepatitis, another drug.  The elevations do not have to occur at the same time or within a 
specified time frame.
For PHL and HL the elevation in transaminases must precede or be coincident with (i.e. on the 
same day) the elevation in TBL, but there is no specified timeframe within which the 
elevations in transaminases and TBL must occur.
3.
IDENTIFICATION OF POTENTIAL HY’S LAW CASES
In order to identify cases of PHL it is important to perform a comprehensive review of 
laboratory data for any patient who meets any of the following identification criteria in 
isolation or in combination:

ALT ≥ 3xULN
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
4(6)

AST ≥ 3xULN

TBL ≥ 2xULN
When the identification criteria are met from laboratory results the Investigator will without 
delay:

Determine whether the patient meets PHL criteria (see Section 2 of this Appendix 
for definition) by reviewing laboratory reports from all previous visits (including 
both central and local laboratory results)
The Investigator will without delay review each new laboratory report and if the identification 
criteria are met will:

Notify the AstraZeneca representative

Determine whether the patient meets PHL criteria (see Section 2 of this Appendix 
for definition) by reviewing laboratory reports from all previous visits

Promptly enter the laboratory data into the laboratory CRF
4.
FOLLOW-UP
4.1
Potential Hy’s Law Criteria not met
If the patient does not meet PHL criteria the Investigator will:

Perform follow-up on subsequent laboratory results according to the guidance 
provided in the Clinical Study Protocol.
4.2
Potential Hy’s Law Criteria met
If the patient does meet PHL criteria the Investigator will:

Notify the AstraZeneca representative who will then inform the central Study Team 
The Study Physician contacts the Investigator, to provide guidance, discuss and agree an 
approach for the study patients’ follow-up and the continuous review of data.  Subsequent to 
this contact the Investigator will:

Monitor the patient until liver biochemistry parameters and appropriate clinical 
symptoms and signs return to normal or baseline levels, or as long as medically 
indicated 

Investigate the etiology of the event and perform diagnostic investigations as 
discussed with the Study Physician
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
5(6)

Complete the three Liver CRF Modules as information becomes available 

If at any time (in consultation with the Study Physician) the PHL case meets serious 
criteria, report it as an SAE using standard reporting procedures
5.
REVIEW AND ASSESSMENT OF POTENTIAL HY’S LAW 
CASES
The instructions in this Section should be followed for all cases where PHL criteria are met.
No later than 3 weeks after the biochemistry abnormality was initially detected, the Study 
Physician contacts the Investigator in order to review available data and agree on whether 
there is an alternative explanation for meeting PHL criteria other than DILI caused by the 
IMP.  The AstraZeneca Medical Science Director and Global Safety Physician will also be 
involved in this review together with other subject matter experts as appropriate.  
According to the outcome of the review and assessment, the Investigator will follow the 
instructions below.
If there is an agreed alternative explanation for the ALT or AST and TBL elevations, a 
determination of whether the alternative explanation is an AE will be made and subsequently 
whether the AE meets the criteria for a SAE:

If the alternative explanation is not an AE, record the alternative explanation on the 
appropriate CRF

If the alternative explanation is an AE/SAE, record the AE /SAE in the CRF 
accordingly and follow the AZ standard processes
If it is agreed that there is no explanation that would explain the ALT or AST and TBL 
elevations other than the IMP:

Report an SAE (report term ‘Hy’s Law’) according to AstraZeneca standard 
processes. 

The ‘Medically Important’ serious criterion should be used if no other serious 
criteria apply

As there is no alternative explanation for the HL case, a causality assessment of 
‘related’ should be assigned.
If, there is an unavoidable delay, of over 3 weeks, in obtaining the information necessary to 
assess whether or not the case meets the criteria for HL, then it is assumed that there is no 
alternative explanation until such time as an informed decision can be made:
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix D
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
6(6)

Report an SAE (report term ‘Potential Hy’s Law’) applying serious criteria and 
causality assessment as per above

Continue follow-up and review according to agreed plan.  Once the necessary 
supplementary information is obtained, repeat the review and assessment to 
determine whether HL criteria are met.  Update the SAE report according to the 
outcome of the review
6.
REFERENCES
FDA Guidance for Industry (issued July 2009) ‘Drug-induced liver injury: Premarketing 
clinical evaluation’:
http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances
/UCM174090.pdf
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix E
Drug Substance
Ceftazidime-avibactam 
Study Code
D4280C00015
Edition Number
1
Date
20 January 2015
Appendix E
Tanner Staging of Development
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix E
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
2(4)
TANNER STAGING OF DEVELOPMENT IN GIRLS
Once the onset of puberty has begun, the resulting sequence of somatic and physiologic 
changes gives rise to the sexual maturity rating, or Tanner stages.  Figure 1 and Figure 2
depict the somatic changes which are also described in Table 1.
Figure 1
Sexual maturity ratings (2 to 5) of pubic hair changes in adolescent 
girls. (Courtesy of 
, MD,
 
 
 England)
PPD
PPD
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix E
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
3(4)
Figure 2
Sexual maturity ratings (1 to 5) of breast changes in adolescent girls. 
(Courtesy of 
, MD, 
 
, 
England)
PPD
PPD
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)


Clinical Study Protocol Appendix E
Drug Substance Ceftazidime-avibactam
Study Code D4280C00015
Edition Number 1
Date 20 January 2015
4(4)
Table 1
Classification of sexual maturity states in girls
REFERENCE
Kliegman et al, 2011
Kliegman RM, Bonita S, St. Geme J, Schor N, Behrma.n RE. Nelson Textbook of Pediatrics. 
19th ed. Philadelphia, PA. Elsevier 2011; Part XIII:649-51. 
090177e18e51c7a8\0.1\Draft\Versioned On:09-May-2018 14:11 (GMT)

SAP_001.pdf: 
Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
Statistical Analysis Plan, GEL, ed 2.0
Released Week Commencing: 02 January 2012
Template Doc ID: LDMS_001_00026934
Parent Doc ID: LDMS_001_00073734
Statistical Analysis Plan
Study Code
C3591004 (D4280C00015)
Edition Number2.0
Date
24th August 2017
A single blind, randomised, multi-centre, active controlled, trial to evaluate 
safety, tolerability, pharmacokinetics and efficacy of ceftazidime and 
avibactam when given in combination with metronidazole, compared with 
meropenem, in children from 3 months to less than 18 years of age with 
complicated intra-abdominal infections (cIAIs)
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
2
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
PPD
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
3
TABLE OF CONTENTS
LIST OF TABLES.....................................................................................................................5
LIST OF ABBREVIATIONS....................................................................................................6
AMENDMENT HISTORY .......................................................................................................8
1. STUDY DETAILS.................................................................................................................9
1.1. Study objectives ........................................................................................................9
1.2. Study design ..............................................................................................................9
1.3. Number of subjects..................................................................................................10
2. ANALYSIS SETS ...............................................................................................................11
2.1. Definition of analysis sets .......................................................................................11
2.1.1. Safety Analysis Set.....................................................................................12
2.1.2. Safety Evaluable Analysis Set....................................................................12
2.1.3. PK Analysis Set ..........................................................................................12
2.1.4. Efficacy analysis sets..................................................................................12
2.1.4.1. Intent-to-Treat Analysis Set ......................................................12
2.1.4.2. Microbiological intent-to-treat set.............................................12
2.1.4.3. Clinically Evaluable Analysis Set.............................................12
2.1.4.4. Microbiologically Evaluable Analysis Set................................13
2.2. Violations and deviations........................................................................................14
3. PRIMARY AND SECONDARY VARIABLES.................................................................15
3.1. Definitions and handling of missing data................................................................15
3.1.1. Demographic and baseline characteristic variables....................................15
3.1.2. Definition of prior and concomitant medication ........................................17
3.1.3. Exposure and compliance variables............................................................18
3.2. Primary outcome (safety) variables.........................................................................18
3.2.1. Definition of AEs........................................................................................19
3.2.1.1. Adverse event............................................................................19
3.2.1.2. Serious AEs...............................................................................19
3.2.1.3. Cephalosporin class effects .......................................................20
3.2.1.4. AEs of Special Interest (AEoSI) ...............................................20
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
4
3.2.2. Laboratory parameters................................................................................20
3.2.3. Physical examinations ................................................................................21
3.2.4. ECG ............................................................................................................21
3.2.5. Vital signs...................................................................................................21
3.3. Secondary outcome (efficacy) variables .................................................................22
3.3.1. Definition of clinical outcome....................................................................22
4. ANALYSIS METHODS .....................................................................................................30
4.1. General principles ...................................................................................................30
4.2. Analysis methods ....................................................................................................31
4.2.1. Baseline characteristic analysis ..................................................................31
4.2.1.1. Patient disposition .....................................................................31
4.2.1.2. Demographics and baseline characteristics...............................32
4.2.1.3. Extent of Exposure and Compliance.........................................32
4.2.2. Safety analysis ............................................................................................33
4.2.2.1. Adverse events ..........................................................................33
4.2.2.2. Laboratory assessments.............................................................34
4.2.2.3. Physical examinations...............................................................35
4.2.2.4. ECGs .........................................................................................35
4.2.2.5. Vital signs..................................................................................36
4.2.3. Analysis of secondary variables .................................................................36
4.2.3.1. Pharmacokinetic outcome variables..........................................36
4.2.3.2. Clinical outcome, microbiological response and emergent 
infections ...........................................................................................37
5. INTERIM ANALYSES.......................................................................................................39
5.1. Data Safety Monitoring Board (DSMB) .................................................................39
6. CHANGES OF ANALYSIS FROM PROTOCOL .............................................................39
7. REFERENCES ....................................................................................................................40
8. APPENDIX..........................................................................................................................41
8.1. Evaluability Review Process...................................................................................41
8.2. Potentially clinically significant criteria..................................................................46
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
5
LIST OF TABLES
Table 1.
Laboratory Parameters..........................................................................................20
Table 2: Visit Windows for End of 72 hours, EOIV, EOT, TOC, and LFU ...........................22
Table 3: Clinical outcome assessments at End of 72 hours.....................................................23
Table 4: Clinical outcome assessments at EOIV.....................................................................25
Table 5: Clinical outcome assessments at EOT.......................................................................26
Table 6: Clinical outcome assessments at TOC.......................................................................27
Table 7.
Clinical outcome assessments at LFU ..................................................................28
Table 8: Per-pathogen microbiological outcome categories....................................................29
Table 9.
Emergent infections..............................................................................................29
Table 10: Per-Pathogen Microbiological Response.................................................................30
Table 11: Evaluability assessments .........................................................................................41
Table 12.
Criteria for potentially clinically significant clinical laboratory tests .................46
Table 13: Criteria for potentially clinically significant electrocardiogram tests .....................47
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
6
LIST OF ABBREVIATIONS
Abbreviation or 
special term
Explanation
AE
adverse event 
AEoSI
adverse event of special interest
ALT
alanine aminotransaminase
AST
aspartate aminotransaminase
BDR
blinded data review
BMI
body mass index
CAZ-AVI
ceftazidime-avibactam
CE
clinically evaluable
CFB
change from baseline
CFU
colony forming unit
cIAI
complicated intra-abdominal infection
CLSI
Clinical and Laboratory Standards Institute
CrCl
creatinine clearance
CRP
c-reactive protein
CSP
clinical study protocol
CSR
clinical study report
CV
coefficient of variation
DSMB
data safety monitoring board
DOB
date of birth
ECG
electrocardiogram
EOIV
end of intravenous treatment
EOT
end of treatment
HR
heart rate
β-hCG 
ß-human chorionic gonadotropin
IAI
Intra-abdominal infection
ITT
intent-to-treat
IV
intravenous
LFU
late follow-up 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
7
Abbreviation or 
special term
Explanation
LLN
lower limit of the normal range 
ME
microbiologically evaluable
MedDRA
Medical Dictionary for Regulatory Activities
MIC
minimum inhibitory concentration
Micro-ITT
microbiological intent-to-treat
N
number of patients or counts
NQ
not quantifiable
NR
not recorded
PCS
potentially clinical significant
PK
Pharmacokinetic
QTm
QT measured
QTcB
QT interval corrected using Bazett’s formula
QTcF
QT interval corrected using Fridericia’s formula
SAE
serious adverse event 
SD
standard deviation
SMQ
standardised MedDRA search query
SOC
system organ class
TOC
test of cure 
ULN
upper limit of the normal range
WBC
white blood cells
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
8
AMENDMENT HISTORY
Date
Brief description of change
17Apr2015
, first version
05May2015
, updates made based upon first round of sponsor 
review
12Jun2015
, updates made based upon second round of 
sponsor review
24Aug2017
, updates based upon protocol amendment edition 2 
March 7 2017
Incorporated changes from blind data review for CAZAVI-CAZ016 
study
Incorporated changes from blind data review for CAZAVI-CAZ015
Major changes include:

Added ITT and Micro ITT analysis sets to the analysis in line 
with 
;

Amended permissible visit windows for clinical and 
microbiological response;

Added in description to include total treatment statistics for table 
summaries;

Clarified approach with respect to microbiological definitions, 
including definition of response, selection of pathogen, 
determination of susceptibility, and grouping of pathogens;

Updated derivation of age for patients with missing date of birth;

Added description of oral medications table summary;

Amended AEs of SI to summarize by topic;

Represented change in sponsor from AstraZeneca to Pfizer;

Added clarification and appendix for ECMA process;

Amended approach for summarising laboratory abnormality 
criteria.
PPD
PPD
PPD
PPD
CCI
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
9
1. STUDY DETAILS
1.1. Study objectives
Primary objective (Safety)

Evaluate the safety and tolerability of ceftazidime-avibactam (CAZ-AVI) plus 
metronidazole given at the selected dose regimen versus meropenem in paediatric 
patients aged ≥3 months to <18 years with complicated intra-abdominal infections 
(cIAI).
Secondary objectives 

Evaluate the descriptive efficacy of CAZ-AVI plus metronidazole versus meropenem 
in paediatric patients aged ≥3 months to <18 years with cIAI.

Evaluate the pharmacokinetic (PK) of CAZ-AVI in paediatric patients aged ≥3 
months to <18 years with cIAI.
Exploratory objectives
Not applicable.
1.2. Study design
This study is a single blind, randomised, multi-centre, active controlled trial. Patients aged 
from 3 months to less than 18 years with cIAI will be randomised to 1 of 2 groups (3:1 ratio): 
CAZ-AVI in combination with metronidazole versus meropenem. 
Intravenous (IV) CAZ-AVI infusions will be given at the following doses per cohort: 

Cohorts 1 and 2: 2000 mg CAZ/500 mg AVI every 8 hours for patients ≥40 kg weight
or 50 mg/kg CAZ/12.5 mg/kg AVI every 8 hours for patients <40kg weight, given as 
a 2-hour infusion.

Cohorts 3 and 4a: 50 mg/kg CAZ/12.5 mg/kg AVI every 8 hours given as a 2-hour 
infusion.

4b: 50mg/kg CAZ/12.5mg/kg AVI every 8 hours for patients ≥6 months to <1 year, 
and 40mg/kg CAZ/10mg/kg AVI every 8 hours for patients ≥3 months to <6 months.
Patients whose creatinine clearance (CrCl) falls to ≤50 mL/min (adjusted to mL/min/1.73m2
using Schwartz formula) while on treatment should have a CAZ-AVI dose reduction of 50% 
administered every 8 hours. Patients whose CrCl drops below 30 mL/min should be removed 
from study therapy. Because the CrCl determination is only an estimate of renal function, in 
instances where the CrCl is approaching thresholds that would require intervention such as a 
dose change or discontinuation of therapy (ie CrCl approaching 50 or 30 mL/min), the 
Investigator should use his or her discretion in determining (ie confirming the value by repeat 
testing, if feasible) whether an immediate dose change, a short period of continued 
observation, or discontinuation of therapy is warranted.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
10
Meropenem 20 mg/kg every 8 hours (±1 hour) given by IV infusion over approximately 15 
to 30 minutes or up to 1 hour, or infusion duration as per local guidelines, with optional oral 
switch therapy as described above. For patients weighing over 50 kg, the maximum dose of 
meropenem should not exceed 1 g every 8 hours. For patients weighing over 50 kg, the 
maximum dose of meropenem should not exceed 1 g every 8 hours. Randomisation will be
stratified as follows: 

Cohort 1: patients aged from 12 years to <18 years;

Cohort 2: patients aged from 6 years to <12 years;

Cohort 3: patients aged from 2 years to <6 years;

Cohort 4: patients aged from 3 months to <2 years.
Patients will receive IV treatment for a minimum of 72 hours (3 full days, ie, 9 doses) before 
having the option to switch to an oral therapy, at the Investigator’s discretion. The total 
period of treatment (ie, IV drug and oral switch treatment) is to be between 7 and 15 days. 
Patients may remain in the IV study treatment for the full 7 to 15 days.
Patients will be assessed for safety and efficacy throughout the study, and blood samples will 
be taken for PK assessment. The duration of each patient’s participation in the study will be a 
minimum of 27 days to a maximum of 50 days after start of study treatment (defined as the 
time point at which first dose of study treatment is administered) at which time there will be 
a late follow-up (LFU) assessment visit. The LFU is to be performed 20 to 35 days after the 
last dose of any treatment.
1.3. Number of subjects
Patients will continue to be recruited into this study until 80 patients complete at least 72 
hours (3 full days, ie, 9 doses) of study treatment (deemed to be evaluable patients).Patients 
will be randomised 3:1 to the CAZ-AVI plus metronidazole or meropenem study treatment 
groups. At least 60 and 20 evaluable patients, respectively, are required in the CAZ-AVI plus 
metronidazole and meropenem groups.
The proposed sample size is based on the probability of observing a ‘rare’ safety event. The 
‘rare’ term used in this section is not based on the regulatory definition but is instead 
intended to reflect uncommon events. Safety data from this study and from Study 
D4280C00016 for complicated urinary tract infection will be combined for analysis. As a 
total of at least 120 patients will be treated with CAZ-AVI in both studies combined, when 
assuming an underlying incidence rate of 3% for a specific ‘rare’ event, this will ensure that 
the probability of observing such an event in at least 1 patient treated with CAZ-AVI exceeds 
95%.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
11
In addition, each of the 4 patient cohorts is required to have a minimum number of evaluable
patients as follows:

Cohort 1: At least 15:5 evaluable patients aged from 12 years to <18 years;

Cohort 2: At least 15:5 evaluable patients aged from 6 years to <12 years;

Cohort 3: No required minimum of evaluable patients aged from 2 years to <6 years.

Cohort 4: No required minimum of evaluable patients aged from 3 months to <2 
years, comprising Cohorts 4a and 4b as follows:

Cohort 4a: Patients aged from 1 year to <2 years;

Cohort 4b: Patients aged from 3 months to <1 year.
Considering patients over all 4 cohorts combined, the maximum number of evaluable 
patients allowed to have been recruited having been diagnosed with complicated appendicitis 
is 90%.
Patients who are randomized and registered as having ended IV treatment with less than 9 
doses do not meet the criteria for evaluable patients and will be eligible for enrolment 
replacement. Data from these replaced patients will be included in the safety analysis set (and 
not the safety evaluable analysis set). The process of replacement will ensure that the next 
patient randomized in the same stratum will be automatically assigned the same treatment 
group as the non-evaluable patient who needs to be replaced. The purpose of this is to 
minimise over-recruitment to reach the required number of evaluable patients in each 
treatment arm. Replacement subjects can themselves be replaced (up to a maximum of 5 
replacements per allocated randomization code).
2. ANALYSIS SETS
2.1. Definition of analysis sets
The analysis of data will be based on different analysis sets according to the purpose of 
analysis, ie, for safety and efficacy. The final decision regarding eligibility of patients for all 
analysis sets will be finalised prior to declaring database lock. Specifically the manual aspect 
of the assessments for the clinically evaluable (CE) and microbiologically evaluable (ME) 
analysis sets will be undertaken by an evaluability review committee, including at a 
minimum: medical personnel, a microbiologist, and a statistician. The review will focus on 
data for which analysis set criteria cannot be determined programmatically, eg, protocol 
deviations and the use of prohibited concomitant medications. Preparation of data will be 
performed by unblinded study team members (protocol deviation data is potentially 
unblinding), and information will be presented in a blinded manner for decision making by 
the evaluability review committee.  A more detailed outline of the criteria which will be 
determined by this review is included within Section 8.1.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
12
2.1.1. Safety Analysis Set
The Safety analysis set will include all randomised patients who received any amount of IV 
study therapy (ie, CAZ-AVI plus metronidazole or meropenem). For the Safety analysis set, 
patients will be included in all outputs according to the study treatment they actually 
received.
2.1.2. Safety Evaluable Analysis Set
The safety evaluable analysis set will be a subset of the patients in the Safety analysis set that 
received at least 9 doses of study treatment. Each subject’s dosing profile will be reviewed by 
unblinded medical personnel to confirm evaluability. Any cases that are not clear will be 
identified and presented in a blinded manner at a formal evaluability and 
clinical/microbiological assessment (ECMA) meeting to determine whether the subject is 
acceptable for inclusion in the safety evaluable analysis set.
2.1.3. PK Analysis Set
The PK analysis set will be a subset of the patients in the Safety analysis set who have at 
least 1 ceftazidime and/or avibactam plasma measurement available.
2.1.4. Efficacy analysis sets
The efficacy analysis of data in this study will be based on 4 subsets of patients (intent-to-
treat (ITT), microbiological intent-to-treat (micro-ITT), CE and ME analysis sets) as defined 
below. The CE and ME analysis sets will be defined separately for each of the visits at which 
efficacy is assessed.
Patients who receive both study therapies will be excluded from these CE and ME analysis 
sets. Patients in the ITT, micro-ITT, CE and ME analysis sets will be summarized according 
to the randomized treatment assignment.
2.1.4.1. Intent-to-Treat Analysis Set
The ITT analysis set will include all patients who have been assigned a randomised 
treatment.
2.1.4.2. Microbiological intent-to-treat set
The micro-ITT set will include all randomised patients who have a baseline pathogen known 
to cause cIAI. All baseline pathogens isolated from the intraabdominal fluid or blood will be 
examined by a microbiologist prior to DBL and a list of those which cause cIAI will be 
identified in order to define this analysis set.
2.1.4.3. Clinically Evaluable Analysis Set
The CE analysis set is defined at the end of 72 hours of study treatment (determined by the 
72 hour efficacy assessment visit), and at each of the End of Intravenous Treatment (EOIV), 
End of Treatment (EOT), Test of Cure (TOC) and Late Follow up (LFU) visits.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
13
The CE analysis set will include all randomised patients who receive any amount of IV study 
drug and have a confirmed diagnosis of cIAI; patients must also meet the following specific 
conditions:

Have received at least 48 hours of IV study drug, defined as 6 doses, in order to be 
considered an evaluable clinical failure, unless deemed a clinical failure based on a 
treatment-limiting AE;

Have received at least 72 hours of IV study drug, defined as 9 doses, in order to be 
considered an evaluable clinical cure;

Have been evaluated at the End of 72 hours assessment and at the specific visits of 
EOIV, EOT, and TOC with a clinical response of cure or failure (or have been 
assessed as a clinical failure at or after EOIV and before the planned assessment 
visit), or for LFU, have been evaluated with a clinical response of sustained cure or 
relapse;

Had no important protocol deviations that would affect assessment of efficacy;

Have not received concomitant antibiotics that would affect assessment of efficacy.
2.1.4.4. Microbiologically Evaluable Analysis Set
The ME analysis set will be defined at the end of 72 hours of study treatment, and at each of 
the EOIV, EOT, TOC and LFU visits. It includes all patients meeting the following criteria:

Randomised patients who have received any amount of IV study drug and have a 
confirmed diagnosis of cIAI;

Have received at least 48 hours of IV study drug, defined as 6 doses, in order to be 
considered an evaluable clinical failure, unless deemed a clinical failure based on a 
treatment-limiting AE;

Have received at least 72 hours of IV study drug, defined as 9 doses, in order to be 
considered an evaluable clinical cure;

At the specific visit had a microbiological response which was not indeterminate 
(note; presumed eradication or presumed persistence is acceptable);

Had no important protocol deviations that would affect assessment of efficacy;

Have not received concomitant antibiotics that would affect assessment of efficacy;

Have at least 1 typical intra-abdominal infection (IAI) bacterial pathogen which has 
been isolated from an adequate microbiological specimen at Baseline that is 
susceptible to both study agents (CAZ-AVI and meropenem).
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
14
2.1.4.4.1. Susceptibility to study drug for ME Analysis Set
Susceptibility to ceftazidime-avibactam for baseline pathogen species of Enterobacteriaceae
and P. aeruginosa will be determined programmatically. A patient will be counted as having 
had at least 1 etiologic pathogen in the initial/pre-study culture that is susceptible to both 
treatment arms if;
For cases when a central microbiology reference laboratory result is present, a pathogen that 
satisfies the following interpretive criteria of susceptibility:

Displays an MIC of ceftazidime-avibactam ≤ 8 mg/L for Enterobacteriaceae and/or 
P. aeruginosa (2017 FDA label, ceftazidime-avibactam highlights of prescribing 
information), categorizing it as susceptible to the combination;

and displays an MIC of meropenem that categorizes it as susceptible by CLSI 
interpretive criteria, namely ≤ 1 mg/L for Enterobacteriaceae, ≤2 mg/L for P. 
aeruginosa (CLSI 2012).
For cases when the local lab result is used, a pathogen that satisfies the following interpretive 
criteria of susceptibility:

displays a disk diffusion diameter for ceftazidime-avibactam (30 g ceftazidime and 
20 g of avibactam) greater than or equal to the susceptible breakpoint, ie, ≥ 21 mm 
for Enterobacteriaceae and P. aeruginosa (2017 FDA label, ceftazidime-avibactam 
highlights of prescribing information);

and disk diffusion diameters categorizing the isolate as susceptible to meropenem 
judged on the CLSI interpretive criteria of ≥ 23 mm for Enterobacteriaceae and 
≥19 mm for P. aeruginosa (CLSI 2012).
Pathogen species not included in the definition above can not be confirmed to be susceptible 
and therefore would not meet the criteria to be included in ME analysis sets.
2.2. Violations and deviations
Protocol deviations are defined as any variations from the protocol, including enrolment of a 
patient who did not meet all inclusion and exclusion criteria and failed to perform the 
assessments and procedures within the required time frame. Protocol deviations will be 
summarized in two ways: a) a summary table will display counts of patients with important 
protocol deviations and b) the analysis sets table will display the counts of patients excluded 
from CE and ME analysis sets due to important protocol deviations that would affect the 
assessment of efficacy. All protocol deviations and their classification (i.e. whether or not it 
was important and whether or not it led to the exclusion from the CE and ME analysis sets) 
will be listed.
The review and assignment of deviations that affect patient-level analysis set statuses will be 
finalized as part of the final data review before database lock.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
15
3. PRIMARY AND SECONDARY VARIABLES
3.1. Definitions and handling of missing data
Baseline
For all variables, the last assessment made prior to the first dose of study drug will be defined 
as the baseline. 
For microbiological samples, if they come from a sterile source and are taken within 1 day of 
baseline and before any antibiotics are administered, it will also be considered for the 
derivation of baseline.
Change from Baseline (CFB)
Change from baseline will be calculated as the post-treatment value minus the baseline value. 
Missing Data
No missing values will be imputed except age for some patients owing to the descriptive 
nature of the study.
3.1.1. Demographic and baseline characteristic variables 
Demographic and baseline characteristics include the following:

Age (in years for patients >=2 years of age, and in months for patients < 2 years of 
age);

Sex (Male, Female);

Ethnicity (Hispanic or Latino, Not Hispanic or Latino);

Race category (White, Black/African American, Asian, Native Hawaiian/Pacific 
Islander, American Indian/Alaska Native, Other);

Height (cm);

Weight (kg);

Body mass index (BMI) (kg/m2);

Medical and Surgical History;

Renal status category (<30 mL/min/1.73m2, ≥30 to <50 mL/min/1.73m2, ≥50 to <80 
mL/min/1.73m2, ≥80 mL/min/1.73m2).
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
16

Study qualifying procedures summarized based on data entered in the following two 
CRF modules:

Procedures related to the infection;

Surgical history (subsetted for surgeries performed on study day -1 or 1).

Appendicitis at screening.

Diagnosis of intraabdominal infection.
Note that procedure type is recorded on either the procedures relating to infection or surgical 
history page depending on the patient. Prior to database lock, the entered values on each page 
will be mapped to the categories of laparotomy, laparoscopy, percutaneous drainage and 
appendectomy not otherwise specified (NOS). Patients can have more than one procedure 
type counted in this way.
Some countries will record date of birth (DOB) only partially, either year or month and year. 
For those patients DOB will be imputed, and age will be derived based on the imputed DOB.
The following algorithm will be used for the imputation of DOB and derivation of age:
1. Use cohort to find the maximum and minimum possible age. 
2. If age is recorded on the CRF, use this value to further narrow down the maximum 
and minimum possible age.
3. Use the date of informed consent alongside the maximum and minimum possible age 
to find the earliest and latest possible DOB.
4. Use any portions of the DOB which have been recorded to narrow down the earliest 
and latest possible DOB from step 3.
5. Find the midpoint of the earliest and latest possible DOB from step 4.
6. Use imputed DOB from step 5 to derive age at informed consent.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
17
The following examples, all from Cohort 3 (2 to < 6 years), illustrate this algorithm:
Example
CRF_age
DOB 
(CRF) 
day/mo/yr
Informed
Consent 
Date
Range of Possible DOBs
Midpoint of 
range of 
possible 
DOBs
Derived 
age
1
blank
xx/xx/2008
31-Aug-
2014
1-Sep-2008
31-Dec-
2008
31-Oct-
2008
5y 9mo
2
3
xx/xx/2011
31-Aug-
2014
1-Jan-2011
31-Aug-
2011
2-May-2011
3y 3 mo
3
blank
xx/xx/2011
31-Aug-
2014
1-Jan-2011
31-Dec-
2011
2-Jul-2011
3y 1 mo
4
blank
xx/xx/2011
31-May-
2014
1-Jan-2011
31-Dec-
2011
2-Jul-2011
2y 10 mo
5
blank
xx/03/2011
10-Mar-
2014
1-Mar-
2011
31-Mar-
2011
16-Mar-
2011
2y 11 mo
A footnote will be added to the demography summary table to specify that imputation has 
been performed for age calculation and the number of patients within each cohort for which 
the imputation has been performed.
The demography listing will present DOB both as recorded in the CRF (eg, with missing 
month / date as applicable) and age as derived at the date of informed consent, and a footnote 
will also be put in place to describe that age imputation has been performed there.
3.1.2. Definition of prior and concomitant medication 
A prior medication is defined as:
a.
A medication that was taken any time in the 2 weeks prior to study entry up to the 
date of randomisation, regardless of whether this was stopped prior to the date of 
randomisation or not
A concomitant medication is defined as
a.
Any medication taken at any time between the date of randomisation and up to the 
LFU visit. 
Consequently, a medication could be counted as both prior and concomitant. Any medication 
prescribed at the LFU visit will not be deemed concomitant.
If any medications reported are not able to be determined as prior medications or 
concomitant medications due to missing or partial start dates and/or stop dates, the following 
imputation rules will be implemented: 

If the year is present but the month and day are missing, then 01JAN will be imputed 
for the start date and 31DEC for the stop date.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
18

If the year and month are present but the day is missing, then 01 will be imputed for 
the start date and the last day of the month for the stop date.
If the start date is missing, it is prior if the stop date is prior to the date of randomization. 
Otherwise, it is both prior and concomitant. If the stop date is missing, it is concomitant if 
start date is later than the date of randomization. If start date is prior to the date of 
randomization, it will be both prior and concomitant. If both stop/start years are missing or 
both stop/start dates otherwise cannot be imputed, then the date will be treated as missing and 
the medication will be treated as both prior and concomitant medications.
In case it appears that some of the medications are clearly ‘prior’ but classified as 
‘concomitant’ and the imputation goes across the first dose day, such medications will be 
reviewed before the data base lock (BDRM) to make the final decision whether they should 
be classed as prior or concomitant.
An antibiotic is called “systemic” when it is classified as J01 (antibacterial for systemic use) 
code based on ATC classification.
3.1.3. Exposure and compliance variables
Exposure (in days) to the study therapy for CAZ-AVI alone, in combination with 
metronidazole, and for meropenem will be calculated as the difference between the last study 
therapy date and time and the first study therapy date and time converted to days plus 1 day.
Total number of infusions for CAZ-AVI alone, in combination with metronidazole, and for 
meropenem will be calculated by summing all the number of infusions together. Average 
daily infusions will be calculated dividing total number of infusions by days of exposure.
Treatment compliance over the entire treatment period will be defined as the number of 
infusions over all doses received, divided by the number of infusions over all doses expected 
during the treatment period, and then multiplied by 100. Any partial infusion will be 
considered as a complete infusion for the purpose of compliance, and the relevant details will 
be listed.
Exposure (in days) will also be calculated for patients who switch to oral therapy, using start 
and stop dates of oral therapy in the same way as described for study therapy above. In 
addition, the combined exposure (in days) of IV study treatment and oral therapy (if 
applicable) will be calculated.
3.2. Primary outcome (safety) variables
The primary outcome variables are for safety and tolerability as assessed by:

Adverse events (AEs) and Serious adverse events (SAEs);

Cephalosporin class effects and additional AEs (including, but not limited to seizures, 
C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic 
anaemia and changes in renal function);

Vital signs (pulse, blood pressure, respiratory rate, temperature);
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
19

Physical examination;

Laboratory parameters, including CrCl;

Electrocardiogram (ECG).
3.2.1. Definition of AEs
3.2.1.1. Adverse event
An AE is the development of an undesirable medical condition or the deterioration of a pre-
existing medical condition, whether or not considered casually related to the product. An 
undesirable medical condition can be symptoms (eg, nausea, chest pain), signs (eg, 
tachycardia, enlarged liver) or the abnormal results of an investigation (eg, laboratory 
findings, ECG). In clinical studies, an AE can include an undesirable medical condition 
occurring at any time, including run-in or washout periods, even if no study treatment has 
been administered. All AEs will be classified using the Medical Dictionary for Regulatory 
Activities (MedDRA) Version 20.0.
The term AE is used to include both serious and non-serious AEs. Non-serious AEs and 
SAEs will be collected for each patient from the time when informed consent or ascent 
(whichever is earliest) is obtained at Screening through to the LFU visit. Any AEs that are 
unresolved at the patient’s last AE assessment will be followed up by the investigator until 
the event is resolved or stabilized. 
Each AE will be graded for severity. Each AE will be assessed for relationship to the study 
therapy as well. Where there is partial date information which does not clearly define 
whether an AE occurs post first infusion of IV therapy, the same imputation rules will be 
utilised as for the definition of prior or concomitant medications in Section 3.1.3, where 
assignment to post first infusion will be assumed where dates are in any way compatible for 
this to be true.
3.2.1.2. Serious AEs
An SAE is an AE occurring during any study phase (ie, run-in, treatment, washout, follow-
up), that fulfils 1 or more of the following criteria:

Results in death;

Is immediately life-threatening;

Requires in-patient hospitalization or prolongation of existing hospitalization;

Results in persistent or significant disability/incapacity or substantial disruption of the
ability to conduct normal life functions;

Is a congenital abnormality or birth defect;

Is an important medical event that may jeopardize the patient or may require medical 
intervention to prevent one of the outcomes listed above.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
20
3.2.1.3. Cephalosporin class effects
Cephalosporin class effects (first time episode of hypersensitivity to class of cephalosporin 
drugs) and additional AEs will also be closely monitored (including, but not limited to 
seizures, C. difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, 
haemolytic anaemia and changes in renal function).
3.2.1.4. AEs of Special Interest (AEoSI)
AEoSI will include the following safety topic groups for AEs:

Liver disorder;

Diarrhoea;

Hypersensitivity/anaphylaxis;

Haematological disorder;

Renal disorder.
3.2.2. Laboratory parameters
Blood and urine samples for determination of clinical chemistry, haematology, and urinalysis 
will be taken at the times indicated in Table 1 of the clinical study protocol (CSP).
Table 1 presents the laboratory parameters that will be measured:
Table 1.
Laboratory Parameters
Clinical Chemistry
Haematology
Urinalysis
Magnesium 
Bicarbonate
Sodium 
Potassium 
Phosphorus 
Chloride 
Calcium 
Alkaline phosphatase 
Gamma glutamyltransferase 
Alanine Amino Transaminase (ALT 
)
Aspartate Amino Transaminase 
(AST) 
Creatine kinase 
Lactate dehydrogenase 
Total bilirubin 
Indirect bilirubin
Glucose, non-fasting
Haematocrit
Haemoglobin
Erythrocyte count
Mean cell volume
Leukocyte count (WBC)
Neutrophils
Lymphocytes
Monocytes
Eosinophils
Basophils
Platelets
Coombs test (direct)
Pregnancy testing
Serum Beta-Human 
chorionic 
gonadotropin ( β-hCG)
Urinalysis (routine and
microscopy) will be
performed according to the
study centre’s standard
procedures
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
21
Table 1.
Laboratory Parameters
Clinical Chemistry
Haematology
Urinalysis
Creatinine
Blood urea nitrogen
C-reactive protein (CRP) (optional) 
Creatinine clearance will be measured throughout the study until LFU using the child’s 
measured height (length) and serum creatinine within the updated “bedside” Schwartz 
formula (Schwartz et al, 2009):
CrCl (mL/min/1.73m2)=0.413×height (length) (cm)/serum creatinine (mg/dL)
3.2.3. Physical examinations
A complete physical examination will be performed and will include an assessment of the 
following: general appearance, skin, head and neck (including ears, eyes, nose and throat), 
lymph nodes, thyroid, respiratory, cardiovascular, abdomen, musculoskeletal (including 
spine and extremities) and neurological systems, including height and weight. BMI (kg/m2) 
will be calculated as the ratio of weight in kg/(height in cm/100)2. BMI will only be 
calculated at Baseline (Day -1/Day 1). BMI will not be calculated for children <2 years of 
age (Cohorts 4a and 4b) as BMI is not considered a screening tool for healthy weight in 
children <2 years of age. 
3.2.4. ECG
Each ECG will be interpreted as appropriate for the patient’s age. ECG variables include 
ECG heart rate, QRS duration, QT interval, RR interval, PR interval, QTc (QTcB and QTcF). 
Where QTm=QT measured, RR = RR interval, and HR = Heart rate; QTcB (QT interval 
corrected by Bazett’s formula) is calculated using the following formula:
QTc = QTm / √(RR) 
Where RR = 60 / HR
QTcF (QT interval corrected by Fridericia’s formula) is calculated dividing QT measured by 
the cube root of RR:
QTc = QTm / 3√(RR)
3.2.5. Vital signs
Vital signs include heart rate (beats per minute), body temperature (°C), respiratory rate 
(breaths per minute), systolic blood pressure (mmHg), and diastolic blood pressure (mmHg).
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
22
3.3. Secondary outcome (efficacy) variables

Plasma concentrations and PK parameters of CAZ and AVI;

Clinical response at End of 72 hours’ treatment, EOIV, EOT, and TOC;

Microbiological response at EOIV, EOT, TOC, and LFU;

Clinical relapse at LFU;

Emergent infections.
3.3.1. Definition of clinical outcome
Clinical response outcomes at End of 72 hours and EOIV are clinical cure, clinical 
improvement, clinical failure and indeterminate, and at EOT, and TOC outcomes are clinical 
cure, clinical failure and indeterminate. Clinical response outcomes at LFU are sustained 
clinical cure, relapse or indeterminate. The derived analyses windows in Table 2 will be used 
to identify permissible values for the analysis for the CE and ME analysis sets:
Table 2: Visit Windows for End of 72 hours, EOIV, EOT, TOC, and LFU
Visit
Protocol-defined Window
Derived Analyses Window
End of 72 hours
After 72 hours of treatment, and up to 8 
hours later
From completion of 9th study 
dose up to 80 hours after start of 
study drug.
End of IV therapy 
(EOIV)
Within 24 hours of completion of the last 
infusion of study drug
On day of last infusion of study 
drug (or +1 day), and no later 
than same day as start of oral 
therapy.
End of Treatment 
(EOT)
Within 48 hours of completion of the last 
dose of oral switch therapy for patients 
who switch, or within 24 hours of the last 
infusion of study drug for those who do not 
receive oral switch therapy
On day of last dose of oral 
therapy (or +2 days) for oral 
switch patients; on day of last 
infusion of study drug (or +1 
day) for patients who do not 
switch
Test of cure (TOC)
8 to 15 days after the last dose of any study 
drug
7 to 19 days after the last dose 
of study drug
Late follow-up 
(LFU)
20 to 35 days after the last dose of any 
study drug
20 to 42 days after the last dose 
of study drug
The following tables present all the definitions for each visit.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
23
3.3.1.1.1. Clinical Outcome at End of 72 hours
The clinical outcome categories at the End of 72 hours are defined in Table 3. Favourable 
clinical outcomes are clinical improvement and clinical cure. 
Table 3: Clinical outcome assessments at End of 72 hours
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms of 
cIAI or improvement to such an extent that no 
further antimicrobial therapy is required.
Clinical Improvement
Patients who are improving but not enough to 
switch to oral therapy and are still on IV study 
drug at End of 72 hours and meet the following 
criterion:

Absence of new signs and symptoms, 
and improvement in at least 1 symptom 
or sign (ie, fever, pain, tenderness, 
elevated WBCs, elevated CRP) from 
Baseline, and with no worsening of any 
symptom or sign.
Clinical Failure
Patients who meet any of the following criteria:

Discontinuation of study drug due to 
insufficient therapeutic effect, including 
persistence, incomplete clinical 
resolution, or worsening in signs and 
symptoms of cIAI that requires 
alternative non-study antimicrobial 
therapy.

Discontinuation of study drug due to an 
AE and requirement for alternative 
non-study antimicrobial therapy for cIAI.

Death in which cIAI is contributory.

Postsurgical wound infections defined as 
an open wound with signs of local 
infection such as purulent exudates, 
erythema, or warmth that requires 
additional antibiotics and/or non-routine 
wound care.

Patients who are improving but not 
enough to switch to oral therapy and are 
still on IV study drug at End of 72 hours 
and who fail to meet the following 
criterion:
Absence of new signs and symptoms, 
and improvement in at least 1 symptom 
or sign (ie, fever, pain, tenderness, 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
24
Table 3: Clinical outcome assessments at End of 72 hours
Outcome 
Definition
elevated WBCs, elevated CRP) from 
Baseline, and with no worsening of any 
symptom or sign.
Indeterminatea
Study data are not available for evaluation of 
efficacy for any reason, including:

Death in which cIAI is clearly 
non-contributory.

Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up).
3.3.1.1.2. Clinical Outcome at EOIV
The clinical outcome categories at EOIV are defined in Table 4.
Favourable clinical outcomes are clinical improvement and clinical cure. A clinical failure at 
EOIV will be carried forward to the EOT and TOC visits.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
25
Table 4: Clinical outcome assessments at EOIV
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms 
of cIAI or improvement to such an extent that 
no further antimicrobial therapy is required
Clinical Improvement
Patients who switch to oral therapy and meet 
all of the following criteria at EOIV:

Afebrile (temperature ≤38.0°C) for at 
least 24 hours

Absence of new and improvement in 
at least 1 symptom or sign (ie, fever, 
pain, tenderness, elevated WBCs, 
elevated CRP) from Baseline and 
worsening of none
Clinical Failurea
Patients who meet any of the following 
criteria:

Discontinuation of study drug due to 
insufficient therapeutic effect, 
including persistence, incomplete 
clinical resolution, or worsening in 
signs and symptoms of cIAI that 
requires alternative non-study 
antimicrobial therapy.

Discontinuation of study drug due to 
an AE and requirement for alternative 
non-study antimicrobial therapy for 
cIAI.

Death in which cIAI is contributory.
Indeterminate
Study data are not available for evaluation of 
efficacy for any reason, including:

Death in which cIAI is clearly 
non-contributory.

Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up).
a A clinical failure at EOIV will be carried forward to EOT and TOC.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
26
3.3.1.1.3. Clinical Outcome at EOT
The clinical outcome categories at EOT are defined in Table 5. A favourable clinical 
outcome is clinical cure. A clinical failure at EOT will be carried forward to the TOC visit.
Table 5: Clinical outcome assessments at EOT
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms 
of cIAI or improvement to such an extent 
that no further antimicrobial therapy is 
required.
Clinical Failurea
Patients who meet any of the following 
criteria:

Discontinuation of study drug due to 
insufficient therapeutic effect, 
including persistence, incomplete 
clinical resolution, or worsening in 
signs and symptoms of cIAI that 
requires alternative non-study 
antimicrobial therapy.

Discontinuation of study drug due to 
an AE and requirement for alternative 
non-study antimicrobial therapy for 
cIAI.

Death in which cIAI is contributory.
Indeterminate
Study data are not available for evaluation of 
efficacy for any reason, including:

Death in which cIAI is clearly 
non-contributory.

Extenuating circumstances 
precluding classification as a cure or 
failure (eg, patient lost to follow-up).
a A clinical failure at EOT will be carried forward to TOC
3.3.1.1.4. Clinical Outcome at TOC
The clinical outcome categories at TOC are defined in Table 6. A favourable clinical 
outcome is clinical cure. Clinical response by pathogen at TOC will also be determined for 
each pathogen isolated at Baseline.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
27
Table 6: Clinical outcome assessments at TOC
Outcome 
Definition
Clinical Cure
Resolution of all acute signs and symptoms 
of cIAI or improvement to such an extent 
that no further antimicrobial therapy is 
required.
Clinical Failure
Patients who meet either of the following 
criteria:

Incomplete resolution or worsening 
of cIAI signs or symptoms or 
development of new signs or 
symptoms requiring alternative 
non-study antimicrobial therapy.

Death in which cIAI is contributory.
Indeterminate
Study data are not available for evaluation of 
efficacy for any reason, including:

Death in which cIAI is clearly 
non-contributory.

Extenuating circumstances precluding 
classification as a cure or failure (eg, 
patient lost to follow-up).
3.3.1.1.5. Clinical Outcome at LFU
Each patient who was considered clinically cured at TOC will be reassessed at LFU for 
evidence of clinical relapse of cIAI symptoms. The clinical outcome categories at LFU are 
defined in Table 7. A favourable clinical outcome at LFU is sustained clinical cure.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
28
Table 7.
Clinical outcome assessments at LFU
Outcome
Definition
Sustained Clinical Cure
Continued favourable response, defined as resolution of all acute 
signs and symptoms of cIAI and no further antimicrobial therapy is 
required.
Clinical Relapse
Patients who meet either of the following criteria:

Reappearance or worsening of signs and symptoms of cIAI 
that requires further antimicrobial therapy and/or surgery.

Death after TOC in which cIAI is contributory.
Indeterminate
Study data are not available for evaluation of efficacy for any 
reason, including:

Death in which cIAI is clearly non-contributory.

Extenuating circumstances precluding classification as 
sustained clinical cure or clinical relapse (eg, patient lost to 
follow-up).
Note: Clinical outcome at LFU will only be assessed in patients who were considered clinically cured at TOC.
3.3.1.1.6. Microbiological response assessments
The per-pathogen microbiological outcome categories are defined in Table 8 using the same 
windows as defined for clinical outcome within Table 2. Favourable microbiological 
outcomes are eradication or presumed eradication. Baseline pathogens will be determined 
based on central laboratory data where available. In the absence of any baseline central 
laboratory data, then local laboratory data will be used to identify baseline pathogens. 
Per-patient microbiological response is a consolidation of the per-pathogen microbiological 
response for each patient; in order for a patient to have a favourable per-patient 
microbiological response, the outcome for each baseline pathogen must be favourable
(eradicated or presumed eradicated). If the outcome for any pathogen is unfavourable 
(persistence or presumed persistence), the patient will be considered to have an unfavourable 
per-patient microbiological response.
In the cases that the overall microbiological responses are different in samples taken from the 
intra-abdominal infection site and blood, the per-patient microbiological response will be 
assessed based on the results from the intra-abdominal infection site.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
29
Table 8: Per-pathogen microbiological outcome categories
Outcome
Definition
Eradication
Source specimen demonstrated absence of the original baseline 
pathogen
Presumed eradication
Source specimen was not available to culture, and the patient was 
assessed as a clinical cure or sustained clinical cure or (for EOIV 
only) clinical improvement
Persistence
Source specimen demonstrates continued presence of the original 
baseline pathogen
Persistence with 
increasing MICa
Source specimen demonstrates continued presence of the original 
baseline pathogen with a minimum inhibitory concentration value 
≥4-fold larger than that observed for the baseline pathogen
Presumed persistence
Source specimen was not available to culture and the patient was 
assessed as a clinical failure or clinical relapse
Indeterminate
Source specimen was not available to culture and the patient’s 
clinical outcome was assessed as indeterminate
a Persistence with increasing MIC is a subset of the Persistence outcome
For patients who have a microbiological outcome of persistence or presumed persistence at a 
particular visit, this outcome will be carried forward to subsequent visits.
3.3.1.1.7. Emergent infections
Pathogens first appearing after Baseline (“emergent infections”) until the LFU are 
categorized in Table 9.
Table 9.
Emergent infections
Infection category
Definition
Superinfection
An intra-abdominal culture identified pathogen other than a
baseline pathogen during the course of active treatment with study
therapy along with worsening signs and symptoms of infection 
requiring alternative antimicrobial therapy.
New infection
An intra-abdominal culture identified pathogen other than a 
baseline pathogen at any time after study treatment has finished 
along with worsening signs and symptoms of infection requiring 
alternative antimicrobial therapy. 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
30
3.3.1.1.8. Per-pathogen microbiological response
Per-pathogen microbiological response is defined in Table 10.
Table 10: Per-Pathogen Microbiological Response
Outcome
Definition
Favourable
All baseline pathogens eradicated or presumed eradicated
Unfavourable
Any baseline pathogen with persistence or presumed 
persistence
Indeterminate
Any baseline pathogen indeterminate, and no baseline 
pathogen persistent
Note: For patients who have a microbiological outcome of persistence at a particular visit, this outcome will be carried 
forward to subsequent visits.
3.3.1.1.9. Pathogen group
Each pathogen will be assigned into one of the following groups to be used in summaries and 
listings, using a pre-defined list of groupings:

Enterobacteriaceae;

Gram-negative other than enterobacteriaceae;

Gram-positive;

Anaerobes.
4. ANALYSIS METHODS
4.1. General principles
Descriptive summaries will be provided where appropriate for each of the primary and 
secondary variables. In general, summaries will be presented by cohort, treatment group and
overall for treatment group across all cohorts. For disposition, demographics, medications, 
and data collected exclusively at baseline the total within each cohort will be presented as 
well. In this sense cohort is usually defined as cohorts 1 to 4, where cohort 4 is a combination 
of the cohorts 4a and 4b. For the following tables however, cohorts 4a and 4b will also be 
summarised in addition to cohorts 1 to 4:

Plasma concentrations;

Study drug administration and accountability;

Overall summary of adverse events in any category;

Overall summary of adverse events by system organ class (SOC) and preferred term;
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
31

Summary of quantitative laboratory variable results and change from baseline results 
by visit;

Summary of ECG variable results and change from baseline results by visit;

Summary of physical examination results by visit.
Unless otherwise specified, demographics and baseline characteristics will be summarized 
for safety analysis set.
Continuous and quantitative variable summaries will include the number of patients (N), 
mean, standard deviation (SD), median, and ranges (minimum and maximum). Plasma 
concentrations will be summarized by the number of patients (N), mean, coefficient variation 
(CV), median, and ranges (minimum and maximum). Categorical and qualitative variable 
summaries will include the frequency and percentages of patients who are in the particular 
category. In general the denominator for the percent calculation will be based upon the total 
number of patients in the study population for each treatment group and cohort, unless 
otherwise specified. 
For the reporting of descriptive statistics, the mean and median values will be presented to 1 
or more decimal precision as the source data, SD values will be presented to 2 or more 
decimal precision, minimum and maximum values will be presented to the same precision as 
the source data, and percent will be presented with 1 decimal precision. In the event the SD 
or mean is at least 4 decimal places, the SD will be displayed to same number of decimal 
places as mean.
To determine upper limit of the normal range (ULN) and lower limit of the normal 
range (LLN) values, site-level ranges will be converted for laboratory data in this study.
These ranges will then be used to define the potentially clinically significant (PCS) criteria in 
Table 12.
All analysis will be performed using SAS®, release 9.4 or higher.
A separate document will be produced containing the templates for table, listing, and figure.
4.2. Analysis methods
4.2.1. Baseline characteristic analysis
Baseline characteristics will be summarized for safety analysis set only. 
4.2.1.1. Patient disposition
The number of patients who are randomized but never treated, who completed the study up to 
the TOC visit, and up to the LFU visit, and the number of patients withdrawing from the 
study therapy and study, including reason for withdrawal, will be summarized by cohort, 
treatment, overall within each cohort, and overall for each treatment for the ITT analysis set. 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
32
All data relevant to randomization and reasons for randomized but never treated as well as 
inclusion and exclusion criteria will be listed. 
The number of patients in each of the analysis sets and the reasons for exclusion from 
analysis sets will be listed and summarized for the ITT analysis set.
A summary of important protocol deviations will be presented to display the number of 
patients with an important protocol deviation overall, and further broken down by deviation 
category for the safety analysis set.
A summary of the number of patients in each country and each centre will be produced for 
the ITT analysis set.
4.2.1.2. Demographics and baseline characteristics
Demographic and baseline characteristics included in Section 3.1.1 will be summarized by 
cohort, treatment group, overall within each cohort, and overall for each treatment. Age for 
cohort 4 will be summarized in months instead of years. For all other cohorts (1-3) age will 
be summarized in years.
Medical history data and current medical conditions (a medical history subset formed of 
conditions which are ongoing at screening) will be summarized by system organ class and 
preferred term for each cohort, treatment group overall within each cohort, and overall for 
each treatment. The surgical history data will also be summarized system organ class and 
preferred term for each cohort, treatment group, overall within each cohort, and overall for 
each treatment. Both the medical history and the surgical history will be coded with 
MedDRA Version 20.0. 
All prior and concomitant medications will be coded using the AZDD Drug dictionary 
medication code (version: 17.1 or later) and systemic antibiotic medications will be
summarized by ATC classification and preferred term (as well as cohort, treatment group, 
overall within each cohort, and overall for each treatment). Prior and concomitant 
medications that are not antibiotics will also be summarized by ATC classification and 
preferred term (as well as cohort, treatment group, overall within each cohort, and overall for 
each treatment).
4.2.1.3. Extent of Exposure and Compliance
Exposure
Exposure (in days) to CAZ-AVI alone and in combination with metronidazole, and to 
meropenem, will be summarized by cohort, treatment group and overall for each treatment.
Average daily infusions and total number of IV infusions will also be summarized 
descriptively by cohort and overall for each treatment.
For patients who switch to oral therapy at the conclusion of their randomized treatment, a 
summary will be provided for the exposure (in days) to oral therapy by type of oral therapy, 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
33
cohort, treatment group, and overall for each treatment to which they were originally 
randomized. A table in the same format will also be presented for the combined exposure 
duration of IV and oral therapies.
Exposure of study and oral therapy will be presented in the study medication listings. 
Treatment compliance
Treatment compliance will be summarized by cohort, treatment group and overall for each 
treatment. Compliance will be summarized descriptively (n, mean, standard deviation, 
median, minimum, maximum) and also with counts and percentages for the categories 
(<80%, 80%-120% and >120%). An additional summary of these statistics will be provided 
which summarizes the CAZ-AVI treatment group broken down into the individual 
components of CAZ-AVI and metronidazole, compared against meropenem.
4.2.2. Safety analysis
The primary variables are for safety and tolerability. No inferential statistical tests will be 
performed for any safety variables. Unless otherwise specified, the Safety analysis set will be 
used for summaries and listings. In addition the Safety evaluable analysis set will be used to 
assess key safety data such as adverse events, laboratory, vital signs and ECG data.
Safety assessments will be based on AE reports and the results of vital sign measurements, 
physical examinations, ECGs and clinical laboratory tests. 
4.2.2.1. Adverse events
The incidence of AEs will be summarized and reviewed for potential significance and 
clinical importance. AEs occurring from the start of the first infusion of IV study therapy will 
be summarized by preferred term and SOC. AEs occurring before the start of study treatment 
will only be listed and not included in tables. 
Adverse events will be grouped in tables by SOC and preferred term for each cohort, 
treatment group and overall for each treatment. All recorded AEs will be listed.
Summaries and listings of AEs leading to death, SAEs and AEs leading to discontinuation of 
study treatment will also be presented. Summaries will also be presented by blinded 
observer's causality assessment and by AE intensity.
AEoSI will be pre-defined using specific AE preferred terms from the MedDRA vocabulary 
for the following safety topic groups:

Liver disorder;

Diarrhoea;

Hypersensitivity/anaphylaxis;
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
34

Haematological disorder;

Renal disorder.
The number and percentage of patients with at least 1 AE within each AEoSI topic group will 
be presented by study cohort, treatment and overall together with a further presentation of the 
AE incidence rates for each PT within each AEoSI topic group.
Cephalosporin class effects and additional AEs (including, but not limited to seizures, C. 
difficile-associated diarrhoea, allergic reactions, hepatic abnormalities, haemolytic anaemia 
and changes in renal function) will be detailed in clinical study report (CSR) by reviewing 
the AEoSI.
4.2.2.2. Laboratory assessments
Local laboratory data for chemistry and haematology parameters will be summarized and 
plotted (box plots) by cohort, treatment group, overall for each treatment, and visit for the 
observed values and for the corresponding change from baseline (CFB) values using 
descriptive statistics.  If a patient has multiple results for a particular test at a particular visit, 
the first non-missing value will be used for the summary. Système International units will be 
reported for all analyses, but listings will reflect the original unit that was provided by the 
local laboratory with the test result. If a particular combination of treatment and cohort for a 
given parameter has fewer than five patients with data, then that combination will not be 
included in the boxplot.
The urinalysis parameters glucose, ketones, protein, nitrite, urobilinogen, and leukocyte 
esterase will be summarised using a shift table showing the number of patients with each 
combination of baseline value compared to maximum post-baseline value observed during 
treatment.
In addition, the following summaries at each applicable visit will also be provided:

The number and percentage of patients with normal values, low values, and high 
values according to local laboratory reference ranges;

Shift tables (from baseline) showing the number of patients with low, normal, or high 
values according to local laboratory reference ranges;

The numbers and percentage of patients with abnormal or out of range values based 
on PCS criteria (Table 12) at any time during the study up to EOT visit, and 
separately at any time up to LFU visit.
The criteria for PCS results for laboratory tests are described in Table 12. For relationship to 
normal reference range, shift table summaries, and PCS summaries, if a patient has multiple 
values for a particular test at a particular visit the first non-missing value will used. Shift 
plots (ie, Scatter plot) of baseline and EOT with reference ranges for the lab tests with 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
35
continuous values will also be provided by cohort, treatment group and overall for each 
treatment. 
The number and percentage of patients who meet potential Hy’s law criteria: AST or ALT ≥3 
× ULN and total bilirubin ≥2 × ULN at any point during the study will be summarized by 
cohort, treatment group and overall. The number of patients with ALP<=2 x ULN (alone and 
in addition to meeting potential Hy’s law criteria) will also be summarised.   The number of 
patients with maximum on-treatment ALT, AST and ALP will be cross-tabulated with the 
maximum on-treatment total bilirubin classified into the groups: <3 x ULN, ≥3 -<5 x ULN, 
≥5 - <10 x ULN and ≥10 x ULN for ALT and AST, <=2 x ULN for ALP, and <2 x ULN and 
>= 2 x ULN for total bilirubin. A listing of PCS values for liver function tests will be 
presented.
Listings of all laboratory values for each patient will be presented, and abnormal or 
out-of-range PCS values will be flagged alongside these results. 
The number and percentage of patients with CrCl in the following ranges: 
<30mL/min/1.73m2, ≥30 to <50 mL/min/1.73m2, ≥50mL/min/1.73m2 to <80mL/min/1.73m2, 
and ≥80mL/min/1.73m2 will be tabulated at each of the Baseline, Day 7, EOIV, TOC and 
LFU visits for each cohort, treatment group, and overall.
4.2.2.3. Physical examinations
The numbers and percentage of patients with normal or abnormal assessment for each body 
system will be summarized by cohort, treatment group and overall for each treatment.
All physical examination data will be listed.
4.2.2.4. ECGs
Descriptive statistics for ECG at each applicable visit and for the corresponding change from 
baseline values at each applicable post-baseline visit will be summarized and plotted (box-
plot) by cohort, treatment group and overall for each treatment. Shift plots from baseline to 
TOC will also be provided by cohort, treatment group and overall for each treatment. 
The number and percentage of patients within overall ECG interpretation category (normal, 
abnormal) for baseline and post-baseline by cohort, treatment group and overall for each 
treatment, and visit will be summarized. The number of patients with normal, abnormal ECG 
interpretation shift results from baseline to the TOC visit will be provided.
Categorical summaries of absolute QT, QTcB, and QTcF values (≥450 msec, ≥480 msec, 
≥500 msec) and CFB values in QT, QTcB, and QTcF values (≥30 msec, ≥60 msec) will be 
presented by treatment group, cohort and visit. The number and percentage of patients with 
post-baseline value of ≥500 msec and CFB value of ≥60 msec will also be presented by 
treatment group, cohort and visit.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
36
Electrocardiogram results and the overall interpretations of these results will be listed 
respectively.
Listings of all ECG values for each patient will be presented with abnormal or out-of-range 
PCS ECG values flagged. These are defined in Table 13.
4.2.2.5. Vital signs
Vital signs will be summarized and plotted (box plots) for the observed values and for the 
corresponding CFB values at each applicable visit by cohort, treatment group and overall for 
each treatment.
Vital signs will be listed.
4.2.3. Analysis of secondary variables
4.2.3.1. Pharmacokinetic outcome variables
A listing of ceftazidime and avibactam concentrations at the nominal sampling windows by 
patient and cohort will be provided. For Cohorts 1 to 4, the plasma concentration will be 
summarized by nominal sampling time window using appropriate descriptive statistics (eg, 
number, mean, SD, minimum, median, maximum, geometric mean, lower and upper SD 
bounds [geometric mean ±SD], and coefficient of variation).
Plasma concentrations that are not quantifiable (NQ) or if there are missing values (e.g. no 
result [NR]) will be handled as follows:

Where there is NR, these will be set to missing.

At a time point where there is less than or equal to 50% of the values are NQ, all NQ 
values will be set to the LLOQ, and all descriptive statistics will be calculated.

At a time point where more than half of the values are NQ, the mean, SD, geometric 
mean and CV% will be set to Not Calculated (NC).  The maximum value will be 
reported from the individual data, and the minimum and median will be set to NQ.

If all values are NQ at a time point, no descriptive statistics will be calculated for that 
time point.  Not calculated (NC) will be written in the field for standard deviation and 
CV% and NQ will be written in fields for mean, geometric mean, minimum, median 
and maximum.

The number of NQ values (n below LLOQ) will be reported for each time point.

Data from subjects excluded from the PK analysis set will be included in the data 
listings, but not in the descriptive statistics.
Geometric mean ±SD will be calculated as exp(u±s) where u and s are the mean and SD on a 
log scale.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
37
Two figures showing plasma concentration (means ± SD) of ceftazidime and avibactam
against time will also be presented by cohort.
Any PK modelling is not the scope of this document.
4.2.3.2. Clinical outcome, microbiological response and emergent infections
Clinical response outcome
Within each analysis set, the proportion of patients with a favourable outcome at End of 72 
hours’ treatment and EOIV is defined using the following formula: 
Number of patients with clinical cure or improvement
(Number of patients in the analysis set)
Within each analysis set, the proportion of patients with a favourable outcome at EOT and 
TOC is defined using the following formula: 
Number of patients with clinical cure
(Number of patients in the analysis set)
Within each analysis set, the proportion of patients with a favourable outcome at LFU is 
defined using the following formula:
Number of patients with sustained clinical cure
(Number of patients in the analysis set)
Where clinical response is summarized for the ITT and micro-ITT analysis sets, the nominal 
visit (i.e. as recorded on the CRF) throughout, whereas for summaries for the CE and ME 
analysis sets, visit windows will be used as defined in Table 2.
Clinical response outcomes will be summarized by cohort, treatment group and overall for 
each treatment in the ITT, micro-ITT, CE and ME analysis sets at End of 72 hours’ 
treatment, EOIV, EOT, TOC, and LFU. 
The number and percentage of patients with each clinical response outcome at each time
point will be summarized by cohort, treatment group and overall for each treatment. For each 
time point the number, percentage and proportion of patients with clinically favourable 
outcome will also be summarized. A two-sided 95% CI for the percentage of subjects with a 
favourable outcome will be presented within each cohort and treatment group, and treatment 
group overall (computed using Jeffreys method). The rate of favourable clinical response at 
TOC will also be presented for each baseline pathogen in the ME at TOC and micro-ITT 
analysis sets.
The analysis for clinical response outcome described above will be repeated and split by 
patients with/without diagnosis of appendicitis at screening in the CE, ME, micro-ITT and 
ITT analysis sets. Additionally the analysis will be repeated again for the CE analysis set 
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
38
only at the end of 72 hour visit window, where the eligibility for this window is amended 
from that in Table 2 to be from 72 hours until 80 hours after first dose of study IV treatment.
Microbiological response 
Where microbiological response is summarized for the ITT and micro-ITT analysis set, the 
nominal visit (i.e. as recorded on the CRF) will be used throughout, whereas for summaries 
for the ME analysis set, visit windows will be used as defined in Table 2.
The number and percentage of patients with a favourable microbiological response outcome 
at each end point will be summarized by cohort, treatment group and overall for each 
treatment in the micro-ITT and ME analysis set at the EOIV, EOT, TOC and LFU visits.
Emergent infections
The proportion of patients with any emergent infection, and further subsetted into super 
infections and/or new infections, will be summarized by cohort, treatment group and overall 
for each treatment for the micro-ITT and ME at TOC analysis sets.
Per-pathogen microbiological response
The number and percentage of patients with per-pathogen microbiological favourable
response will be summarized within pathogen group by cohort, treatment group and overall 
for each treatment for the ME analysis set at the EOIV, EOT, TOC and LFU visits. This 
summary will be repeated to display the favourable response in the same manner, with 
additional subsetting by baseline CAZ-AVI MIC and by baseline meropenem MIC. All pre-
pathogen analysis will also be presented for the ITT and micro-ITT analysis sets.
Baseline pathogen susceptibility and MIC
The number and percentage of patients with each pathogen at baseline will be presented 
within pathogen group by cohort, treatment, overall for each treatment group for the micro-
ITT and ME at TOC analysis sets.
The number and percentage of patients with baseline aerobic Gram-negative pathogens
classed as susceptible, non-susceptible, intermediate, and resistant to each of CAZ-AVI, 
ceftazidime and meropenem will be summarized for the micro-ITT analysis set alongside the 
number of patients with a pathogen, the number of isolates, and the number of isolates tested.
Culture results and susceptibility testing results will be based upon the CLSI assessments and 
listed by cohort and treatment group. The results of the in vitro susceptibility tests of each 
baseline aerobic, Gram-negative pathogen (‘Susceptible’ and ‘Non-susceptible’) in all 
isolates, site of infection isolates, and blood isolates will be summarized by cohort, treatment 
group and overall for each treatment for the micro ITT analysis set.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
39
MIC frequencies for each infecting species within pathogen group will be reported 
separately. Descriptive statistics for MICs will be reported for each infecting species and
MIC range. Additionally, for infecting species for which the number is 10 or more, the MIC 
to inhibit the growth of 50% (MIC50), and for which the number is 10 or more the MIC to 
inhibit the growth of 90% of organisms (MIC90) will be reported.
5. INTERIM ANALYSES
As this study is descriptive in nature, no interim or final inferential analyses will be 
performed for either efficacy or safety. 
5.1. Data Safety Monitoring Board (DSMB)
An data safety monitoring board (DSMB) is deemed necessary since the trial has a long 
period of enrolment, is multi-centre and multi-national.
The DSMB is charged with reviewing and evaluating the study safety (AEs, SAEs, and PCS
laboratory results) at periodic intervals. The DSMB members will be familiarised with AEs 
and SAEs likely to occur in this patient population, based on experience in adults and 
adolescents, as well as with this class of drugs (cephalosporins). The DSMB will conduct 
pre-planned and possibly ad hoc reviews of accumulating data.
Based on the findings of these reviews, the DSMB may make recommendations to the 
sponsor regarding the study, including, but not limited to: continue the study without 
modification, modify the protocol or informed consent/assent document(s), or temporarily 
stop enrolment in all or some of the study centres. The sponsor will be responsible for 
discussing and, if considered appropriate, implementing the DSMB recommendations. 
Further details can be found in the DSMB charter.
6. CHANGES OF ANALYSIS FROM PROTOCOL
Although protocol section 8.5.2.3 states that “Baseline pathogens will be determined based 
on central laboratory data”, section 5.2.1 of the protocol gives the option for the sample to be 
analyzed by central or local lab. Therefore, in case central lab is not available for the 
determination of baseline pathogens, local lab will be used if available (SAP Section 3.3.1
under subsection “Microbiological response assessments”).
An additional criterion was added for the CE and ME analysis sets (Sections 2.1.4.3 and 
2.1.4.4) whereby a patient should not have received concomitant antibiotics that would affect 
the assessment of efficacy. This extra constraint was implemented as a result of discussions 
held during formal ECMA review meetings.
Categories of CrCl used for analysis purposes were given in protocol section 8.5.1.2 as 
mL/min, however since the Schwartz formula used to derive CrCl was based on 
mL/min/1.73m2, this was the unit used for CrCl categories.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
40
7. REFERENCES
1.
Schwartz et al, 2009
Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, et al. New 
equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009 Mar;20(3):629-37.
2.
CLSI 2012
Performance Standards for Antimicrobial Susceptibility Testing; Twenty-First Informational 
Supplement. CLSI document M100-S22. CLSI Wayne, Pennsylvania.
3.
Brown SD, Traczewski MM. 2011
Ceftazidime/NXL-104 Spectrum of activity and tentative disk diffusion breakpoints. Aug-5 
2011.
4.
Allergan, 2017
AVYCAZ (ceftazidime and avibactam) for injection, for intravenous use FDA label. 
Ceftazidime-avibactam highlights of prescribing information.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
41
8. APPENDIX
8.1. Evaluability Review Process
Assessment of patient’s evaluability for each analysis set will be determined by the criteria 
described in Section 2.1.  Where possible, assignments will be made using programming 
algorithms.  In some cases manual review of data may be necessary in order to determine 
assignment (see Table 11).  
Data will be reviewed, and cases identified for presentation and discussion at the blinded 
evaluability and clinical/microbiological assessment (ECMA) meeting.  Potentially 
unblinding data (e.g. protocol deviations, concomitant medication and study drug dosing) 
will only be reviewed by team members who are unblinded, and case summaries will be 
presented for discussion at the blinded ECMA meeting for determination of evaluability.
The output of the each ECMA meeting will be a spreadsheet of analysis set assignments of 
the cases that were discussed and decided to be excluded from any analysis set. This 
spreadsheet will be provided to the programming group and incorporated into the database.  
Result of assessment and rationale for any manual updates to analysis set assignments will be 
documented in the form of ECMA minutes.  
Evaluability of each patient to each analysis set will be finalized prior to database lock.
Table 11: Evaluability assessments
Analysis set
Description
Analysis set criterion
Assessment performed
Safety 
Analysis Set 
(SAS)
randomised patients who 
received any amount of IV 
study therapy
a) randomised
Programmed
b) any amount of IV drug
* any dose of CAZ-AVI, or
* any dose of meropenem
Safety 
Evaluable 
Analysis Set 
(SES)
subset of the patients in the 
SAS that received at least 9 
doses of study treatment.
a) in SAS
Programmed 
b) at least 
* 9 doses of CAZ-AVI or 
* 9 doses of meropenem 
Manual confirmation by 
unblinded team, with 
blinded discussion of 
selected cases during 
ECMA meeting, if 
required
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
42
Analysis set
Description
Analysis set criterion
Assessment performed
PK Analysis 
Set
subset of the patients in the 
SAS who have at least 1 
ceftazidime and/or avibactam 
plasma measurement 
available
a) in SAS
Programmed
b) at least 1 ceftazidime and/or 
avibactam plasma 
measurement
ITT Analysis 
Set
all patients who have been 
assigned a randomised 
treatment.
a) randomized
Programmed
Micro-ITT 
Analysis Set
randomised patients who have 
a baseline pathogen known to 
cause cIAI
a) randomised 
Programmed
b) at least 1 baseline pathogen 
in intra-abdominal fluid or in 
blood known to cause cIAI
Programmed and manual:
A list of all baseline 
pathogens in this study 
will be manually 
classified by 
microbiologist as always, 
or never known to cause 
cIAI.
20170707A cIAI 
ISOLATE CODING-CLA
Patients who have at least 
one baseline pathogen 
classified as “always” are 
automatically eligible for 
the micro-ITT. The 
remaining patients will be 
excluded from the micro-
ITT.
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
43
Analysis set
Description
Analysis set criterion
Assessment performed
CE at 72h, 
CE at EOIV 
CE at EOT 
CE at TOC 
CE at LFU
Patients who receive both 
study therapies will be 
excluded from CE and ME 
analysis sets
a) Subject did not receive both 
study therapies
Programmed
randomised patients who 
receive any amount of IV study 
drug and have a confirmed 
diagnosis of cIAI
b) randomised 
Programmed
c) any amount of study drug 
Programmed
d) confirmed diagnosis of cIAI 
Programmed (based on 
inclusion criteria)
received at least 48 h of IV 
study drug in order to be 
considered an evaluable 
clinical failure, unless deemed 
a clinical failure based on a 
treatment-limiting AE
e) Clinical failure (or relapse 
at LFU) and ≥ 48h treatment
OR
e) Clinical failure (or relapse 
at LFU) and treatment-limiting 
AE with < 48h treatment  
A manual review of IV 
study drug will be 
performed by unblinded 
personnel. These flags 
will be incorporated into 
the database, and the 
remaining criteria of 
clinical response will be 
assessed 
programmatically.
The determination of 
‘treatment-limiting AEs’ 
will be made 
programmatically based 
on a field from the CRF: 
“DISCONTINUATION 
OF STUDY DRUG DUE 
TO AN AE AND 
REQUIREMENT FOR 
ALTERNATIVE NON 
STUDY 
ANTIMICROBIAL 
THERAPY FOR CIAI”. 
Have received at least 72 
hours of IV study drug in 
order to be considered an 
evaluable clinical cure
f) Cure (or improvement or 
sustained cure) and ≥72h 
treatment
Have been evaluated at the 
End of 72h and at the specific 
visits of EOIV, EOT, and TOC 
with a clinical response of 
cure or failure (or have been 
assessed as a clinical failure 
before the planned assessment 
visit), or for LFU, have been 
evaluated with a clinical 
response of sustained cure or 
relapse
g) Outcome of cure (or 
improvement) OR failure at 
relevant visit 
(OR failure carried forward 
from previous visit)
[OR sustained cure or relapse 
at LFU]
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
44
Analysis set
Description
Analysis set criterion
Assessment performed
Had no important protocol 
deviations that would affect 
assessment of efficacy
h) No protocol deviations 
affecting efficacy
Manual review of 
protocol deviations by 
unblinded personnel to 
select cases for discussion 
at ECMA meeting, during 
which a blinded 
assessment will be made 
of the evaluability of 
these cases.
Have not received 
concomitant antibiotics that 
would impact assessment of 
efficacy
i) No concomitant antibiotics 
affecting efficacy
Manual review of reasons 
for concomitant antibiotic 
medications to select 
cases for discussion at 
ECMA meeting, during 
which a blinded 
assessment will be made 
of evaluability for these
cases. 
ME at 72h 
ME at EOIV 
ME at EOT  
ME at TOC 
ME at LFU
Patients who receive both 
study therapies will be 
excluded from CE and ME 
analysis sets
As per CE
randomised patients who have 
received any amount of IV 
study drug and have a 
confirmed diagnosis of cIAI
As per CE
As per CE
As per CE
Have received at least 48 
hours of IV study drug in 
order to be considered an 
evaluable clinical failure, 
unless deemed a clinical 
failure based on a treatment-
limiting AE
As per CE
Have received at least 72 
hours of IV study drug in 
order to be considered an 
As per CE
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
45
Analysis set
Description
Analysis set criterion
Assessment performed
evaluable clinical cure
At the specific visit had a 
microbiological response 
which was not indeterminate 
j) Micro response not 
indeterminate (presumed 
eradication or presumed 
persistence is acceptable)
Programmed.
Had no important protocol 
deviations that would affect 
assessment of efficacy
As per CE
Have not received 
concomitant antibiotics that 
would impact assessment of 
efficacy
As per CE
Have at least 1 typical IAI
bacterial pathogen which has 
been isolated from an 
adequate microbiological 
specimen at Baseline that is 
susceptible to both study 
agents (CAZ-AVI and 
meropenem)
k) ≥1 typical cIAI bacterial 
pathogen isolated from an 
adequate microbiological 
specimen at baseline
As per micro-ITT
l) susceptible to both study 
agents (CAZ-AVI and 
meropenem)
Programmed, see Section 
2.1.4.4.1for definition of 
susceptibility
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
46
8.2. Potentially clinically significant criteria
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BUN, blood urea nitrogen;
  LLN, lower limit of normal; N/A, not applicable; RBC, red blood cell (erythrocytes); ULN, upper limit of 
  normal; WBC, white blood cell (leukocytes).
Note that for PCS low flags, both the lower limit and percentage decrease criteria must be met.
Table 12.
Criteria for potentially clinically significant clinical laboratory tests
Category
Parameter
Lower limit
Upper limit
Percent
decrease from
baseline
Percent
increase from
baseline
Haematology
Haemoglobin 
Haematocrit 
RBC 
WBC 
Neutrophils 
Lymphocytes 
Eosinophils 
Platelets 
<0.6 x LLN
<0.6 x LLN
<0.8 x LLN
<0.5 x LLN
<0.5 x LLN
<0.2 x LLN
N/A 
<0.4 x LLN
>1.3 x ULN
>1.3 x ULN
>1.3 x ULN
>2.0 x ULN
>2.2 x ULN
>2.2 x ULN
>4.0 x ULN
>2.0 x ULN
>25%
>25%
>20%
>60%
>70%
>70%
N/A
>40%
>30%
>30%
>30%
>100%
>100%
>100%
>400%
>100%
Chemistry
ALT 
Albumin 
Alkaline phosphatase
AST 
Bicarbonate 
BUN 
Calcium 
Chloride 
Creatinine 
Direct bilirubin 
Glucose, non-fasting 
Potassium 
Sodium 
Total bilirubin 
N/A
<0.6 x LLN
<0.5 x LLN
N/A
<0.7 x LLN
N/A
<0.7 x LLN
<0.8 x LLN
N/A
N/A
<0.6 x LLN
<0.8 x LLN
<0.85 x LLN
N/A
>3.0 x ULN
N/A
>3.0 x ULN
>3.0 x ULN
>1.3 x ULN
>3.0 x ULN
>1.3 x ULN
>1.2 x ULN
>2.0 × ULN
>2.5 x ULN
>4.0 x ULN
>1.2 x ULN
>1.1 x ULN
>2.5 x ULN
N/A
>60%
>80%
N/A
>50%
N/A
>30%
>20%
N/A
N/A
>40%
>15%
>10%
N/A
>300%
N/A
>300%
>300%
>30%
>300%
>30%
>20%
>100%
>150%
>200%
>20%
>10%
>300%
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)


Statistical Analysis Plan 
Study Code C3591004 (D4280C00015)
Edition Number 2.0 
Date 24th August 2017
47
Table 13: Criteria for potentially clinically significant electrocardiogram tests
Parameter
Age Range
Lower limit
Upper limit
Heart Rate
< 12 years
>=12 years
< 50 bpm and decrease >=15 bpm from 
baseline
< 50 bpm and decrease >=15 bpm from 
baseline
> 120 bpm and increase >= 15 bpm from 
baseline
> 110 bpm and increase >= 15 bpm from 
baseline
PR Interval
< 12 years
>=12 years
<= 90 ms
<= 100 ms
>= 170 ms
>= 180 ms
QRS Duration
<12 years
>=12 years
<= 55 ms
<= 70 ms
>= 90 ms
>= 100 ms
QT
<= 200 ms
>= 500 msec and increase of >=60 msec 
from baseline
QTcB
>= 450 msec
>= 500 msec
Increase of >= 30 msec from baseline
Increase of >= 60 msec from baseline
>= 450 msec and increase of >= 30 msec 
from baseline
>= 500 msec and increase of >= 60 msec 
from baseline
QTcF
>= 450 msec
>= 500 msec
Increase of >= 30 msec from baseline
Increase of >= 60 msec from baseline
>= 450 msec and increase of >= 30 msec 
from baseline
>= 500 msec and increase of >= 60 msec 
from baseline
090177e18e51c7a9\0.1\Draft\Versioned On:09-May-2018 14:13 (GMT)